

83121

## SEARCH REQUEST FORM

Requestor's  
Name:

John Eric Angell

78697

Serial

Number:

09/880,038

Date:

12/31/02

Phone:

12015 office

Art Unit:

1635

mail by 11E12

## Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

please search the compound of claim 2. [A]

Species: HFC drawing provided on pg. 2

AND any nucleic acid

Point of Contact:  
Barb O'Brien  
Technical Information Specialist  
STIC CM1 6A05 308-4291

## STAFF USE ONLY

Date completed: 1-3-03

Searcher:

PROB

Terminal time:

33

Elapsed time:

prep 45

CPU time:

Total time:

Number of Searches:

Number of Databases:

Search Site

STIC

CM-1

Pre-S

Type of Search

N.A. Sequence

A.A. Sequence

3

Structure

Bibliographic

Vendors

IG

616 STN

Dialog


APS

Geninfo

SDC

DARC/Questel

Other



=> fil reg; d stat que 16  
FILE 'REGISTRY' ENTERED AT 14:23:29 ON 03 JAN 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 JAN 2003 HIGHEST RN 478001-04-6  
DICTIONARY FILE UPDATES: 2 JAN 2003 HIGHEST RN 478001-04-6


TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L1 STR




C=O @18 19 C=S @20 21

VAR G1=9/10/15  
VAR G5=0/18/20/S/N  
REP G7=(0-1) O  
REP G8=(1-6) CH2  
NODE ATTRIBUTES:  
NSPEC IS RC AT 6  
CONNECT IS E1 RC AT 9  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L3 14781 SEA FILE=REGISTRY.SSS FUL L1  
L4 STR



REP G1=(16-16) CH2

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

*subset search  
done on this  
structure  
(species)*

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

~~L6~~ ~~1 SEA FILE=REGISTRY SUB=L3 SSS FUL L4~~

100.0% PROCESSED 8100 ITERATIONS

SEARCH TIME: 00.00.01

~~1 ANSWERS~~

=> fil capl; d que nos 17; fil uspatf; d que nos 18

FILE 'CAPLUS' ENTERED AT 14:23:29 ON 03 JAN 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Jan 2003 VOL 138 ISS 2

FILE LAST UPDATED: 2 Jan 2003 (20030102/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L1 STR  
L3 14781 SEA FILE=REGISTRY SSS FUL L1  
L4 STR  
L6 1 SEA FILE=REGISTRY SUB=L3 SSS FUL L4  
~~L7 5 SEA FILE=CAPLUS ABB=ON L6~~



FILE 'USPATFULL' ENTERED AT 14:23:30 ON 03 JAN 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 2 Jan 2003 (20030102/PD)  
FILE LAST UPDATED: 2 Jan 2003 (20030102/ED)  
HIGHEST GRANTED PATENT NUMBER: US6502243  
HIGHEST APPLICATION PUBLICATION NUMBER: US2003005504  
CA INDEXING IS CURRENT THROUGH 2 Jan 2003 (20030102/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Jan 2003 (20030102/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2002  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2002

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<  
>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> <<<  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

L1 STR  
L3 14781 SEA FILE=REGISTRY SSS FUL L1  
L4 STR  
L6 1 SEA FILE=REGISTRY SUB=L3 SSS FUL L4  
~~L8 2 SEA FILE=USPATFULL ABB=ON L6~~

=> dup-rem-17-18 --

FILE 'CAPLUS' ENTERED AT 14:23:30 ON 03 JAN 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:23:30 ON 03 JAN 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)  
PROCESSING COMPLETED FOR L7  
PROCESSING COMPLETED FOR L8

~~L53 6-DUP-REM-L7 L8 (1 DUPLICATE REMOVED)~~  
ANSWERS '1-5' FROM FILE CAPLUS  
ANSWER '6' FROM FILE USPATFULL

=> d ibib ab hitstr-153-1-6

L53 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS

DUPLICATE 1

ACCESSION NUMBER: 1999:537972 CAPLUS  
DOCUMENT NUMBER: 131:144715  
TITLE: Process for the preparation of alkylphosphocholines and the production thereof in pure form  
INVENTOR(S): Engel, Jurgen; Kutscher, Bernd; Schumacher, Wolfgang; Niemeyer, Ulf; Olbrich, Alfred; Nssner, Gerhard  
PATENT ASSIGNEE(S): Asta Medica A.-G., Germany  
SOURCE: U.S., 5 pp., Cont.-in-part of U. S. Ser. No. 905,817, abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5942639	A	19990824	US 1997-938331	19970925
US 6028209	A	20000222	US 1999-296260	19990422
PRIORITY APPLN. INFO.:			DE 1991-4122127 A	19910704
			US 1992-905817 B2	19920629
			US 1997-938331 A1	19970925

OTHER SOURCE(S): CASREACT 131:144715


AB A process for the prepn. of C14-C18-alkylphosphocholines by reacting an n-alkanol with a chain length of C14-C18 with phosphorus oxychloride in an inert solvent or also without solvent in the presence or absence of a basic substance in a single vessel process and subsequent reaction of the reaction product in an inert solvent with a choline salt in the presence of a basic substance to form phosphoric acid diester chloride, subsequent hydrolysis and isolation of alkylphosphocholine as well as optionally purifn. using a mixed-bed ion exchanger or in successive steps with an acid ion exchanger and a basic ion exchanger. Thus, reaction of POCl3 with hexadecanol in chloroform in the presence of pyridine followed by treatment with choline tosylate, hydrolysis, and Amberlite MB 3 ion exchanger gave 53% hexadecyl phosphocholine. The prepd. compds. are useful in treatment for tumors.

IT 139256-98-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 139256-98-7 CAPLUS

CN Ethanaminium, 2-[[heptadecyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L53 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:474728 CAPLUS

DOCUMENT NUMBER: 127:156354

TITLE: Phosphatidylcholine biosynthesis as a target for phospholipid analogs

AUTHOR(S): Geilen, Christoph C.; Wieder, Thomas; Orfanos, Constantin E.

CORPORATE SOURCE: Department of Dermatology, University Medical Center Benjamin Franklin, The Free University of Berlin,

SOURCE: Berlin, D-12200, Germany  
Advances in Experimental Medicine and Biology (1996),  
416(Platelet-Activating Factor and Related Lipid  
Mediators 2), 333-336  
CODEN: AEMBAP; ISSN: 0065-2598

PUBLISHER: Plenum

DOCUMENT TYPE: Journal


LANGUAGE: English

AB In different cell lines, different phospholipid analogs inhibited cell proliferation and phosphatidylcholine biosynthesis; all the biol. active phospholipid analogs contained a phosphocholine head group. The mechanism of phosphatidylcholine biosynthesis inhibition was inhibition of the rate-limiting enzyme CTP:phosphocholine cytidyltransferase. Thus, interfering with the cell membrane metab. of phospholipids by using membrane-active agents such as the phospholipid analogs may be a useful approach for treatment of cancer.

IT 139256-98-7  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(phosphatidylcholine biosynthesis as a target for phospholipid analogs in relation to cell proliferation inhibition and cancer treatment)

RN 139256-98-7 CAPLUS

CN Ethanaminium, 2-[[[(heptadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



L53 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:530679 CAPLUS

DOCUMENT NUMBER: 121:130679

TITLE: Phospholipid analogs: side chain- and polar head group-dependent effects on phosphatidylcholine biosynthesis

AUTHOR(S): Geilen, Christoph C.; Haase, Anne; Wieder, Thomas; Arndt, Dietrich; Zeisig, Reiner; Reutter, Werner

CORPORATE SOURCE: Inst. Molekularbiol. Biochem., Freien Univ. Berlin, Berlin-Dahlem, D-14195, Germany

SOURCE: Journal of Lipid Research (1994), 35(4), 625-32  
CODEN: JLPRAW; ISSN: 0022-2275

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In recent studies the authors showed that the phospholipid analog hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis by affecting the translocation of the rate-limiting enzyme of phosphatidylcholine biosynthesis, CTP:phosphocholine cytidyltransferase (EC 2.7.7.15), to membranes, where it is active (Geilen et al. 1992, J. Biol. Chem. 267: 6719-6724). The present study was performed to investigate the structure-dependency of this effect. It is shown that the inhibitory properties of phospholipid analogs are dependent on their alkyl side chain length (dodecylphosphocholine < tetradecylphosphocholine < hexadecylphosphocholine < heptadecylphosphocholine < octadecylphosphocholine > eicosylphosphocholine). Furthermore, it is demonstrated that this inhibition of phosphatidylcholine biosynthesis by phospholipid analogs is also dependent on the polar head group (hexadecylphosphocholine .mchgt. hexadecylphosphoethanolamine =

hexadecylphosphoserine). These effects result from an inhibition of the CTP:phosphocholine cytidyltransferase and are not due to an inhibition of choline uptake or differences in the cellular uptake of the phospholipid analogs investigated.


IT 139256-98-7

RL: BIOL (Biological study)

(phosphatidylcholine formation and cell proliferation inhibition by, structure in relation to)

RN 139256-98-7 CAPLUS

CN Ethanaminium, 2-[[[(heptadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



L53 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:428538 CAPLUS

DOCUMENT NUMBER: 119:28538

TITLE: Process for the preparation of alkylphosphocholines and their purification

INVENTOR(S): Engel, Juergen; Kutscher, Bernd; Schumacher, Wolfgang; Niemeyer, Ulf; Olbrich, Alfred; Noessner, Gerhard

PATENT ASSIGNEE(S): Asta Medica A.-G., Germany

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 521297	A1	19930107	EP 1992-108826	19920526
EP 521297	B1	19970917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
AT 158295	E	19971015	AT 1992-108826	19920526
ES 2108715	T3	19980101	ES 1992-108826	19920526
DE 4220852	A1	19930114	DE 1992-4220852	19920625
DE 4220852	C2	20001019		
NO 9202612	A	19930105	NO 1992-2612	19920702
PL 169571	B1	19960830	PL 1992-295129	19920702
IL 102379	A1	19961031	IL 1992-102379	19920702
CA 2073126	AA	19930105	CA 1992-2073126	19920703
AU 9219441	A1	19930107	AU 1992-19441	19920703
AU 652646	B2	19940901		
CN 1068331	A	19930127	CN 1992-105432	19920703
CN 1034941	B	19970521		
HU 61560	A2	19930128	HU 1992-2233	19920703
HU 219243	B	20010328		
ZA 9204980	A	19930428	ZA 1992-4980	19920703
JP 05186483	A2	19930727	JP 1992-176913	19920703
JP 3171279	B2	20010528		
AU 9466059	A1	19940922	AU 1994-66059	19940629
AU 663259	B2	19950928		
NO 9801742	A	19930105	NO 1998-1742	19980417
			DE 1991-4122127	A 19910704


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): CASREACT 119:28538

Angell

09/880038

- AB C14-18 alkylphosphocholines were prepd. by 1) reaction of a C14-18 n-alkanol with POCl<sub>3</sub>, optionally in the presence of a solvent and base, 2) treatment of the product with a choline salt in an inert solvent in the presence of a base to give the diester chloride, and 3) hydrolysis. Thus, POCl<sub>3</sub> in CHCl<sub>3</sub> at 5-12.degree. was treated with hexadecanol in CHCl<sub>3</sub> and with pyridine over 1.25 h. After 1.5 h stirring at 0-5.degree., choline tosylate and pyridine were added over 15 min. The mixt. was stirred 3 h at room temp. and then H<sub>2</sub>O was added over 20 min to give crude hexadecylphosphocholine. This was stirred with acetone, dissolved in EtOH, filtered, and the filtrate stirred with Amberlyte MB3. The mixt. was filtered and the filtrate was evapd. to give a product which was crystd. from CH<sub>2</sub>Cl<sub>2</sub> to give 53% hexadecylphosphocholine.
- IT **139256-98-7P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, one-pot procedure for)
- RN 139256-98-7 CAPLUS  
 CN Ethanaminium, 2-[[[(heptadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



L53 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 1992:106694 CAPLUS

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

116:106694  
 Preparation of alkyl phosphates or N-alkylphosphoramidates as well as synergistic antitumor pharmaceuticals contg. them and alkylglycerins.

PATENT ASSIGNEE(S):

Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Germany  
 Austrian, 23 pp.

SOURCE:

CODEN: AUXXAK

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AT 393505	B	19911111	AT 1987-1045	19870427
AT 8701045	A	19910415	AT 1987-1045	19870427


PRIORITY APPLN. INFO.:

MARPAT 116:106694

OTHER SOURCE(S):

AB R-Y-P(O)(O-)-X-R1 [I; R = satd. or unsatd. C12-24-hydrocarbyl; X = O, NH, NR<sub>2</sub>; Y = O, NH; R1 = substituted C2-8-alkyl; R2 = C1-8-alkyl, substituted C2-8-alkyl] as well as pharmaceuticals contg. I and 1-30 wt.% R3OCH<sub>2</sub>CH(OR<sub>4</sub>)CH<sub>2</sub>OH [II; R3 = C3-12-alkyl and R4 = H, or R3 = H and R4 = C3-12-alkyl] as well as the usual pharmaceutical additives/diluents are prepd. POCl<sub>3</sub> in THF was added to a soln. of Me(CH<sub>2</sub>)<sub>15</sub>OH and Et<sub>3</sub>N in THF at .ltoreq.10.degree., a soln. of H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>OH and Et<sub>3</sub>N in dioxane was added, the mixt. was allowed to react at 65-70.degree. and filtered, the filtrate reacted with HCO<sub>2</sub>H at 40-50.degree. for 15 min, and the reaction mixt. was cooled to -20.degree. to give Me(CH<sub>2</sub>)<sub>15</sub>OP(O)(OH)O(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>. The title compds. were tested for their cytotoxic activity against L1210 cells in vitro and had EC<sub>90</sub> values ranging from 2.9 to 10.0 .mu.g/mL. No examples are given for the synergistic combination of I and II in a

IT pharmaceutical compn.  
 139256-98-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, for synergistic antitumor pharmaceutical compns. with  
 glycerin derivs.)  
 RN 139256-98-7 CAPLUS  
 CN Ethanaminium, 2-[[[(heptadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-,  
 inner salt (9CI) (CA INDEX NAME)



L53 ANSWER 6 OF 6 USPATFULL  
 ACCESSION NUMBER:

TITLE: 2000:21703 USPATFULL

INVENTOR(S): Process for the preparation of alkylphosphocholines and  
 the production thereof in pure form  
 Engel, Jurgén, Alzenau, Germany, Federal Republic of  
 Kutscher, Bernd, Maintal, Germany, Federal Republic of  
 Schumacher, Wolfgang, Langen, Germany, Federal Republic  
 of  
 Niemeyer, Ulf, Offenbach, Germany, Federal Republic of  
 Olbrich, Alfred, Obertshausen, Germany, Federal  
 Republic of  
 Nossner, Gerhard, Offenbach, Germany, Federal Republic  
 of  
 PATENT ASSIGNEE(S): Asta Medica AG, Frankfurt, Germany, Federal Republic of  
 (non-U.S. corporation)

NUMBER	KIND	DATE
US 6028209		20000222
US 1999-296260		19990422 (9)
Continuation of Ser. No. US 1997-938331, filed on 25 Sep 1997, now patented, Pat. No. US 5942639 which is a continuation-in-part of Ser. No. US 1992-905817, filed on 29 Jun 1992, now abandoned		

NUMBER	DATE
DE 1991-4122127	19910704
Utility	
Granted	
Ambrose, Michael G.	
Pillsbury Madison & Sutro LLP	
11	
1	
450	

PRIORITY INFORMATION:  
 DOCUMENT TYPE:  
 FILE SEGMENT:  
 PRIMARY EXAMINER:  
 LEGAL REPRESENTATIVE:  
 NUMBER OF CLAIMS:  
 EXEMPLARY CLAIM:  
 LINE COUNT:  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A process for the preparation of C.sub.14 -C.sub.18 -  
 alkylphosphocholines by reacting an n-alkanol with a chain length of  
 C.sub.14 -C.sub.18 with phosphorus oxychloride in an inert solvent or  
 also without solvent in the presence or absence of a basic substance in  
 a single vessel process and subsequent reaction of the reaction product  
 in an inert solvent with a choline salt in the presence of a basic  
 substance to form phosphoric acid diester chloride, subsequent  
 hydrolysis and isolation of alkylphosphocholine as well as optionally  
 purification using a mixed-bed ion exchanger or in successive steps with

an acid ion exchanger and a basic ion exchanger.  
IT 139256-98-7P

(prepn. of, one-pot procedure for)

RN 139256-98-7 USPATFULL

CN Ethanaminium, 2-[[ (heptadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-,  
inner salt (9CI) (CA INDEX NAME)



=> fil reg; d stat que 139

~~FILE: REGISTRY~~ ENTERED AT 14:24:00 ON 03 JAN 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 JAN 2003 HIGHEST RN 478001-04-6  
DICTIONARY FILE UPDATES: 2 JAN 2003 HIGHEST RN 478001-04-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002




Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L1

STR




*same full file  
search as before*

VAR G1=9/10/15  
VAR G5=O/18/20/S/N  
REP G7=(0-1) O  
REP G8=(1-6) CH2  
NODE ATTRIBUTES:  
NSPEC IS RC AT 6  
CONNECT IS E1 RC AT 9  
DEFAULT MLEVEL IS ATOM  
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE  
L3 14781 SEA FILE=REGISTRY SSS FUL L1  
L37 STR





VAR G1=9/10/15  
 VAR G5=O/18/20/S/N  
 REP G7=(0-1) O  
 REP G8=(1-6) CH2  
 VAR G9=CH2/22  
 VAR G10=CH3/24

# NODE ATTRIBUTES:

CHARGE IS \*+ AT 6 -any positive charge  
 NSPEC IS RC AT 6  
 CONNECT IS E1 RC AT 9  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

# GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 25

# STEREO ATTRIBUTES: NONE

~~L39~~ 9300-SEA-FILE=REGISTRY-SUB=L3-SSS FUL L37

100.0% PROCESSED 14781 ITERATIONS  
 SEARCH TIME: 00.00.02

9300-ANSWERS

*subset search  
 done on this  
 structure*

=> fil capl; d que nos 127; d que nos 135; d que nos 142  
 FILE 'CAPLUS' ENTERED AT 14:24:11 ON 03 JAN 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Jan 2003 VOL 138 ISS 2  
 FILE LAST UPDATED: 2 Jan 2003 (20030102/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```

L1      STR
L3      14781 SEA FILE=REGISTRY SSS FUL L1
L11     26175 SEA FILE=CAPLUS ABB=ON L3
L15     102786 SEA FILE=CAPLUS ABB=ON NUCLEIC ACID#/OBI
L19     40081 SEA FILE=CAPLUS ABB=ON NUCLEIC ACIDS/CT
L22     1399423 SEA FILE=CAPLUS ABB=ON PHARMAC?/SC
L24     51585 SEA FILE=CAPLUS ABB=ON CYTOTOXIC?/OBI
L25     148308 SEA FILE=CAPLUS ABB=ON ANTITUMOR AGENTS+OLD/CT
L27     14 SEA FILE=CAPLUS ABB=ON L11(L)-L15-AND L22 AND L19 AND (L24 OR
      (L25))

```

```

L1      STR
L3      14781 SEA FILE=REGISTRY SSS FUL L1
L11     26175 SEA FILE=CAPLUS ABB=ON L3
L19     40081 SEA FILE=CAPLUS ABB=ON NUCLEIC ACIDS/CT
L24     51585 SEA FILE=CAPLUS ABB=ON CYTOTOXIC?/OBI
L29     2504 SEA FILE=CAPLUS ABB=ON L19(L) (THU OR PAC OR BAC OR PKT OR
      DMA)/RL
L30     3828 SEA FILE=CAPLUS ABB=ON L11(L) (THU OR PAC OR BAC OR PKT OR
      DMA)/RL
L35     9 SEA FILE=CAPLUS ABB=ON L29 AND L30 AND L24

```

Roles

THU - therapeutic use  
 PAC - pharmacological activity  
 BAC - biological activity  
 PKT - pharmacokinetics  
 DMA - drug mechanism of action

```

L1      STR
L3      14781 SEA FILE=REGISTRY SSS FUL L1
L19     40081 SEA FILE=CAPLUS ABB=ON NUCLEIC ACIDS/CT
L24     51585 SEA FILE=CAPLUS ABB=ON CYTOTOXIC?/OBI
L25     148308 SEA FILE=CAPLUS ABB=ON ANTITUMOR AGENTS+OLD/CT
L37     STR
L39     9300 SEA FILE=REGISTRY SUB=L3 SSS FUL L37
L40     22585 SEA FILE=CAPLUS ABB=ON L39
L42     35 SEA FILE=CAPLUS ABB=ON L40 AND L19 AND (L24 OR L25) AND
      PHARMAC?/SX/SC

```

=> s (127 or 135 or 142) not 17

L55 48 (L27 OR L35 OR L42) NOT L7 printed w/ first search

=> fil uspatf; d que nos 149; s 149 not 18

FILE=USPATFULL ENTERED AT 14:25:23 ON 03 JAN 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 2 Jan 2003 (20030102/PD)

FILE LAST UPDATED: 2 Jan 2003 (20030102/ED)

HIGHEST GRANTED PATENT NUMBER: US6502243

HIGHEST APPLICATION PUBLICATION NUMBER: US2003005504

CA INDEXING IS CURRENT THROUGH 2 Jan 2003 (20030102/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Jan 2003 (20030102/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2002

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2002

>>> USPAT2 is now available. USPATFULL contains full text of the  
 >>> original, i.e., the earliest published granted patents or  
 >>> applications. USPAT2 contains full text of the latest US

<<<  
 <<<  
 <<<

>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

L1 STR  
L3 14781 SEA FILE=REGISTRY SSS FUL L1  
L37 STR  
L39 9300 SEA FILE=REGISTRY SUB=L3 SSS FUL L37  
L44 981 SEA FILE=REGISTRY ABB=ON L39 AND USPATFULL/LC  
L45 1095 SEA FILE=USPATFULL ABB=ON L44  
L46 4666 SEA FILE=USPATFULL ABB=ON NUCLEIC ACIDS/CT  
L47 4162 SEA FILE=USPATFULL ABB=ON CYTOTOXIC?/IT, TI, AB, CLM  
L48 16542 SEA FILE=USPATFULL ABB=ON NEOPLASM INHIBITORS/CT OR ANTITUMOR  
AGENTS/CT  
~~L49 16 SEA FILE=USPATFULL ABB=ON L45 AND L46 AND (L47 OR L48)~~

~~L56 16 L49 NOT L8~~ *previously printed*

=> dup.rem.155,156

FILE 'CAPLUS' ENTERED AT 14:25:29 ON 03 JAN 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:25:29 ON 03 JAN 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)  
PROCESSING COMPLETED FOR L55  
PROCESSING COMPLETED FOR L56

~~L57 59 DUP REM L55 L56 (5 DUPLICATES REMOVED)~~  
ANSWERS '1-48' FROM FILE CAPLUS  
ANSWERS '49-59' FROM FILE USPATFULL

=> d:ibib-abs-hitstr:1-59; fil hom

L57 ANSWER 1 OF 59 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1  
ACCESSION NUMBER: 2002:571542 CAPLUS  
DOCUMENT NUMBER: 137:129881  
TITLE: Polymeric, pH-sensitive, serum-stable liposomes  
INVENTOR(S): Papahadjopoulos, Demetrios; Meyer, Olivier; Leroux,  
Jean-Christophe  
PATENT ASSIGNEE(S): The Regents of the University of California, USA  
SOURCE: U.S., 21 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent

Searched by Barb O'Bryen, STIC 308-4291

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6426086	B1	20020730	US 1999-243098	19990202
			US 1998-73471P	P 19980203


PRIORITY APPLN. INFO.:  
 AB A pH-sensitive, serum-stable liposome loaded with an agent and having a lipid bilayer, complexed with a mol. comprising (a) a thermally-sensitive polymer showing lower crit. soln. temp. behavior in aq. solns. and bearing a hydrophobic substituent, (b) a hydrophobic substituent of less than 10 kD covalently bound to the thermally-sensitive polymer, and (c) a pH sensitive substituent covalently bound to the thermally-sensitive polymer, which pH sensitive substituent remains ionizable following covalent bonding and whose pH sensitivity does not depend on cleavage of the covalent bond to the thermally-sensitive polymer, the liposome and mol. being complexed by the insertion of hydrophobic substituent into the lipid bilayer of the liposome. Complexed liposomes in an aq. soln. release at least 20% of the agent when the pH of the soln. is changed from pH 7.4 to pH 3.5. For example, the pH-dependent release of fluorescent markers from liposomes and liposome-polymer systems after a 5 min incubation at 37.degree. was obsd. A decrease in pH from 7.2 to 4.9 produced a 10-fold increase in the total amt. of dye released from egg phosphatidylcholine (EPC) liposomes assocd. with poly(N-isopropylacrylamide-methacrylic acid-octadecyl acrylate). Interestingly, preincubation of liposomes with the same polymer lacking the alkyl chain (octadecyl acrylate) did not induce pH-triggered liposomal leakage, indicating that the presence of alkyl chains in the structure of the copolymer is important for liposome pH-dependent response, possibly due to efficient complexation of the polymer to the liposome membrane via octadecyl chains.

IT 26853-31-6 326495-35-6  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polymeric, pH-sensitive, serum-stable liposomes)

RN 26853-31-6 CAPLUS

CN 3,5,8-Trioxa-4-phosphaheptacosan-17-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[[(1-oxohexadecyl)oxy]methyl]-, inner salt, 4-oxide, (7R,17Z)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).  
 Double bond geometry as shown.



RN 326495-35-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1,1,2,2-d4-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 2 OF 59 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 2  
 ACCESSION NUMBER: 2001:906093 CAPLUS  
 DOCUMENT NUMBER: 136:25134  
 TITLE: Use of ultrasound for delivering bioactive agents  
 INVENTOR(S): Unger, Evan C.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U. S. Ser. No. 290,324.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001051131	A1	20011213	US 1999-413110	19991006
US 6033645	A	20000307	US 1996-666129	19960619
WO 2001024705	A1	20010412	WO 2000-US27025	20000929


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:  
 US 1996-666129 A3 19960619  
 US 1999-290324 A2 19990412  
 US 1999-413110 A 19991006


AB Methods for enhancing the bioavailability of a bioactive agent in vivo is disclosed. Embodiments of the invention involve administering a bioactive agent and an acoustically active compn. to a patient. Ultrasound energy may be applied in an amt. sufficient to activate the acoustically active compn. In preferred form, the acoustically active compn. is administered to the patient at a rate which comprises continuous infusion. To a soln. of saline, propylene glycol and glycerol (8:1:1) were added dipalmitoylphosphatidyl-choline, dipalmitoylphosphatidylethanolamine-PEG5000 and dipalmitoylphosphatidic acid in a molar ratio of 82:8:10. The resulting mixt. was heated to about 45.degree., filtered, and cooled to room temp. The vial contg. the mixt. was placed under vacuum to evacuate any gas, after which the vial was pressurized with perfluoropropane (PFP). The vial was then sealed, placed on a shaker and agitated at room temp. to provide a soln. of PFP-filled vesicles having a mean diam. of about 2.5 mm. The soln. of PFP-vesicles was administered i.v. to a healthy human subject at a dose of about 10 mL per Kg of body wt., providing a vesicle dose of about 1.5x10<sup>7</sup> vesicles/Kg. After

injection, a saline flush (5 mL) was administered in the same injection site. Transducers (2.5, 3.5 and 5.0 MHz) were used to image the heart region in both short-axis and long-axis views. After injection of the saline flush, the ultrasound image rapidly darkened until the heart was not visible due to severe shadowing. This severe shadowing lasted for a period of time of about 30 s to about 1 min. Upon dissipation of the shadowing, the ultrasound image revealed only transient contrast enhancement of the myocardial tissues.


- IT 2644-64-6, Dipalmitoylphosphatidylcholine 4539-70-2,  
Distearoylphosphatidylcholine. 18656-38-7,  
Dimyristoylphosphatidylcholine, 68737-67-7,  
Dioleoylphosphatidylcholine,  
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);  
USES (Uses)  
(use of ultrasound for delivering bioactive agents)
- RN 2644-64-6 CAPLUS
- CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



- RN 4539-70-2 CAPLUS
- CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)




- RN 18656-38-7 CAPLUS
- CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 68737-67-7 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[ (9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (18Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

L57 ANSWER 3 OF 59 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 3  
ACCESSION NUMBER: 2001:666681 CAPLUS  
DOCUMENT NUMBER: 135:247192  
TITLE: Charged nucleic acid therapeutic agents encapsulated in lipid particles containing four lipid components  
INVENTOR(S): Semple, Sean C.; Klimuk, Sandra K.; Harasym, Troy; Hope, Michael J.; Ansell, Steven M.; Cullis, Pieter; Scherrer, Peter; Debeyer, Dan  
PATENT ASSIGNEE(S): Inex Pharmaceuticals Corp., Can.  
SOURCE: U.S., 48 pp., Cont.-in-part of U.S. Ser. No. 856,374, abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6287591	B1	20010911	US 1998-78954	19980514
PRIORITY APPLN. INFO.:			US 1997-856374	B2 19970514

AB Lipid-therapeutic agent particles are prepd. contg. a charged therapeutic agent encapsulated in lipid portion contg. at least two lipid components including a protonatable or deprotonatable lipid such as an amino lipid and a lipid that prevents particle aggregation during lipid-therapeutic agent particle formation such as a PEG-modified or polyamide oligomer-modified lipid. Other lipid components may also be present and these include a neutral lipid such as DSPC, POPC, DOPE or SM, and a sterol such as Chol. The therapeutic agent is encapsulated by combining a mixt. of the lipids with a buffered aq. soln. of a charged therapeutic agent to form an intermediate mixt. contg. lipid-encapsulated therapeutic agent particles, and changing the pH of the intermediate mixt. to neutralize at least some surface charges on the particles. The method permits high

ratios of therapeutic agent to lipid and encapsulation efficiencies in excess of 50. The method is particularly useful for prepg. lipid-encapsulated nucleic acids such as an antisense polyanionic nucleic acid having exclusively phosphodiester linkages. The encapsulated nucleic acid can be contacted with a cell to introduce the nucleic acid into the cell such as for treatment or prevention of a disease characterized by aberrant expression of a gene. A pharmaceutical compn. may be prepd. contg. the lipid-encapsulated therapeutic agent particles and a carrier.

IT 816-94-4, Dspc 2462-63-7, Dope 26662-91-9,  
Popc

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)


(charged **nucleic acid** therapeutic agents

encapsulated in lipid particles contg. four lipid components)

RN 816-94-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 2462-63-7 CAPLUS

CN 9-Octadecenoic acid (9Z)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me


RN 26662-91-9 CAPLUS

CN 3,5,8-Trioxa-4-phosphahexacos-17-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[[(1-oxohexadecyl)oxy]methyl]-, inner salt, 4-oxide, (17Z)- (9CI)



(CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 4 OF 59 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 4  
 ACCESSION NUMBER: 2001:241683 CAPLUS  
 DOCUMENT NUMBER: 134:271256  
 TITLE: Methods of forming protein-linked lipidic microparticles, and compositions thereof  
 INVENTOR(S): Papahadjopoulos, Demetrios; Hong, Keelung; Zheng, Weiwen; Kirpotin, Dmitri B.  
 PATENT ASSIGNEE(S): The Regents of the University of California, USA  
 SOURCE: U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 967,791. CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6210707	B1	20010403	US 1998-76618	19980512
US 6071533	A	20000606	US 1997-967791	19971110
CA 2330741	AA	19991118	CA 1999-2330741	19990511
WO 9958694	A1	19991118	WO 1999-US10375	19990511
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9939834	A1	19991129	AU 1999-39834	19990511
EP 1078079	A1	20010228	EP 1999-922950	19990511
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002514432	T2	20020521	JP 2000-548485	19990511
US 6410049	B1	20020625	US 1999-420908	19991020
US 2002001612	A1	20020103	US 2001-765107	20010116
US 2002182249	A1	20021205	US 2002-121962	20020412
US 2003003143	A1	20030102	US 2002-177939	20020621
PRIORITY APPLN. INFO.:				
			US 1996-30578P	P 19961112
			US 1997-967791	A2 19971110
			US 1998-76618	A 19980512
			WO 1999-US10375	W 19990511
			US 1999-420908	A1 19991020
			US 2001-765107	A1 20010116

AB The present invention provides for lipid/nucleic acid complexes that have increased shelf life and high transfection activity in vivo following i.v. injection, and methods of prepg. such complexes. The methods generally involve contacting a nucleic acid with an org. polycation to produce a condensed nucleic acid, and then combining the condensed nucleic acid with a lipid comprising an amphiphilic cationic lipid to produce the lipid/nucleic acid complex. This complex can be further stabilized by the addn. of a hydrophilic polymer attached to hydrophobic side chains. The complex can also be made specific for specific cells, by incorporating a targeting moiety such as an Fab' fragment attached to a hydrophilic polymer. The present invention further relates to lipidic microparticles with attached proteins which have been first conjugated to linker mols. having a hydrophilic polymer domain and a hydrophobic domain capable of stable assocn. with the microparticle, or proteins which have been engineered to contain a hydrophilic domain and a lipid moiety permitting stable assocn. with the microparticle. For example, maleimido-propionylantido-PEG-distearoylphosphatidylethanolamine (Mal-PEG-DSPE) was prepd., conjugated with a single chain Fv antibody reactive against HER2 oncoprotein, and formulated into immunoliposomes for targeting of HER2-overexpressing human breast cancer cells.

IT 4537-76-2, Distearoylphosphatidylethanolamine


RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of protein-linked lipidic microparticles for targeting of

nucleic acids)

RN 4537-76-2 CAPLUS

CN Octadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



IT 207403-10-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of protein-linked lipidic microparticles for targeting of

nucleic acids)


RN 207403-10-9 CAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[6-hydroxy-6-oxido-1,12-dioxo-9-[(1-oxooctadecyl)oxy]-5,7,11-trioxa-2-aza-6-phosphanonacos-1-yl]-.omega.-[2-[[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 2462-63-7, DOPE 26662-91-9, 1-Palmitoyl-2-oleoyl-phosphatidylcholine 178744-28-0 216165-62-7 321975-96-6 331942-29-1


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (prepn. of protein-linked lipidic microparticles for targeting of nucleic acids)

RN 2462-63-7 CAPLUS

CN 9-Octadecenoic acid (9Z)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Me

RN 26662-91-9 CAPLUS

CN 3,5,8-Trioxa-4-phosphahexacos-17-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[[(1-oxohexadecyl)oxy]methyl]-, inner salt, 4-oxide, (17Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 178744-28-0 CAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[7-hydroxy-7-oxido-13-oxo-10-[(1-oxooctadecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphatriacont-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 216165-62-7 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-ethoxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, 4-oxide (9CI) (CA INDEX NAME)




RN 321975-96-6 CAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-(7,10,11-trihydroxy-7-oxido-6,8-dioxa-3-aza-7-phosphaundec-1-yl)-.omega.-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 331942-29-1 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphahexacos-17-en-1-aminium, 4-ethoxy-N,N,N-trimethyl-9-oxo-7-[[[(1-oxohexadecyl)oxy]methyl]-, 4-oxide, (17Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 5 OF 59 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 5  
 ACCESSION NUMBER: 1998:604601 CAPLUS  
 DOCUMENT NUMBER: 129:235651  
 TITLE: Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride  
 INVENTOR(S): Kim, Sinil; Howell, Stephen B.  
 PATENT ASSIGNEE(S): Depotech Corporation, USA  
 SOURCE: U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 352,342, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5807572	A	19980915	US 1995-473019	19950606
US 6071534	A	20000606	US 1998-19337	19980205
PRIORITY APPLN. INFO.:			US 1988-151553	B2 19880218
			US 1990-563365	B2 19900806
			US 1991-709744	B1 19910603
			US 1993-20483	B1 19930223

US 1994-352342 B2 19941207  
US 1995-473019 A3 19950606

AB Disclosed are multivesicular liposomes contg. biol. active substances, the multivesicular liposomes having defined size distribution, adjustable av. size, adjustable internal chamber size and no., and a modulated rate of the biol. active substance in contrast to the previous art. The process comprises dissolving a lipid component in volatile org. solvents, adding an immiscible aq. component contg. at least one biol. active substance to be encapsulated, and adding to either or both the org. solvents and the lipid component, a hydrochloride effective to control the release rate of the biol. active substance from the multivesicular liposome, making a water-in-oil emulsion from the two components, immersing the emulsion into a second aq. component, dividing the emulsion into small solvent spherules which contain even smaller aq. chambers, and then removing the solvents to give an aq. suspension of multivesicular liposomes encapsulating biol. active substances. Multivesicular liposomes with encapsulation of 59% cytarabine (I) contg. hydrochloric acid (II) were prepd. Percentage of retained I at 24 h was 93% in contrast to 52% when II was not used.

IT 4235-95-4


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(multivesicular liposomes having biol. active substance encapsulated therein in presence of hydrochloride)

RN 4235-95-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 6 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:927448 CAPLUS

TITLE: Nucleic acid-based modulation of VEGF/VEGF receptor genes, and use in the treatment and/or diagnosis of female reproductive diseases and angiogenesis-associated conditions

INVENTOR(S): Escobedo, Jaime; McSwiggen, James; Pavco, Pamela; Stinchcomb, Dan; Sandberg, Jennifer; Gordon, Gilad


Searched by Barb O'Bryen, STIC 308-4291

PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Incorporated, USA; Chiron Corporation  
 SOURCE: PCT Int. Appl., 172 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096927	A2	20021205	WO 2002-US17674	20020529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:				
			US 2001-870161	A 20010529
			US 2001-334461P	P 20011130
			US 2002-138674	A 20020503
AB	The invention discloses nucleic acid mols., including dsRNA, siRNA, antisense, 2,5-A chimeras, aptamers, and enzymic nucleic acid mols., such as hammerhead ribozymes, DNazymes, and allozymes, which modulate the expression of vascular endothelial growth factor receptor (VEGF) and/or vascular endothelial growth factor receptor (VEGFr) genes for the treatment and/or diagnosis of diseases and conditions assocd. with angiogenesis, such as cancer, tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age-related macular degeneration, proliferative diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis, psoriasis, wound healing, and female reproductive disorders and conditions, including but not limited to endometriosis, endometrial carcinoma, gynecol. bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.			
IT	INDEXING IN PROGRESS			
IT	158571-62-1, Lipofectamine			
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (formulation contg.; <b>nucleic acid</b> -based modulation of VEGF/VEGF receptor genes, and use in treatment and/or diagnosis of female reproductive diseases and angiogenesis-assocd. conditions)			
RN	158571-62-1 CAPLUS			
CN	1-Propanaminium, N-[3-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-3-oxopropyl]-N,N-dimethyl-2,3-bis[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, salt with trifluoroacetic acid (1:1), mixt. with 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl di-(9Z)-9-octadecenoate (9CI) (CA INDEX NAME)			
CM	1			
CRN	2462-63-7			
CMF	C41 H78 N O8 P			

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

CM 2

CRN 185097-43-2

CMF C54 H106 N5 O5 . C2 F3 O2


CM 3

CRN 181508-68-9


CMF C54 H106 N5 O5

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B






CM 4

CRN 14477-72-6

CMF C2 F3 O2



L57 ANSWER 7 OF 59 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:716321 CAPLUS  
DOCUMENT NUMBER: 137:246527  
TITLE: Multivalent MHC constructs: Immunoanalysis, diagnosis and therapy  
INVENTOR(S): Winther, Lars; Petersen, Lars Oestergaard; Buus, Soeren; Schoeller, Joergen; Ruub, Erik; Aamellem, Oeystein  
PATENT ASSIGNEE(S): Dako A/S, Den.; Dynal Biotech Asa  
SOURCE: PCT Int. Appl., 304 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072631	A2	20020919	WO 2002-DK169	20020313
WO 2002072631	C1	20021128		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.:  
DK 2001-435 A 20010314  
DK 2001-436 A 20010314  
DK 2001-441 A 20010314  
US 2001-275447P P 20010314  
US 2001-275448P P 20010314  
US 2001-275470P P 20010314

AB The authors disclose MHC mol. constructs (classical and non-classical) conjugated to sol. or insol. carriers wherein the affinity and avidity of the constructs exceed that of comparable MHC tetramers. In one example, the construct is comprised of biotinylated HLA-A2 bound to FITC-labeled streptavidin conjugated to sol. derivatized dextran. The above construct loaded with MART-1 or influenza virus peptides was shown to effect T-cell activation at a lower concn. than. Also comprised by the present invention is the sample-mounted use of MHC mols., MHC mol. multimers, and MHC mol. constructs.

IT 18656-38-7, Dimyristoylphosphatidylcholine  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(for vaccines of multivalent constructs of MHC antigens)

RN 18656-38-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L57 ANSWER 8 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:594655 CAPLUS

DOCUMENT NUMBER: 137:159311

TITLE: Polymer combinations that result in stabilized aerosols for gene delivery to the lungs

INVENTOR(S): Zou, Yiyu; Perez-Soler, Roman

PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, USA

SOURCE: PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060412	A2	20020808	WO 2002-US2909	20020201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002187105	A1	20021212	US 2002-61444	20020201

PRIORITY APPLN. INFO.: US 2001-266174P P 20010201

AB The use of non-viral delivery of therapeutically effective compns. through aerosols for therapy or research purpose has been limited by low efficiency mainly caused by an inefficient delivery system and destruction of formulation (gene and/or delivery system) by aerosol shearing power. This invention develops formulations that are established polymer combination formulations. The formulations are highly efficient in delivering genes in vivo through aerosols and are able to protect the delivered gene from the destruction by aerosol shearing power.


IT 216165-62-7

RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(polymer combinations that result in stabilized aerosols for gene delivery to the lungs)

RN 216165-62-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-ethoxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, 4-oxide (9CI) (CA INDEX NAME)



L57 ANSWER 9 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:332010 CAPLUS

DOCUMENT NUMBER: 136:345764

TITLE: Lipid formulations for targeted delivery

INVENTOR(S): Cullis, Pieter R.; MacLachlan, Ian; Fenske, David B.

PATENT ASSIGNEE(S): The University of British Columbia, Can.; Inex Pharmaceuticals Corporation

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034236	A2	20020502	WO 2001-CA1513	20011025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002014854	A5	20020506	AU 2002-14854	20011025
PRIORITY APPLN. INFO.: US 2000-243185P P 20001025				
WO 2001-CA1513 W 20011025				

AB The present invention provides lipid-based systemic delivery vehicles and method for selectively targeting an active agent to a specific tissue site. The methods include designing a lipid-based systemic delivery vehicle having a plurality of constituent parts, and thereafter varying the amts. of each of the plurality of constituent parts to impart tissue selectivity. After tissue selectivity is imparted it is possible to selectively target an active agent to a specific tissue site.

IT 68737-67-7, Dioleoyl phosphatidyl choline

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)


(lipid formulations for targeted delivery)

RN 68737-67-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[ (9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (18Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

L57 ANSWER 10 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:315065 CAPLUS

DOCUMENT NUMBER: 136:337344

TITLE: Methods of high-throughput screening for internalizing ligands or antibodies and their receptors

INVENTOR(S): Marks, James D.; Nielsen, Ulrik B.; Kirpotin, Dmitri B.

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002033044	A2	20020425	WO 2001-US32311	20011017

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002182643	A1	20021205	US 2001-981636	20011016
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2000-241279P P 20001018

AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve (i) contacting the cell with a reporter non-covalently coupled to a ligand; (ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and (iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

IT 26662-91-9, 1-Palmitoyl-2-oleoylphosphatidylcholine


RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);

ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(liposomes contg.; methods of high-throughput screening for  
internalizing ligands or antibodies and receptors)

RN 26662-91-9 CAPLUS

CN 3,5,8-Trioxa-4-phosphahexacos-17-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[[(1-oxohexadecyl)oxy]methyl]-, inner salt, 4-oxide, (17Z)- (9CI)  
(CA INDEX NAME)

Double bond geometry as shown.




IT 4539-70-2, Distearoylphosphatidylcholine

RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);  
THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study);  
USES (Uses)

(liposomes contg.; methods of high-throughput screening for  
internalizing ligands or antibodies and receptors)

RN 4539-70-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L57 ANSWER 11 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:314759 CAPLUS

DOCUMENT NUMBER: 136:330567

TITLE: A method to incorporate N-(4-hydroxyphenyl)retinamide  
in liposomes

INVENTOR(S): Lopez-Berestein, Gabriel; Tari, Ana M.; Lim, Soo-Jeong

PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032413	A2	20020425	WO 2001-US32310	20011017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,  
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002143062 A1 20021003 US 2001-982113 20011017

PRIORITY APPLN. INFO.: US 2000-241445P P 20001017

AB Disclosed herein are simple and unique methods of methods of prep. liposomal compns. of N-(4-hydroxyphenyl)retinamide (4HPR) and/or other retinoids. Also disclosed are liposomal 4HPR compns. prep. by such methods and use of such compns. in the treatment of diseases, such as breast cancer. This invention further provides methods for improving the efficacy of N-(4-hydroxyphenyl) retinamide (4HPR) as a chemopreventive agent in the presence of agents that potentiates its ability increase the expression of inducible nitric oxide synthase (iNOS), and NO prodn. in cells. Examples were given for prepn. of liposomal 4-HPR and their antitumor activity.

IT 18194-24-6, Dimyristoylphosphatidylcholine


RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(incorporation of N-(4-hydroxyphenyl)retinamide in liposomes)

RN 18194-24-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 12 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:923645 CAPLUS

DOCUMENT NUMBER: 136:48434

TITLE: Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal

INVENTOR(S): Meyer, Olivier

PATENT ASSIGNEE(S): Transgene S.A., Fr.

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095946	A2	20011220	WO 2001-IB1287	20010613
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

US 2002025941 A1 20020228 US 2001-880038 20010614  
 PRIORITY APPLN. INFO.: FR 2000-7604 A 20000614  
 US 2000-246090P P 20001107

OTHER SOURCE(S): MARPAT 136:48434

AB The present invention relates to a combination product comprising at least one nucleic acid contg. a sequence encoding a polypeptide or interest and at least one phospholipid of interest, for use which is simultaneous, consecutive or spread out over time, characterized in that said polypeptide and phospholipid of interest have cytotoxic activity.

IT **2462-63-7**, DOPE


RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (adjuvant; combination product for **cytotoxic** treatment in particular antitumor treatment in a mammal comprising **nucleic acid** encoding a polypeptide and phospholipid used with adjuvants)

RN 2462-63-7 CAPLUS

CN 9-Octadecenoic acid (9Z)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


Me

IT **58066-85-6**, Hexadecylphosphocholine

RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (combination product for **cytotoxic** treatment in particular antitumor treatment in a mammal comprising **nucleic acid** encoding a polypeptide and phospholipid used with adjuvants)

RN 58066-85-6 CAPLUS

CN Ethanaminium, 2-[[[(hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



L57 ANSWER 13 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:903792 CAPLUS

DOCUMENT NUMBER: 136:42838

TITLE: Delivery systems for a peptide, protein or nucleic acid

INVENTOR(S): Barman, Shikha P.; McKeever, Una; Hedley, Mary Lynne

PATENT ASSIGNEE(S): Zycos Inc., USA

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001093835	A1	200111213	WO 2001-US17971	20010601
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-208830P P 20000602

AB The invention features a microparticle compn. for the delivery of bioactive agents into cells that includes a polymeric matrix, an anionic or zwitterionic lipid having a pKa of < .apprx. 2.5, and a bioactive agent, e.g. a peptide, protein, or nucleic acid. The compns. of the invention can be used to deliver bioactive compds., such as nucleic acids encoding immunostimulatory peptides and/or therapeutic proteins. For example, poly(glycolic acid-lactic acid) microparticles contg. DNA encoding a peptide having an amino acid sequence of proteolipid protein (PLP) were prepd. and injected i.v. to a multiple sclerosis patient whose T cells secrete excess Th1 cytokines (i.e., IL-2 and .gamma.-IFN). Expression of PLP-like peptide by APCs results in the switching of the cytokine profile of the T cells, such that they instead produce Th2 cytokines (i.e., IL-4 and IL-10) in response to autoantigens. Also, DNA encapsulated in PEG-DSPE contg. microparticles was protected from the nuclease, compared to DNA in non-lipid contg. microparticles.


IT 145035-96-7, PEG-DSPE

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (microparticles for delivery of peptide, protein or nucleic acid)

RN 145035-96-7 CAPLUS


CN Poly(oxy-1,2-ethanediyl), .alpha.-[7-hydroxy-7-oxido-13-oxo-10-[(1-oxooctadecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphatriacont-1-yl]-.omega.-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 14 OF 59 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2001:816426 CAPLUS  
DOCUMENT NUMBER: 135:348932  
TITLE: Liposomes for oral delivery of proteinaceous and other drugs  
INVENTOR(S): Yatvin, Milton B.; Betageri, Guru  
PATENT ASSIGNEE(S): Enzrel, Inc., USA  
SOURCE: PCT Int. Appl., 34 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082897	A2	20011108	WO 2001-US14002	20010501
WO 2001082897	A3	20021128		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.: US 2000-562207 A2 20000502

AB This invention comprises pharmaceutical compns. for administering a biol. active compd. to an animal. Particularly provided are proliposomal compns. that are advantageously used to deliver biol. active compds. to the gastrointestinal tract after oral administration, i.e., an enteric-coated tablet. The proliposome compn. comprises a lipid, such as sphingosine, ceramide stearylamine, or dicetyl phosphate, a phospholipid, such as phosphatidylcholine, phosphatidyl glycerol, phosphatidylethanolamine, phosphatidylinositol, etc., or cholesterol. The enteric coating is selected from Eudragit and cellulose acetate phthalate. The compn. further comprises a protective coating selected from hydroxypropyl Me cellulose and polyethylene glycol. The protective coating further comprises a plasticizer, such as tri-Et citrate and polyvinyl pyrrolidone. The biol. active compd. is a nutrient, a hormone, a nucleic acid, an antibiotic drug, an enzyme, an antigen, an antiviral drug, an antiproliferative drug, an antineoplastic drug, an anti-inflammatory drug, a peptide or a protein. A proliposomal compn. is prepd. by lyophilization, spray drying in the presence or absence of a surfactant, or pan drying. For example, enteric-coated proliposomal tablets were prepd. by spray-drying using glyburide as a model drug, and combinations of cholesterol, dicetyl phosphate, stearylamine,

distearoylphosphatidylcholine (DSPC) or dimyristoylphosphatidylcholine (DMPC), and Eudragit L30 D-55 as enteric coatings. A slightly higher percentage of the drug was encapsulated in DMPC. The presence of cholesterol reduces the particle size of the formulation. Enhanced transport of glyburide across Caco-2 cells was obsd. with such liposomal formulations.


IT 816-94-4, Distearoylphosphatidylcholine 18194-24-6,  
Dimyristoylphosphatidylcholine  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(liposomes for oral delivery of proteinaceous and other drugs and nutrients)  
RN 816-94-4 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 18194-24-6 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 15 OF 59 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2001:396643 CAPLUS  
DOCUMENT NUMBER: 135:24670  
TITLE: Modular targeted liposomal delivery system  
INVENTOR(S): Meers, Paul R.; Shangguan, Tony; Cabral-lilly, Donna;  
Ahl, Patrick; Erukulla, Ravi; Janoff, Andrew  
PATENT ASSIGNEE(S): The Liposome Company, Inc., USA  
SOURCE: PCT Int. Appl., 82 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

-----  
 WO 2001037807 A1 20010531 WO 2000-US31712 20001117  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1231895 A1 20020821 EP 2000-980515 20001117  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

## PRIORITY APPLN. INFO.:

US 1999-167297P P 19991124  
 US 2000-209088P P 20000602  
 WO 2000-US31712 W 20001117

AB A liposome including a fusogenic liposome, a linking moiety and a targeting moiety. The fusogenic liposome is a lipid bilayer encapsulating contents. The linking moiety is electrostatically bound to the lipid bilayer, and the targeting moiety is covalently bound to the linking moiety. The liposome may also include a stabilizing moiety interposed between the linking and targeting moieties, and covalently bound to both. Alternatively, the stabilizing and targeting moieties may be covalently bound to sep. linking moieties, the linking moieties being electrostatically bound to the lipid bilayer. E.g., conjugates of a PEG deriv., folic acid, and DOPE were prepd.

IT 4235-95-4

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (modular targeted liposomal delivery system)


RN 4235-95-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Searched by Barb O'Bryen, STIC 308-4291

L57 ANSWER 16 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:265217 CAPLUS

DOCUMENT NUMBER: 134:285587

TITLE: Improved methods for delivering bioactive agents using vesicles and ultrasound energy

INVENTOR(S): Unger, Evan C.

PATENT ASSIGNEE(S): ImaRx Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024705	A1	20010412	WO 2000-US27025	20000929
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2001051131	A1	20011213	US 1999-413110	19991006
PRIORITY APPLN. INFO.:			US 1999-413110	A 19991006
			US 1996-666129	A3 19960619
			US 1999-290324	A2 19990412
AB	Methods for enhancing the bioavailability of a bioactive agent in vivo are disclosed. Embodiments of the invention involve administering a bioactive agent and an acoustically active compn. to a patient. Ultrasound energy may be applied in an amt. sufficient to activate the acoustically active compn. In preferred form, the acoustically active compn. is administered to the patient at a rate which comprises continuous infusion. To a soln. of saline, propylene glycol, and glycerol (8:1:1) were added dipalmitoylphosphatidylcholine, dipalmitoylphyosphatidylethanolamine-polyethylene glycol-5000, and dipalmitoylphosphatidic acid in a molar ratio of 82:8:10. The resulting mixt. was heated to about 45.degree. and filtered. The filtered mixt. was placed in a vial and allowed to cool to room temp. The vial was placed under vacuum to evacuate any gas, after which the vial was pressurized with perfluoropropane gas. The vial was then sealed, placed on a shaker and agitated at room temp. to provide a soln. of perfluoropropane-filled vesicles having a mean diam. of about 2.5 .mu.m. The concn. of vesicles in the soln. was about 1.5x10 <sup>9</sup> vesicle/mL.			
IT	63-89-8, Dipalmitoylphosphatidylcholine 816-94-4, Distearoylphosphatidylcholine 4235-95-4 18194-24-6, Dimyristoylphosphatidylcholine 68737-67-7, Dioleoylphosphatidylcholine			
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (improved methods for delivering bioactive agents using vesicles and ultrasound energy)			
RN	63-89-8 CAPLUS			
CN	3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)			


Absolute stereochemistry. Rotation (+).



RN 816-94-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 4235-95-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


Me

RN 18194-24-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

NAME)

Absolute stereochemistry.




RN 68737-67-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-  
10-oxo-7-[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (18Z)-  
(9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me


REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 17 OF 59 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2000:756557 CAPLUS  
DOCUMENT NUMBER: 133:340221  
TITLE: Cationic PEG-lipids and methods of use  
INVENTOR(S): Cullis, Pieter R.; Chen, Tao; Fenske, David B.;  
Palmer, Lorne R.; Wong, Kim  
PATENT ASSIGNEE(S): University of British Columbia, Can.  
SOURCE: PCT Int. Appl., 153 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2000062813 A2 20001026 WO 2000-CA451 20000420  
WO 2000062813 A3 20010809  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,  
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
EP 1173600 A2 20020123 EP 2000-920309 20000420  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO  
JP 2002542341 T2 20021210 JP 2000-611949 20000420  
WO 2001080900 A2 20011101 WO 2001-CA555 20010420  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,  
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
US 2002072121 A1 20020613 US 2001-839707 20010420  
PRIORITY APPLN. INFO.: US 1999-130151P P 19990420  
US 2000-553639 A 20000420  
WO 2000-CA451 W 20000420  
US 2000-227949P P 20000825  
AB The present invention provides cationic-polymer-lipid conjugates (CPLs)  
such as distal cationic-poly(ethylene glycol)-lipid conjugates which can  
be incorporated into conventional and stealth liposomes or other  
lipid-based formulation for enhancing cellular uptake. The CPLs of the  
present invention comprise a lipid moiety, a hydrophilic polymer; and a  
polycationic moiety. Method of increasing intracellular delivery of  
nucleic acids are also provided. For example, DSPE (121 mg) reacted with  
t-Boc-NH-PEG 3400-COONHS (500 mg) to obtain DSPE-PEG-NH2 as DSPE-CPL-1  
with one protonable cationic group (yield 500 mg, 80%).  
IT 816-94-4, Distearoylphosphatidylcholine 4235-95-4  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cationic polymer-lipid conjugates for enhancing intracellular drug  
delivery)  
RN 816-94-4 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-  
oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 4235-95-4 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-

10-oxo-7-[[ (9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

L57 ANSWER 18 OF 59 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2000:725503 CAPLUS  
DOCUMENT NUMBER: 133:301180  
TITLE: Polyethyleneimine/DNA formulations for aerosol  
delivery  
INVENTOR(S): Densmore, Charles L., Jr.; Knight, Jack Vernon;  
Waldrep, John Clifford; Orson, Frank McNair; Kinsey,  
Berma M.  
PATENT ASSIGNEE(S): Research Development Foundation, USA  
SOURCE: PCT Int. Appl., 82 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059548	A1	20001012	WO 2000-US40044	20000331
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1173224	A1	20020123	EP 2000-923636	20000331
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002541125	T2	20021203	JP 2000-609109	20000331
PRIORITY APPLN. INFO.:			US 1999-127575P	P 19990402
			WO 2000-US40044	W 20000331



AB The present invention demonstrates that polycationic, non-lipid-DNA formulations are resistant to nebulizer-induced degrdn. and are much more specific and efficient than lipid-based formulations in transfecting respiratory tract tissues in vivo. Results presented here demonstrate that polyethyleneimine (PEI) formulations are about 10-fold more effective than previous lipid-based formulations when delivered in vivo by jet nebulizer. Therefore, aerosolized polyethyleneimine-based formulations are provided for use in targeting gene therapy via the respiratory tract. PEI-DNA complexes were aerosolized using an Aerotech II (AT-II) nebulizer at 10 L/min flow rate using air or air contg. 5% CO<sub>2</sub>. AT-II is a high output, efficient nebulizer demonstrated to produce aerosols in the optimal range of 1-2 .mu.m mass median aerodynamic diam. for peripheral lung delivery. The nebulization of 10 mL soln. took approx. 30 min.

IT 99732-49-7, Exosurf

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyethyleneimine/DNA formulations for aerosol delivery)

RN 99732-49-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)-, mixt. with formaldehyde polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol and 1-hexadecanol (9CI) (CA INDEX NAME)

CM 1

CRN 36653-82-4

CMF C16 H34 O


HO-(CH<sub>2</sub>)<sub>15</sub>-Me

CM 2

CRN 63-89-8

CMF C40 H80 N O8 P

Absolute stereochemistry. Rotation (+).



CM 3

CRN 25301-02-4


CMF (C14 H22 O . C2 H4 O . C H2 O)x

CCI PMS

CM 4

CRN 140-66-9

CMF C14 H22 O



CM 5

CRN 75-21-8


CMF C2 H4 O



CM 6

CRN 50-00-0

CMF C H2 O



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 19 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:707020 CAPLUS

DOCUMENT NUMBER: 133:280557

TITLE: Lipid-based artificial particles inducing cell-mediated immunity

INVENTOR(S): Sugimoto, Masanobu; Arella, Max; Furuichi, Yasuhiro

PATENT ASSIGNEE(S): Sapientia Therapeutics Ltd., Can.; AGENE Research Institute

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057919	A2	20001005	WO 2000-CA319	20000323
WO 2000057919	A3	20010208		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1165142	A2	20020102	EP 2000-912299	20000323
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

## PRIORITY APPLN. INFO.:

US 1999-276057 A 19990325  
WO 2000-CA319 W 20000323


AB Artificial immunogenic particles (1), methods for producing the same and uses thereof are disclosed. The immunogenic particles (1) of the invention comprise a lipid-based matrix (3), glycolipids (5, 6) and peptide-lipid conjugates (7, 8) embedded into this matrix (3). These particles (1) are highly efficient in inducing cell-mediated immunity (CMI) when administered to a host. The immunogenic particles (1) of the invention can be used as immunostimulating agents (e.g. vaccines), and as immunotherapeutic agents for preventing and/or treating infectious diseases and cancers in which CMI responses play an important role.

IT 2644-64-6, DPPC

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(artificial particles comprising lipid-based matrix, glycoprotein, peptide-lipid conjugate for inducing cell-mediated immunity and for treating inflammation and cancer)

RN 2644-64-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L57 ANSWER 20 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:98268 CAPLUS

DOCUMENT NUMBER: 132:156844

TITLE: Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier

INVENTOR(S): Jeong, Seo Young; Kwon, Ick Chan; Chung, Hesson

PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006120	A1	20000210	WO 1999-KR414	19990730
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9950689	A1	20000221	AU 1999-50689	19990730
KR 2000012106	A	20000225	KR 1999-31339	19990730
EP 1100464	A1	20010523	EP 1999-935145	19990730
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO  
JP 2002521423 T2 20020716 JP 2000-561977 19990730  
PRIORITY APPLN. INFO.: KR 1998-31249 A 19980731  
WO 1999-KR414 W 19990730

AB The present invention relates to oil-in-water lipid emulsions composed of non-triglyceride oils and solid lipid nanoparticles (SLN) composed of triglyceride or Et stearate used as gene transfection agents and drug delivery systems and method for prepg. thereof. The present invention also concerns the method of transferring genes or drugs efficiently into cells by using the lipid emulsions and solid lipid nanoparticles. Also the present invention relates to the method of prepg. lipid emulsions contg. lipophilic or amphiphilic drugs by using squalene or squalane as the core oil. The present invention also concerns the method of prepg. the solid lipid nanoparticles contg. lipophilic or amphiphilic drugs by using Et stearate as the core fat.

IT 4235-95-4


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lipid emulsion and solid lipid nanoparticle as gene or drug carrier)

RN 4235-95-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 21 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:606754 CAPLUS

DOCUMENT NUMBER: 133:213073

TITLE: Liposomal delivery system for nucleic acids for gene therapy

INVENTOR(S): Thierry, Alain R.

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: U.S., 39 pp., Cont.-in-part of U.S. Ser. No. 286,730.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

Searched by Barb O'Bryen, STIC 308-4291

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6110490	A	20000829	US 1996-522246	19960129
US 5908635	A	19990601	US 1994-286730	19940805
WO 9603977	A1	19960215	WO 1995-US9867	19950804

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT  
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:  
US 1994-286730 A2 19940805  
WO 1995-US9867 W 19950804

AB The present invention is directed to a liposomal prepn. which is based on specific lipid components. The liposomal compds. are also combined with a biol. active agent, forming liposomal compds. These compds. are useful in drug delivery, where specific therapeutic compds. are provided in the liposomes. The specific lipid components of the present invention provide a highly efficient and stable delivery system for nucleic acids. Consequently, one embodiment of the invention provide the liposomal preps. which are suitable for use in gene therapy.


IT 2462-63-7, Dioleoylphosphatidyl ethanolamine  
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(liposomal delivery system for **nucleic acids** for gene therapy)

RN 2462-63-7 CAPLUS

CN 9-Octadecenoic acid (9Z)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 22 OF 59 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2000:817472 CAPLUS  
DOCUMENT NUMBER: 133:366436

Searched by Barb O'Bryen, STIC 308-4291

TITLE: Amidino compounds and drug carriers containing them  
 INVENTOR(S): Shimizu, Kazuhiro; Koiwai, Kazutomo; Isozaki, Masashi  
 PATENT ASSIGNEE(S): Terumo Corp., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000319200	A2	20001121	JP 1999-129460	19990511
PRIORITY APPLN. INFO.:			JP 1999-129460	19990511

OTHER SOURCE(S): MARPAT 133:366436


AB This present invention relates to amidino compds. and use thereof as an ingredient for drug carriers in the forms of macromols., microaggregates, microparticles, microspheres, nanospheres, liposomes, or emulsions. For example, .alpha.-(5-cholesten-3.beta.-oxy)-4-amidinotoluene hydrochloride (prepn. given) 3, dipalmitoylphosphatidylcholine 2l, and cholesterol 6 .mu.mol were dissolved in 1 mL CHCl<sub>4</sub> to form lipoid membranes, to which 0.5 .mu.mol calcein in Tris buffer soln. was added to form liposome dispersion solns.

IT 2644-64-6

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (drug carriers contg. amidino compds. and phospholipids)

RN 2644-64-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L57 ANSWER 23 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:96098 CAPLUS

DOCUMENT NUMBER: 132:156841

TITLE: Novel phospholipids with synthetic, unsaturated alkyl and acyl chains

INVENTOR(S): Eibl, Hansjoerg; Hottkowitz, Thomas

PATENT ASSIGNEE(S): Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Germany

SOURCE: Ger. Offen., 86 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19835611	A1	20000210	DE 1998-19835611	19980806
CA 2339495	AA	20000217	CA 1999-2339495	19990806
WO 2000008031	A1	20000217	WO 1999-EP5710	19990806

W: CA, JP, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE

EP 1102775 A1 20010530 EP 1999-942816 19990806

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

JP 2002522442 T2 20020723 JP 2000-563664 19990806

PRIORITY APPLN. INFO.: DE 1998-19835611 A 19980806

WO 1999-EP5710 W 19990806

OTHER SOURCE(S): MARPAT 132:156841

AB The title phospholipids and phospholipid analogs AP(O)(O-)OB [A = R1OCH2CH(OR2)CH2O, R1OCH2CH(CH2OR2)O, R1OCH2(CH2)gCH2O, R1OCH2CH[(CH2)gH]O, OCH2CH(OR1)(CH2)gH, OCH2(CH2)pCH2CH:CH(CH2)qH, OCH2(CH2)sCH2CH:CHCH2(CH2)tCH2CH:CH(CH2)rH, R1, R2 = H, (un)satd. acyl or alkyl; g = 0-8; p, q, r, s, t .gtoreq.0; 12 .ltoreq. (p + q) .ltoreq. 30; 8 .ltoreq. (r + s + t) .ltoreq.26; B = [(CH2)nN+MeR3]m(CH2)x[CH2[CH(OH)]yC H2O]zH; R3 = (hydroxy-substituted) C1-3 alkyl; m = 0-2; n = 2-8; x = 0-8; y = 1-4; z = 0-5] are useful as constituents of liposomes to be used for drug delivery, as transport vehicles in gene therapy, or as solubilizing agents for water-insol. active agents. Unsatd. alkylphosphocholines are further useful as antitumor and antiprotozoal agents. The fatty acyl and fatty alkyl residues R1, R2, and A are prepd. from cyclic lactones by cleavage with a TMS halide, alcoholysis of the TMS ester, conversion of the halo carboxy ester with Ph3P to a phosphonium salt, reaction of the latter with an aldehyde and a base followed by sapon. to form a (Z)-fatty acid salt, and redn. if desired to an alkenol with LiAlH4. Thus, 1,6-dibromohexane reacted with PPh3 to form a bisphosphonium salt which underwent a Li-free Wittig reaction with Et 9-formylnonanoate followed by sapon. to form (Z,Z)-10,16-docosadien-1-ol, which was incorporated into (Z,Z)-10,16-docosadien-1-yl-1-phosphocholine. This compd. was highly effective at 84 or 170 .mu.mol/kg/wk in a std. test for antitumor activity.

IT 257908-36-4


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel phospholipids with synthetic, unsatd. alkyl and acyl chains)

RN 257908-36-4 CAPLUS

CN Ethanaminium, 2-[[[[(11Z)-11,21-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 119700-63-9 121045-76-9 139257-00-4  
148439-03-6 220755-87-3 220755-92-0  
220755-97-5 257908-37-5 257908-38-6  
257908-39-7 257908-40-0 257908-41-1  
257908-42-2 257908-43-3 257908-44-4  
257908-45-5 257908-46-6 257908-47-7  
257908-48-8 257908-49-9 257908-50-2  
257908-51-3 257908-52-4 257908-53-5  
257908-54-6 257908-55-7 257908-56-8  
257908-57-9 257908-58-0 257908-59-1  
257908-60-4 257908-61-5 257908-62-6  
257908-63-7 257908-64-8 257908-65-9  
257908-66-0 257908-67-1 257908-68-2  
257908-69-3 257908-70-6 257908-71-7

257908-72-8 257908-73-9 257908-74-0  
257908-75-1 257908-76-2 257908-77-3  
257908-78-4 257908-79-5 257908-80-8  
257908-81-9 257908-82-0 257908-83-1  
257908-84-2 257908-85-3 257908-86-4  
257908-87-5 257908-88-6 257908-90-0  
257908-92-2 257908-94-4 257908-95-5  
257908-96-6 257908-97-7 257908-98-8  
257908-99-9 257909-00-5 257909-01-6  
257909-02-7 257909-03-8 257909-04-9  
257909-05-0 257909-06-1 257909-07-2  
257909-08-3 257909-09-4 257909-10-7  
257909-11-8 257909-12-9 257909-13-0  
257909-14-1 257909-15-2 257909-16-3  
257909-17-4 257909-18-5 257909-19-6  
257909-20-9 257909-21-0 257909-22-1  
257909-23-2 257909-24-3 257909-25-4  
257909-26-5 257909-27-6 257909-28-7  
257909-29-8 257909-30-1 257909-31-2  
257909-32-3 257909-33-4 257909-34-5  
257909-35-6 257909-36-7 257909-37-8  
257909-38-9 257909-39-0 257909-40-3  
257909-41-4 257909-42-5 257909-43-6  
257909-44-7 257909-45-8 257909-46-9  
257909-47-0 257909-48-1 257909-49-2  
257909-50-5 257909-51-6 257909-52-7  
257909-53-8 257909-54-9 257909-55-0  
257909-56-1 257909-57-2 257909-58-3  
257909-59-4 257909-60-7 257909-61-8  
257909-62-9 257909-63-0 257909-64-1  
257909-65-2 257909-66-3 257909-67-4  
257909-68-5 257909-69-6 257909-70-9  
257909-71-0 257909-72-1 257909-73-2  
257909-74-3 257909-75-4 257909-76-5  
257909-77-6 257909-78-7 257909-79-8  
257909-80-1 257909-81-2 257909-82-3  
257909-83-4 257909-84-5 257909-85-6  
257909-86-7 257909-87-8 257909-88-9  
257909-89-0 257909-90-3 257909-91-4  
257909-92-5 257909-93-6 257909-94-7  
257909-96-9 257909-98-1 257909-99-2  
257910-00-2 257910-01-3 257910-02-4  
257910-03-5 257910-04-6 257910-05-7  
257910-06-8 257910-07-9 257910-08-0  
257910-09-1 257910-10-4 257910-11-5  
257910-12-6 257910-13-7 257910-14-8  
257910-15-9 257910-16-0 257910-17-1  
257910-18-2 257910-19-3 257910-20-6  
257910-21-7 257910-22-8 257910-23-9  
257910-24-0 257910-25-1 257910-26-2  
257910-27-3 257910-28-4 257910-29-5  
257910-30-8 257910-31-9 257910-32-0  
257910-33-1 257910-34-2 257910-35-3  
257910-36-4 257910-37-5 257910-38-6  
257910-39-7 257910-40-0 257910-41-1  
257910-42-2 257910-43-3 257910-44-4  
257910-45-5 257910-46-6 257910-47-7  
257910-48-8 257910-49-9 257910-50-2  
257910-51-3 257910-52-4 257910-53-5  
257910-54-6 257910-55-7 257910-56-8  
257910-57-9 257910-58-0 257910-59-1 25791  
0-60-4 257910-61-5 257910-62-6  
257910-63-7 257910-64-8 257910-65-9




257910-66-0 257910-67-1 257910-68-2  
 257910-69-3 257910-70-6 257910-71-7  
 257910-72-8 257910-73-9 257910-74-0

RL: PRP (Properties)

(novel phospholipids with synthetic, unsatd. alkyl and acyl chains)


RN 119700-63-9 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy(22-tricosenyloxy)phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 121045-76-9 CAPLUS


CN Ethanaminium, 2-[[hydroxy(22-tricosenyloxy)phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 139257-00-4 CAPLUS

CN Ethanaminium, 2-[[[(11Z)-11-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 148439-03-6 CAPLUS

CN Ethanaminium, 2-[[[(9Z)-9-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 220755-87-3 CAPLUS

CN 1-Propanaminium, 3-[[[(10Z)-10-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 220755-92-0 CAPLUS

CN 1-Butanaminium, 4-[[[(10Z)-10-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 220755-97-5 CAPLUS

CN 1-Butanaminium, 4-[[[(11Z)-11-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-37-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z)-14-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-38-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(15Z)-15-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-39-7 CAPLUS


CN Ethanaminium, 2-[[hydroxy[(16Z)-16-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257908-40-0 CAPLUS


CN Ethanaminium, 2-[[hydroxy(17-octadecenyl)phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257908-41-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z)-3-nonadecenyl]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-42-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z)-4-nonadecenyl]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-43-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z)-5-nonadecenyl]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-44-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z)-6-nonadecenyl]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-45-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z)-7-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-46-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z)-8-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-47-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z)-9-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-48-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z)-10-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-49-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z)-11-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-50-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z)-12-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-51-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z)-13-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-52-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z)-14-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-53-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(15Z)-15-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-54-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(16Z)-16-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-55-7 CAPLUS


CN Ethanaminium, 2-[[hydroxy[(17Z)-17-nonadecen-1-yloxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257908-56-8 CAPLUS


CN Ethanaminium, 2-[[hydroxy[(18Z)-18-nonadecen-1-yloxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257908-57-9 CAPLUS

CN Ethanaminium, 2-[[[[(3Z)-3-eicosen-1-yloxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-58-0 CAPLUS

CN Ethanaminium, 2-[[[[(4Z)-4-eicosen-1-yloxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-59-1 CAPLUS

CN Ethanaminium, 2-[[[[(5Z)-5-eicosen-1-yloxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-60-4 CAPLUS

CN Ethanaminium, 2-[[[(6Z)-6-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-61-5 CAPLUS

CN Ethanaminium, 2-[[[(7Z)-7-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-62-6 CAPLUS

CN Ethanaminium, 2-[[[(8Z)-8-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-63-7 CAPLUS

CN Ethanaminium, 2-[[[(10Z)-10-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-64-8 CAPLUS


CN Ethanaminium, 2-[[[(12Z)-12-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257908-65-9 CAPLUS  
 CN Ethanaminium, 2-[[[(13Z)-13-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257908-66-0 CAPLUS  
 CN Ethanaminium, 2-[[[(14Z)-14-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257908-67-1 CAPLUS  
 CN Ethanaminium, 2-[[[(15Z)-15-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257908-68-2 CAPLUS  
 CN Ethanaminium, 2-[[[(16Z)-16-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-69-3 CAPLUS  
 CN Ethanaminium, 2-[[[(17Z)-17-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257908-70-6 CAPLUS


CN Ethanaminium, 2-[[[(18Z)-18-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257908-71-7 CAPLUS


CN Ethanaminium, 2-[[[(19Z)-19-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257908-72-8 CAPLUS

CN Ethanaminium, 2-[[[(3Z)-3-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-73-9 CAPLUS

CN Ethanaminium, 2-[[[(4Z)-4-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-74-0 CAPLUS

CN Ethanaminium, 2-[[[(5Z)-5-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-75-1 CAPLUS

CN Ethanaminium, 2-[[[(6Z)-6-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-76-2 CAPLUS

CN Ethanaminium, 2-[[[(7Z)-7-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-77-3 CAPLUS

CN Ethanaminium, 2-[[[(8Z)-8-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-78-4 CAPLUS

CN Ethanaminium, 2-[[[(9Z)-9-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-79-5 CAPLUS

CN Ethanaminium, 2-[[[(10Z)-10-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-80-8 CAPLUS

CN Ethanaminium, 2-[[[(11Z)-11-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-81-9 CAPLUS

CN Ethanaminium, 2-[[[(12Z)-12-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-82-0 CAPLUS

CN Ethanaminium, 2-[[[(13Z)-13-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-83-1 CAPLUS

CN Ethanaminium, 2-[[[(14Z)-14-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-84-2 CAPLUS

CN Ethanaminium, 2-[[[(15Z)-15-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-85-3 CAPLUS

CN Ethanaminium, 2-[[[(16Z)-16-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-86-4 CAPLUS

CN Ethanaminium, 2-[[[(17Z)-17-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-87-5 CAPLUS

CN Ethanaminium, 2-[[[(18Z)-18-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-88-6 CAPLUS


CN Ethanaminium, 2-[[[(19Z)-19-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257908-90-0 CAPLUS


CN Ethanaminium, 2-[[[(20-heneicosenyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257908-92-2 CAPLUS

CN Ethanaminium, 2-[[[(3Z)-3-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-94-4 CAPLUS

CN Ethanaminium, 2-[[[(4Z)-4-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-95-5 CAPLUS

CN Ethanaminium, 2-[[[(5Z)-5-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-96-6 CAPLUS

CN Ethanaminium, 2-[[[(6Z)-6-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-97-7 CAPLUS

CN Ethanaminium, 2-[[[(7Z)-7-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-98-8 CAPLUS

CN Ethanaminium, 2-[[[(8Z)-8-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257908-99-9 CAPLUS

CN Ethanaminium, 2-[[[(9Z)-9-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-00-5 CAPLUS

CN Ethanaminium, 2-[[[(10Z)-10-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-01-6 CAPLUS

CN Ethanaminium, 2-[[[(11Z)-11-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-02-7 CAPLUS

CN Ethanaminium, 2-[[[(12Z)-12-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-03-8 CAPLUS

CN Ethanaminium, 2-[[[(14Z)-14-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-04-9 CAPLUS

CN Ethanaminium, 2-[[[(15Z)-15-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-05-0 CAPLUS

CN Ethanaminium, 2-[[[(16Z)-16-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-06-1 CAPLUS

CN Ethanaminium, 2-[[[(17Z)-17-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-07-2 CAPLUS

CN Ethanaminium, 2-[[[(18Z)-18-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-08-3 CAPLUS

CN Ethanaminium, 2-[[[(19Z)-19-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-09-4 CAPLUS


CN Ethanaminium, 2-[[[(20Z)-20-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257909-10-7 CAPLUS


CN Ethanaminium, 2-[[[(21Z)-21-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257909-11-8 CAPLUS

CN Ethanaminium, 2-[[[hydroxy[(3Z)-3-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257909-12-9 CAPLUS

CN Ethanaminium, 2-[[[hydroxy[(4Z)-4-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257909-13-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z)-5-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-14-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z)-6-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-15-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z)-7-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-16-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z)-8-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-17-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z)-9-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-18-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z)-10-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-19-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z)-11-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-20-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z)-12-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-21-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z)-13-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-22-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z)-14-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-23-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(15Z)-15-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-24-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(16Z)-16-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-25-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(17Z)-17-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-26-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(18Z)-18-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-27-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(19Z)-19-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-28-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(20Z)-20-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-29-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(21Z)-21-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-30-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z)-3-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-31-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z)-4-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-32-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z)-5-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-33-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z)-6-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-34-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z)-7-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-35-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z)-8-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-36-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z)-9-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-37-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z)-10-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-38-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z)-11-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-39-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z)-12-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-40-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z)-13-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-41-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z)-14-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-42-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(16Z)-16-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-43-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(17Z)-17-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-44-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(18Z)-18-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-45-8 CAPLUS

CN 1-Propanaminium, 3-[[[(3Z)-3-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-46-9 CAPLUS

CN 1-Propanaminium, 3-[[[(4Z)-4-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-47-0 CAPLUS

CN 1-Propanaminium, 3-[[[(5Z)-5-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-48-1 CAPLUS

CN 1-Propanaminium, 3-[[[(6Z)-6-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-49-2 CAPLUS

CN 1-Propanaminium, 3-[[[(7Z)-7-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-50-5 CAPLUS

CN 1-Propanaminium, 3-[[[(8Z)-8-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-51-6 CAPLUS

CN 1-Propanaminium, 3-[[[(9Z)-9-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257909-52-7 CAPLUS

CN 1-Propanaminium, 3-[[[(10Z)-10-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)




Double bond geometry as shown.



RN 257909-53-8 CAPLUS

CN 1-Propanaminium, 3-[[[(11Z)-11-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-54-9 CAPLUS

CN 1-Propanaminium, 3-[[[(12Z)-12-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-55-0 CAPLUS

CN 1-Propanaminium, 3-[[[(13Z)-13-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-56-1 CAPLUS


CN 1-Propanaminium, 3-[[[(14Z)-14-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257909-57-2 CAPLUS


CN 1-Propanaminium, 3-[[[(15-hexadecenyl)oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257909-58-3 CAPLUS

CN 1-Propanaminium, 3-[[[(3Z)-3-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-59-4 CAPLUS

CN 1-Propanaminium, 3-[[[(4Z)-4-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-60-7 CAPLUS

CN 1-Propanaminium, 3-[[[(5Z)-5-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-61-8 CAPLUS

CN 1-Propanaminium, 3-[[[(6Z)-6-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-62-9 CAPLUS

CN 1-Propanaminium, 3-[[[(7Z)-7-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-63-0 CAPLUS

CN 1-Propanaminium, 3-[[[(8Z)-8-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-64-1 CAPLUS

CN 1-Propanaminium, 3-[[[(9Z)-9-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-65-2 CAPLUS

CN 1-Propanaminium, 3-[[[(10Z)-10-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-66-3 CAPLUS

CN 1-Propanaminium, 3-[[[(11Z)-11-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-67-4 CAPLUS

CN 1-Propanaminium, 3-[[[(12Z)-12-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-68-5 CAPLUS

CN 1-Propanaminium, 3-[[[(13Z)-13-heptadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-69-6 CAPLUS

CN 1-Propanaminium, 3-[[[(14Z)-14-heptadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-70-9 CAPLUS


CN 1-Propanaminium, 3-[[[(15Z)-15-heptadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257909-71-0 CAPLUS


CN 1-Propanaminium, 3-[[[16-heptadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257909-72-1 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(3Z)-3-octadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-73-2 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(4Z)-4-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-74-3 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(5Z)-5-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-75-4 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(6Z)-6-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-76-5 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(7Z)-7-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-77-6 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(8Z)-8-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-78-7 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(10Z)-10-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-79-8 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(11Z)-11-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-80-1 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(12Z)-12-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-81-2 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(13Z)-13-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-82-3 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(14Z)-14-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-83-4 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(15Z)-15-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-84-5 CAPLUS


CN 1-Propanaminium, 3-[[hydroxy[(16Z)-16-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257909-85-6 CAPLUS


CN 1-Propanaminium, 3-[[hydroxy[(17Z)-17-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257909-86-7 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(3Z)-3-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-87-8 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(4Z)-4-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-88-9 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(5Z)-5-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-89-0 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(6Z)-6-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-90-3 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(7Z)-7-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-91-4 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(8Z)-8-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257909-92-5 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(9Z)-9-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)




Double bond geometry as shown.



RN 257909-93-6 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(10Z)-10-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-94-7 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(11Z)-11-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-96-9 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(12Z)-12-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-98-1 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(13Z)-13-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257909-99-2 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(14Z)-14-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-00-2 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(15Z)-15-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-01-3 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(16Z)-16-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-02-4 CAPLUS


CN 1-Propanaminium, 3-[[hydroxy[(17Z)-17-nonadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257910-03-5 CAPLUS


CN 1-Propanaminium, 3-[[hydroxy(18-nonadecenyl)phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257910-04-6 CAPLUS

CN 1-Propanaminium, 3-[[[[(3Z)-3-eicosenyl]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-05-7 CAPLUS

CN 1-Propanaminium, 3-[[[(4Z)-4-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-06-8 CAPLUS

CN 1-Propanaminium, 3-[[[(5Z)-5-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-07-9 CAPLUS

CN 1-Propanaminium, 3-[[[(6Z)-6-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-08-0 CAPLUS

CN 1-Propanaminium, 3-[[[(7Z)-7-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-09-1 CAPLUS

CN 1-Propanaminium, 3-[[[(8Z)-8-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-10-4 CAPLUS

CN 1-Propanaminium, 3-[[[(9Z)-9-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-11-5 CAPLUS

CN 1-Propanaminium, 3-[[[(10Z)-10-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-12-6 CAPLUS

CN 1-Propanaminium, 3-[[[(12Z)-12-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-13-7 CAPLUS

CN 1-Propanaminium, 3-[[[(13Z)-13-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-14-8 CAPLUS

CN 1-Propanaminium, 3-[[[(14Z)-14-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-15-9 CAPLUS

CN 1-Propanaminium, 3-[[[(15Z)-15-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-16-0 CAPLUS

CN 1-Propanaminium, 3-[[[(16Z)-16-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-17-1 CAPLUS

CN 1-Propanaminium, 3-[[[(17Z)-17-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-18-2 CAPLUS


CN 1-Propanaminium, 3-[[[(18Z)-18-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257910-19-3 CAPLUS


CN 1-Propanaminium, 3-[[[(19-eicosenyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257910-20-6 CAPLUS

CN 1-Propanaminium, 3-[[[(3Z)-3-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-21-7 CAPLUS

CN 1-Propanaminium, 3-[[[(4Z)-4-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-22-8 CAPLUS

CN 1-Propanaminium, 3-[[[(5Z)-5-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-23-9 CAPLUS

CN 1-Propanaminium, 3-[[[(6Z)-6-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-24-0 CAPLUS

CN 1-Propanaminium, 3-[[[(7Z)-7-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-25-1 CAPLUS

CN 1-Propanaminium, 3-[[[(8Z)-8-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-26-2 CAPLUS

CN 1-Propanaminium, 3-[[[(9Z)-9-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-27-3 CAPLUS

CN 1-Propanaminium, 3-[[[(10Z)-10-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-28-4 CAPLUS

CN 1-Propanaminium, 3-[[[(11Z)-11-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-29-5 CAPLUS

CN 1-Propanaminium, 3-[[[(12Z)-12-heneicosenyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-30-8 CAPLUS

CN 1-Propanaminium, 3-[[[(13Z)-13-heneicosenyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-31-9 CAPLUS

CN 1-Propanaminium, 3-[[[(14Z)-14-heneicosenyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-32-0 CAPLUS

CN 1-Propanaminium, 3-[[[(15Z)-15-heneicosenyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-33-1 CAPLUS

CN 1-Propanaminium, 3-[[[(16Z)-16-heneicosenyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257910-34-2 CAPLUS

CN 1-Propanaminium, 3-[[[(17Z)-17-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-35-3 CAPLUS

CN 1-Propanaminium, 3-[[[(18Z)-18-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-36-4 CAPLUS


CN 1-Propanaminium, 3-[[[(19Z)-19-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257910-37-5 CAPLUS


CN 1-Propanaminium, 3-[[[(20-heneicosenyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257910-38-6 CAPLUS

CN 1-Propanaminium, 3-[[[(3Z)-3-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-39-7 CAPLUS

CN 1-Propanaminium, 3-[[[(4Z)-4-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-40-0 CAPLUS

CN 1-Propanaminium, 3-[[[(5Z)-5-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-41-1 CAPLUS

CN 1-Propanaminium, 3-[[[(6Z)-6-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-42-2 CAPLUS

CN 1-Propanaminium, 3-[[[(7Z)-7-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-43-3 CAPLUS

CN 1-Propanaminium, 3-[[[(8Z)-8-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-44-4 CAPLUS

CN 1-Propanaminium, 3-[[[(9Z)-9-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-45-5 CAPLUS

CN 1-Propanaminium, 3-[[[(11Z)-11-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-46-6 CAPLUS

CN 1-Propanaminium, 3-[[[(12Z)-12-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-47-7 CAPLUS

CN 1-Propanaminium, 3-[[[(14Z)-14-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-48-8 CAPLUS

CN 1-Propanaminium, 3-[[[(15Z)-15-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-49-9 CAPLUS

CN 1-Propanaminium, 3-[[[(16Z)-16-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-50-2 CAPLUS

CN 1-Propanaminium, 3-[[[(17Z)-17-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-51-3 CAPLUS

CN 1-Propanaminium, 3-[[[(18Z)-18-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-52-4 CAPLUS

CN 1-Propanaminium, 3-[[[(19Z)-19-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-53-5 CAPLUS


CN 1-Propanaminium, 3-[[[(20Z)-20-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257910-54-6 CAPLUS


CN 1-Propanaminium, 3-[[[(21-docosenyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257910-55-7 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(3Z)-3-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-56-8 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(4Z)-4-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-57-9 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(5Z)-5-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-58-0 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(6Z)-6-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-59-1 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(7Z)-7-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-60-4 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(8Z)-8-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-61-5 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(9Z)-9-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-62-6 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(10Z)-10-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-63-7 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(11Z)-11-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-64-8 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(12Z)-12-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-65-9 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(13Z)-13-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-66-0 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(14Z)-14-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-67-1 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(15Z)-15-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-68-2 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(16Z)-16-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-69-3 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(17Z)-17-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-70-6 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(18Z)-18-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-71-7 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(19Z)-19-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-72-8 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(20Z)-20-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257910-73-9 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(21Z)-21-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257910-74-0 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(3Z)-3-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 257910-75-1 257910-76-2 257910-77-3  
 257910-78-4 257910-79-5 257910-80-8  
 257910-81-9 257910-82-0 257910-83-1  
 257910-84-2 257910-85-3 257910-86-4  
 257910-87-5 257910-88-6 257910-89-7  
 257910-90-0 257910-91-1 257910-92-2  
 257910-93-3 257910-94-4 257910-95-5  
 257910-96-6 257910-97-7 257910-98-8  
 257910-99-9 257911-00-5 257911-01-6  
 257911-02-7 257911-03-8 257911-04-9  
 257911-05-0 257911-06-1 257911-07-2  
 257911-08-3 257911-09-4 257911-10-7  
 257911-11-8 257911-12-9 257911-13-0  
 257911-14-1 257911-15-2 257911-16-3  
 257911-17-4 257911-18-5 257911-19-6  
 257911-20-9 257911-21-0 257911-22-1  
 257911-23-2 257911-24-3 257911-25-4  
 257911-26-5 257911-27-6 257911-28-7  
 257911-29-8 257911-30-1 257911-31-2  
 257911-32-3 257911-33-4 257911-34-5  
 257911-35-6 257911-36-7 257911-37-8  
 257911-38-9 257911-39-0 257911-40-3  
 257911-41-4 257911-42-5 257911-43-6  
 257911-44-7 257911-45-8 257911-46-9  
 257911-47-0 257911-48-1 257911-49-2  
 257911-50-5 257911-51-6 257911-52-7  
 257911-53-8 257911-54-9 257911-55-0  
 257911-56-1 257911-57-2 257911-58-3  
 257911-59-4 257911-60-7 257911-61-8  
 257911-62-9 257911-63-0 257911-64-1  
 257911-65-2 257911-66-3 257911-67-4  
 257911-68-5 257911-69-6 257911-70-9  
 257911-71-0 257911-72-1 257911-73-2  
 257911-74-3 257911-75-4 257911-76-5  
 257911-77-6 257911-78-7 257911-79-8  
 257911-80-1 257911-81-2 257911-82-3  
 257911-83-4 257911-84-5 257911-85-6  
 257911-86-7 257911-87-8 257911-88-9  
 257911-89-0 257911-90-3 257911-91-4  
 257911-92-5 257911-93-6 257911-94-7  
 257911-95-8 257911-96-9 257911-97-0  
 257911-98-1 257911-99-2 257912-00-8  
 257912-01-9 257912-02-0 257912-03-1  
 257912-04-2 257912-05-3 257912-06-4  
 257912-07-5 257912-08-6 257912-09-7

257912-10-0 257912-11-1 257912-12-2  
257912-13-3 257912-14-4 257912-15-5  
257912-16-6 257912-17-7 257912-18-8  
257912-19-9 257912-20-2 257912-21-3  
257912-22-4 257912-23-5 257912-24-6  
257912-25-7 257912-26-8 257912-27-9  
257912-28-0 257912-29-1 257912-30-4  
257912-31-5 257912-32-6 257912-33-7  
257912-34-8 257912-35-9 257912-36-0  
257912-37-1 257912-38-2 257912-39-3  
257912-40-6 257912-41-7 257912-42-8  
257912-43-9 257912-44-0 257912-45-1  
257912-46-2 257912-47-3 257912-48-4  
257912-49-5 257912-50-8 257912-51-9  
257912-52-0 257912-53-1 257912-54-2  
257912-55-3 257912-56-4 257912-57-5  
257912-58-6 257912-59-7 257912-60-0  
257912-61-1 257912-62-2 257912-63-3  
257912-64-4 257912-65-5 257912-66-6  
257912-67-7 257912-68-8 257912-69-9  
257912-70-2 257912-71-3 257912-72-4  
257912-73-5 257912-74-6 257912-75-7  
257912-76-8 257912-77-9 257912-78-0  
257912-79-1 257912-80-4 257912-81-5  
257912-82-6 257912-83-7 257912-84-8  
257912-85-9 257912-86-0 257912-87-1  
257912-88-2 257912-89-3 257912-90-6  
257912-91-7 257912-92-8 257912-93-9  
257912-94-0 257912-95-1 257912-96-2  
257912-97-3 257912-98-4 257912-99-5 25791  
3-00-1 257913-01-2 257913-02-3  
257913-03-4 257913-04-5 257913-05-6  
257913-06-7 257913-07-8 257913-08-9  
257913-09-0 257913-10-3 257913-11-4  
257913-12-5 257913-13-6 257913-14-7


RL: PRP (Properties)

(novel phospholipids with synthetic, unsatd. alkyl and acyl chains)

RN 257910-75-1 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(4Z)-4-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-76-2 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(5Z)-5-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-77-3 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(6Z)-6-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-78-4 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(7Z)-7-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-79-5 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(8Z)-8-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-80-8 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(9Z)-9-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-81-9 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(10Z)-10-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-82-0 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(11Z)-11-tetracosenyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-83-1 CAPLUS

CN - 1-Propanaminium, 3-[[hydroxy[(12Z)-12-tetracosenyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-84-2 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(13Z)-13-tetracosenyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-85-3 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(14Z)-14-tetracosenyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-86-4 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(15Z)-15-tetracosenyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-87-5 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(16Z)-16-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-88-6 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(17Z)-17-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-89-7 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(18Z)-18-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-90-0 CAPLUS

CN 1-Butanaminium, 4-[[[(3Z)-3-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257910-91-1 CAPLUS

CN 1-Butanaminium, 4-[[[(4Z)-4-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-92-2 CAPLUS

CN 1-Butanaminium, 4-[[[(5Z)-5-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-93-3 CAPLUS

CN 1-Butanaminium, 4-[[[(6Z)-6-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-94-4 CAPLUS

CN 1-Butanaminium, 4-[[[(7Z)-7-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-95-5 CAPLUS

CN 1-Butanaminium, 4-[[[(8Z)-8-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-96-6 CAPLUS

CN 1-Butanaminium, 4-[[[(9Z)-9-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-97-7 CAPLUS

CN 1-Butanaminium, 4-[[[(10Z)-10-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-98-8 CAPLUS

CN 1-Butanaminium, 4-[[[(11Z)-11-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257910-99-9 CAPLUS

CN 1-Butanaminium, 4-[[[(12Z)-12-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-00-5 CAPLUS

CN 1-Butanaminium, 4-[[[(13Z)-13-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-01-6 CAPLUS


CN 1-Butanaminium, 4-[[[(14Z)-14-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257911-02-7 CAPLUS


CN 1-Butanaminium, 4-[[[(15-hexadecenyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257911-03-8 CAPLUS

CN 1-Butanaminium, 4-[[[(3Z)-3-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-04-9 CAPLUS

CN 1-Butanaminium, 4-[[[(4Z)-4-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-05-0 CAPLUS

CN 1-Butanaminium, 4-[[[(5Z)-5-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257911-06-1 CAPLUS

CN 1-Butanaminium, 4-[[[(6Z)-6-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-



trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-07-2 CAPLUS

CN 1-Butanaminium, 4-[[[(7Z)-7-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-08-3 CAPLUS

CN 1-Butanaminium, 4-[[[(8Z)-8-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-09-4 CAPLUS

CN 1-Butanaminium, 4-[[[(9Z)-9-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-10-7 CAPLUS

CN 1-Butanaminium, 4-[[[(10Z)-10-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-11-8 CAPLUS

CN 1-Butanaminium, 4-[[[(11Z)-11-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-12-9 CAPLUS

CN 1-Butanaminium, 4-[[[(12Z)-12-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-13-0 CAPLUS

CN 1-Butanaminium, 4-[[[(13Z)-13-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-14-1 CAPLUS

CN 1-Butanaminium, 4-[[[(14Z)-14-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-15-2 CAPLUS

CN 1-Butanaminium, 4-[[[(15Z)-15-heptadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-16-3 CAPLUS

CN 1-Butanaminium, 4-[[[(16-heptadecenyloxy)hydroxyphosphinyl]oxy]-N,N,N-


trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257911-17-4 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(3Z)-3-octadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-18-5 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(4Z)-4-octadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-19-6 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(5Z)-5-octadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-20-9 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(6Z)-6-octadecenyl]oxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257911-21-0 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(7Z)-7-octadecenyl]oxy]phosphinyl]oxy]-N,N,N-

trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-22-1 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(8Z)-8-octadecenyl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-23-2 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(10Z)-10-octadecenyl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-24-3 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(11Z)-11-octadecenyl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-25-4 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(12Z)-12-octadecenyl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-26-5 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(13Z)-13-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-27-6 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(14Z)-14-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-28-7 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(15Z)-15-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-29-8 CAPLUS


CN 1-Butanaminium, 4-[[hydroxy[(16Z)-16-octadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257911-30-1 CAPLUS


CN 1-Butanaminium, 4-[[hydroxy(17-octadecenyloxy)phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257911-31-2 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(3Z)-3-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-32-3 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(4Z)-4-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-33-4 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(5Z)-5-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-34-5 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(6Z)-6-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-35-6 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(7Z)-7-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257911-36-7 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(8Z)-8-nonadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-37-8 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(9Z)-9-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-38-9 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(10Z)-10-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-39-0 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(11Z)-11-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-40-3 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(12Z)-12-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-41-4 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(13Z)-13-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-42-5 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(14Z)-14-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-43-6 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(15Z)-15-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-44-7 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(16Z)-16-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-45-8 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(17Z)-17-nonadecenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257911-46-9 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy(18-nonadecenyloxy)phosphinyl]oxy]-N,N,N-




trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257911-47-0 CAPLUS

CN 1-Butanaminium, 4-[[[(3Z)-3-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-48-1 CAPLUS

CN 1-Butanaminium, 4-[[[(4Z)-4-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-49-2 CAPLUS

CN 1-Butanaminium, 4-[[[(5Z)-5-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-50-5 CAPLUS

CN 1-Butanaminium, 4-[[[(6Z)-6-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257911-51-6 CAPLUS

CN 1-Butanaminium, 4-[[[(7Z)-7-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-

trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-52-7 CAPLUS

CN 1-Butanaminium, 4-[[[(8Z)-8-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-53-8 CAPLUS

CN 1-Butanaminium, 4-[[[(9Z)-9-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-54-9 CAPLUS

CN 1-Butanaminium, 4-[[[(10Z)-10-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-55-0 CAPLUS

CN 1-Butanaminium, 4-[[[(12Z)-12-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-56-1 CAPLUS

CN 1-Butanaminium, 4-[[[(13Z)-13-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-57-2 CAPLUS

CN 1-Butanaminium, 4-[[[(14Z)-14-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-58-3 CAPLUS

CN 1-Butanaminium, 4-[[[(15Z)-15-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-59-4 CAPLUS

CN 1-Butanaminium, 4-[[[(16Z)-16-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-60-7 CAPLUS

CN 1-Butanaminium, 4-[[[(17Z)-17-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-61-8 CAPLUS


CN 1-Butanaminium, 4-[[[(18Z)-18-eicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257911-62-9 CAPLUS


CN 1-Butanaminium, 4-[[[(19-eicosenyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257911-63-0 CAPLUS

CN 1-Butanaminium, 4-[[[(3Z)-3-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-64-1 CAPLUS

CN 1-Butanaminium, 4-[[[(4Z)-4-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-65-2 CAPLUS

CN 1-Butanaminium, 4-[[[(5Z)-5-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257911-66-3 CAPLUS

CN 1-Butanaminium, 4-[[[(6Z)-6-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-

trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-67-4 CAPLUS

CN 1-Butanaminium, 4-[[[(7Z)-7-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-68-5 CAPLUS

CN 1-Butanaminium, 4-[[[(8Z)-8-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-69-6 CAPLUS

CN 1-Butanaminium, 4-[[[(9Z)-9-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-70-9 CAPLUS

CN 1-Butanaminium, 4-[[[(10Z)-10-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-71-0 CAPLUS

CN 1-Butanaminium, 4-[[[(11Z)-11-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-72-1 CAPLUS

CN 1-Butanaminium, 4-[[[(12Z)-12-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-73-2 CAPLUS

CN 1-Butanaminium, 4-[[[(13Z)-13-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-74-3 CAPLUS

CN 1-Butanaminium, 4-[[[(14Z)-14-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-75-4 CAPLUS

CN 1-Butanaminium, 4-[[[(15Z)-15-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-76-5 CAPLUS

CN 1-Butanaminium, 4-[[[(16Z)-16-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-77-6 CAPLUS

CN 1-Butanaminium, 4-[[[(17Z)-17-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-78-7 CAPLUS

CN 1-Butanaminium, 4-[[[(18Z)-18-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-79-8 CAPLUS


CN 1-Butanaminium, 4-[[[(19Z)-19-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257911-80-1 CAPLUS


CN 1-Butanaminium, 4-[[[(20-heneicosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257911-81-2 CAPLUS

CN 1-Butanaminium, 4-[[[(3Z)-3-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-82-3 CAPLUS

CN 1-Butanaminium, 4-[[[(4Z)-4-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-83-4 CAPLUS

CN 1-Butanaminium, 4-[[[(5Z)-5-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-84-5 CAPLUS

CN 1-Butanaminium, 4-[[[(6Z)-6-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257911-85-6 CAPLUS

CN 1-Butanaminium, 4-[[[(7Z)-7-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)




Double bond geometry as shown.



RN 257911-86-7 CAPLUS

CN 1-Butanaminium, 4-[[[(8Z)-8-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-87-8 CAPLUS

CN 1-Butanaminium, 4-[[[(9Z)-9-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-88-9 CAPLUS

CN 1-Butanaminium, 4-[[[(11Z)-11-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-89-0 CAPLUS

CN 1-Butanaminium, 4-[[[(12Z)-12-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257911-90-3 CAPLUS

CN 1-Butanaminium, 4-[[[(14Z)-14-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-

trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-91-4 CAPLUS

CN 1-Butanaminium, 4-[[[(15Z)-15-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-92-5 CAPLUS

CN 1-Butanaminium, 4-[[[(16Z)-16-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-93-6 CAPLUS

CN 1-Butanaminium, 4-[[[(17Z)-17-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-94-7 CAPLUS

CN 1-Butanaminium, 4-[[[(18Z)-18-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257911-95-8 CAPLUS

CN 1-Butanaminium, 4-[[[(19Z)-19-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-

trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-96-9 CAPLUS


CN 1-Butanaminium, 4-[[[(20Z)-20-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257911-97-0 CAPLUS


CN 1-Butanaminium, 4-[[[(21Z)-21-docosenyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257911-98-1 CAPLUS

CN 1-Butanaminium, 4-[[[hydroxy[(3Z)-3-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257911-99-2 CAPLUS

CN 1-Butanaminium, 4-[[[hydroxy[(4Z)-4-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-00-8 CAPLUS

CN 1-Butanaminium, 4-[[[hydroxy[(5Z)-5-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-01-9 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(6Z)-6-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-02-0 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(7Z)-7-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-03-1 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(8Z)-8-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-04-2 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(9Z)-9-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257912-05-3 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(10Z)-10-tricosenyloxy]phosphinyl]oxy]-N,N,N-

trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-06-4 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(11Z)-11-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-07-5 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(12Z)-12-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-08-6 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(13Z)-13-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-09-7 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(14Z)-14-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-10-0 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(15Z)-15-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-11-1 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(16Z)-16-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-12-2 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(17Z)-17-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-13-3 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(18Z)-18-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-14-4 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(19Z)-19-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-15-5 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(20Z)-20-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-16-6 CAPLUS


CN 1-Butanaminium, 4-[[hydroxy[(21Z)-21-tricosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257912-17-7 CAPLUS


CN 1-Butanaminium, 4-[[hydroxy(22-tricosenyloxy)phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257912-18-8 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(3Z)-3-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-19-9 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(4Z)-4-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257912-20-2 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(5Z)-5-tetracosenyloxy]phosphinyl]oxy]-N,N,N-

trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-21-3 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(6Z)-6-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-22-4 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(7Z)-7-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-23-5 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(8Z)-8-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-24-6 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(9Z)-9-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.






RN 257912-25-7 CAPLUS  
CN 1-Butanaminium, 4-[[hydroxy[(10Z)-10-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257912-26-8 CAPLUS  
CN 1-Butanaminium, 4-[[hydroxy[(11Z)-11-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257912-27-9 CAPLUS  
CN 1-Butanaminium, 4-[[hydroxy[(12Z)-12-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257912-28-0 CAPLUS  
CN 1-Butanaminium, 4-[[hydroxy[(13Z)-13-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257912-29-1 CAPLUS  
CN 1-Butanaminium, 4-[[hydroxy[(14Z)-14-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-30-4 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(15Z)-15-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-31-5 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(16Z)-16-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-32-6 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(17Z)-17-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-33-7 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(18Z)-18-tetracosenyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-34-8 CAPLUS

CN Ethanaminium, 2-[[[(3Z,7Z)-3,7-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-35-9 CAPLUS

CN Ethanaminium, 2-[[[(4Z,8Z)-4,8-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-36-0 CAPLUS

CN Ethanaminium, 2-[[[(5Z,9Z)-5,9-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-37-1 CAPLUS

CN Ethanaminium, 2-[[[(6Z,10Z)-6,10-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-38-2 CAPLUS

CN Ethanaminium, 2-[[[(7Z,11Z)-7,11-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-39-3 CAPLUS


CN Ethanaminium, 2-[[[(8Z,12Z)-8,12-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257912-40-6 CAPLUS  
 CN Ethanaminium, 2-[[[(9Z,13Z)-9,13-hexadecadienyloxy]hydroxyphosphinyl]oxy]-  
 N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257912-41-7 CAPLUS  
 CN Ethanaminium, 2-[[[(3Z,8Z)-3,8-hexadecadienyloxy]hydroxyphosphinyl]oxy]-  
 N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257912-42-8 CAPLUS  
 CN Ethanaminium, 2-[[[(4Z,9Z)-4,9-hexadecadienyloxy]hydroxyphosphinyl]oxy]-  
 N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257912-43-9 CAPLUS  
 CN Ethanaminium, 2-[[[(5Z,10Z)-5,10-hexadecadienyloxy]hydroxyphosphinyl]oxy]-  
 N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257912-44-0 CAPLUS  
 CN Ethanaminium, 2-[[[(6Z,11Z)-6,11-hexadecadienyloxy]hydroxyphosphinyl]oxy]-  
 N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-45-1 CAPLUS

CN Ethanaminium, 2-[[[(7Z,12Z)-7,12-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-46-2 CAPLUS

CN Ethanaminium, 2-[[[(8Z,13Z)-8,13-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-47-3 CAPLUS

CN Ethanaminium, 2-[[[(3Z,9Z)-3,9-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-48-4 CAPLUS

CN Ethanaminium, 2-[[[(4Z,10Z)-4,10-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-49-5 CAPLUS

CN Ethanaminium, 2-[[[(5Z,11Z)-5,11-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-50-8 CAPLUS

CN Ethanaminium, 2-[[[(6Z,12Z)-6,12-hexadecadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-51-9 CAPLUS

CN Ethanaminium, 2-[[[(7Z,13Z)-7,13-hexadecadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-52-0 CAPLUS

CN Ethanaminium, 2-[[[(3Z,10Z)-3,10-hexadecadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-53-1 CAPLUS

CN Ethanaminium, 2-[[[(4Z,11Z)-4,11-hexadecadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-54-2 CAPLUS

CN Ethanaminium, 2-[[[(5Z,12Z)-5,12-hexadecadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-55-3 CAPLUS

CN Ethanaminium, 2-[[[(6Z,13Z)-6,13-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-56-4 CAPLUS

CN Ethanaminium, 2-[[[(3Z,11Z)-3,11-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-57-5 CAPLUS

CN Ethanaminium, 2-[[[(4Z,12Z)-4,12-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-58-6 CAPLUS

CN Ethanaminium, 2-[[[(5Z,13Z)-5,13-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-59-7 CAPLUS

CN Ethanaminium, 2-[[[(3Z,12Z)-3,12-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-60-0 CAPLUS

CN Ethanaminium, 2-[[[(4Z,13Z)-4,13-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-61-1 CAPLUS

CN Ethanaminium, 2-[[[(3Z,13Z)-3,13-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-62-2 CAPLUS

CN Ethanaminium, 2-[[[(3Z,7Z)-3,7-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-63-3 CAPLUS

CN Ethanaminium, 2-[[[(4Z,8Z)-4,8-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257912-64-4 CAPLUS

CN Ethanaminium, 2-[[[(5Z,9Z)-5,9-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257912-65-5 CAPLUS

CN Ethanaminium, 2-[[[(6Z,10Z)-6,10-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-66-6 CAPLUS

CN Ethanaminium, 2-[[[(7Z,11Z)-7,11-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-67-7 CAPLUS

CN Ethanaminium, 2-[[[(8Z,12Z)-8,12-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-68-8 CAPLUS

CN Ethanaminium, 2-[[[(9Z,13Z)-9,13-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-69-9 CAPLUS

CN Ethanaminium, 2-[[[(10Z,14Z)-10,14-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-70-2 CAPLUS

CN Ethanaminium, 2-[[[(3Z,8Z)-3,8-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-71-3 CAPLUS

CN Ethanaminium, 2-[[[(4Z,9Z)-4,9-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-72-4 CAPLUS

CN Ethanaminium, 2-[[[(5Z,10Z)-5,10-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-73-5 CAPLUS

CN Ethanaminium, 2-[[[(6Z,11Z)-6,11-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-74-6 CAPLUS

CN Ethanaminium, 2-[[[(7Z,12Z)-7,12-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-75-7 CAPLUS

CN Ethanaminium, 2-[[[(8Z,13Z)-8,13-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-76-8 CAPLUS

CN Ethanaminium, 2-[[[(9Z,14Z)-9,14-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-77-9 CAPLUS

CN Ethanaminium, 2-[[[(3Z,9Z)-3,9-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-78-0 CAPLUS

CN Ethanaminium, 2-[[[(4Z,10Z)-4,10-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-79-1 CAPLUS

CN Ethanaminium, 2-[[[(5Z,11Z)-5,11-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-80-4 CAPLUS

CN Ethanaminium, 2-[[[(6Z,12Z)-6,12-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-81-5 CAPLUS

CN Ethanaminium, 2-[[[(7Z,13Z)-7,13-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-82-6 CAPLUS

CN Ethanaminium, 2-[[[(8Z,14Z)-8,14-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-83-7 CAPLUS

CN Ethanaminium, 2-[[[(3Z,10Z)-3,10-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-84-8 CAPLUS

CN Ethanaminium, 2-[[[(4Z,11Z)-4,11-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-85-9 CAPLUS

CN Ethanaminium, 2-[[[(5Z,12Z)-5,12-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-86-0 CAPLUS

CN Ethanaminium, 2-[[[(6Z,13Z)-6,13-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-87-1 CAPLUS

CN Ethanaminium, 2-[[[(7Z,14Z)-7,14-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-88-2 CAPLUS

CN Ethanaminium, 2-[[[(3Z,11Z)-3,11-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-89-3 CAPLUS

CN Ethanaminium, 2-[[[(4Z,12Z)-4,12-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-90-6 CAPLUS

CN Ethanaminium, 2-[[[(5Z,13Z)-5,13-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-91-7 CAPLUS

CN Ethanaminium, 2-[[[(6Z,14Z)-6,14-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-92-8 CAPLUS

CN Ethanaminium, 2-[[[(3Z,12Z)-3,12-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-93-9 CAPLUS

CN Ethanaminium, 2-[[[(4Z,13Z)-4,13-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-94-0 CAPLUS

CN Ethanaminium, 2-[[[(5Z,14Z)-5,14-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-95-1 CAPLUS

CN Ethanaminium, 2-[[[(3Z,13Z)-3,13-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-96-2 CAPLUS

CN Ethanaminium, 2-[[[(4Z,14Z)-4,14-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-97-3 CAPLUS

CN Ethanaminium, 2-[[[(3Z,14Z)-3,14-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-98-4 CAPLUS

CN Ethanaminium, 2-[[[hydroxy[(3Z,7Z)-3,7-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257912-99-5 CAPLUS

CN Ethanaminium, 2-[[[hydroxy[(4Z,8Z)-4,8-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-00-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,9Z)-5,9-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-01-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,10Z)-6,10-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-02-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,11Z)-7,11-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-03-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,12Z)-8,12-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257913-04-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,13Z)-9,13-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257913-05-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,14Z)-10,14-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-06-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,15Z)-11,15-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-07-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,8Z)-3,8-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-08-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,9Z)-4,9-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257913-09-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,10Z)-5,10-octadecadienyloxy]phosphinyl]oxy]-

N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-10-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,11Z)-6,11-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-11-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,12Z)-7,12-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-12-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,13Z)-8,13-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-13-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,14Z)-9,14-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-14-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,15Z)-10,15-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 257913-15-8 257913-16-9 257913-17-0  
257913-18-1 257913-19-2 257913-20-5  
257913-21-6 257913-22-7 257913-23-8  
257913-24-9 257913-25-0 257913-26-1  
257913-27-2 257913-28-3 257913-29-4  
257913-30-7 257913-31-8 257913-32-9  
257913-33-0 257913-34-1 257913-35-2  
257913-36-3 257913-37-4 257913-38-5  
257913-39-6 257913-40-9 257913-41-0  
257913-42-1 257913-43-2 257913-44-3  
257913-45-4 257913-46-5 257913-47-6  
257913-48-7 257913-49-8 257913-50-1  
257913-51-2 257913-52-3 257913-53-4  
257913-54-5 257913-55-6 257913-56-7  
257913-57-8 257913-58-9 257913-59-0  
257913-60-3 257913-61-4 257913-62-5  
257913-63-6 257913-64-7 257913-65-8  
257913-66-9 257913-67-0 257913-68-1  
257913-69-2 257913-70-5 257913-71-6  
257913-72-7 257913-73-8 257913-74-9  
257913-75-0 257913-76-1 257913-77-2  
257913-78-3 257913-79-4 257913-80-7  
257913-81-8 257913-82-9 257913-83-0  
257913-84-1 257913-85-2 257913-86-3  
257913-88-5 257913-90-9 257913-92-1  
257913-94-3 257913-96-5 257913-98-7  
257914-00-4 257914-02-6 257914-04-8  
257914-06-0 257914-08-2 257914-10-6  
257914-12-8 257914-14-0 257914-16-2  
257914-18-4 257914-20-8 257914-22-0  
257914-23-1 257914-24-2 257914-25-3  
257914-26-4 257914-27-5 257914-28-6  
257914-29-7 257914-30-0 257914-31-1  
257914-32-2 257914-33-3 257914-34-4  
257914-35-5 257914-36-6 257914-37-7  
257914-38-8 257914-39-9 257914-40-2  
257914-41-3 257914-42-4 257914-43-5  
257914-44-6 257914-45-7 257914-46-8  
257914-47-9 257914-48-0 257914-49-1  
257914-50-4 257914-51-5 257914-53-7  
257914-55-9 257914-57-1 257914-59-3  
257914-61-7 257914-63-9 257914-65-1  
257914-67-3 257914-69-5 257914-71-9  
257914-73-1 257914-75-3 257914-77-5  
257914-79-7 257914-81-1 257914-83-3  
257914-85-5 257914-87-7 257914-89-9  
257914-91-3 257914-93-5 257914-95-7  
257914-96-8 257914-97-9 257914-98-0  
257914-99-1 257915-00-7 257915-01-8  
257915-02-9 257915-03-0 257915-04-1  
257915-05-2 257915-06-3 257915-07-4  
257915-08-5 257915-09-6 257915-10-9  
257915-11-0 257915-12-1 257915-13-2  
257915-14-3 257915-15-4 257915-16-5  
257915-17-6 257915-18-7 257915-19-8  
257915-20-1 257915-21-2 257915-22-3

257915-23-4 257915-24-5 257915-25-6  
 257915-26-7 257915-27-8 257915-28-9  
 257915-29-0 257915-30-3 257915-31-4  
 257915-32-5 257915-33-6 257915-34-7  
 257915-35-8 257915-36-9 257915-37-0  
 257915-38-1 257915-39-2 257915-40-5  
 257915-41-6 257915-42-7 257915-43-8  
 257915-44-9 257915-45-0 257915-46-1  
 257915-47-2 257915-48-3 257915-49-4  
 257915-50-7 257915-51-8 257915-52-9  
 257915-53-0 257915-54-1 257915-55-2  
 257915-56-3 257915-57-4 257915-58-5  
 257915-59-6 257915-60-9 257915-61-0  
 257915-62-1 257915-63-2 257915-64-3  
 257915-65-4 257915-66-5 257915-67-6  
 257915-68-7 257915-69-8 257915-70-1  
 257915-71-2 257915-72-3 257915-73-4  
 257915-74-5 257915-75-6 257915-76-7  
 257915-77-8 257915-78-9 257915-79-0 25791  
 5-80-3 257915-81-4 257915-82-5  
 257915-83-6 257915-84-7 257915-85-8  
 257915-86-9 257915-87-0 257915-88-1  
 257915-89-2 257915-90-5 257915-91-6  
 257915-92-7 257915-93-8 257915-94-9


RL: PRP (Properties)

(novel phospholipids with synthetic, unsatd. alkyl and acyl chains)

RN 257913-15-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,9Z)-3,9-octadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-16-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,10Z)-4,10-octadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-17-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,11Z)-5,11-octadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-18-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,12Z)-6,12-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-19-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,13Z)-7,13-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-20-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,14Z)-8,14-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-21-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,15Z)-9,15-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-22-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,10Z)-3,10-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-23-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,11Z)-4,11-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-24-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,12Z)-5,12-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-25-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,13Z)-6,13-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-26-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,14Z)-7,14-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-27-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,15Z)-8,15-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-28-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,11Z)-3,11-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-29-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,12Z)-4,12-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-30-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,13Z)-5,13-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-31-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,14Z)-6,14-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-32-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,15Z)-7,15-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-33-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,12Z)-3,12-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-34-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,13Z)-4,13-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-35-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,14Z)-5,14-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-36-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,15Z)-6,15-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-37-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,13Z)-3,13-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257913-38-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,14Z)-4,14-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257913-39-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,15Z)-5,15-octadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-40-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,14Z)-3,14-octadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-41-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,15Z)-4,15-octadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-42-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,15Z)-3,15-octadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-43-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,7Z)-3,7-nonadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-44-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,8Z)-4,8-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-45-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,9Z)-5,9-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-46-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,10Z)-6,10-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-47-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,11Z)-7,11-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-48-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,12Z)-8,12-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-49-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,13Z)-9,13-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-50-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,14Z)-10,14-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-51-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,15Z)-11,15-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-52-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,16Z)-12,16-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257913-53-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,8Z)-3,8-nonadecadienyloxy]phosphinyl]oxy]-

N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-54-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,9Z)-4,9-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-55-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,10Z)-5,10-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-56-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,11Z)-6,11-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-57-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,12Z)-7,12-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-58-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,13Z)-8,13-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-59-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,14Z)-9,14-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-60-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,15Z)-10,15-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-61-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,16Z)-11,16-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-62-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,9Z)-3,9-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-63-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,10Z)-4,10-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-64-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,11Z)-5,11-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-65-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,12Z)-6,12-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-66-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,13Z)-7,13-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-67-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,14Z)-8,14-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-68-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,15Z)-9,15-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-69-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,16Z)-10,16-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-70-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,10Z)-3,10-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-71-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,11Z)-4,11-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-72-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,12Z)-5,12-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-73-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,13Z)-6,13-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-74-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,14Z)-7,14-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-75-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,15Z)-8,15-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-76-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,16Z)-9,16-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-77-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,11Z)-3,11-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257913-78-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,12Z)-4,12-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257913-79-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,13Z)-5,13-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-80-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,14Z)-6,14-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-81-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,15Z)-7,15-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-82-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,16Z)-8,16-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-83-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,12Z)-3,12-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-84-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,13Z)-4,13-nonadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-85-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,14Z)-5,14-nonadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-86-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,15Z)-6,15-nonadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-88-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,16Z)-7,16-nonadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-90-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,13Z)-3,13-nonadecadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-92-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,14Z)-4,14-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-94-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,15Z)-5,15-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-96-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,16Z)-6,16-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257913-98-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,14Z)-3,14-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-00-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,15Z)-4,15-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-02-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,16Z)-5,16-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-04-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,15Z)-3,15-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-06-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,16Z)-4,16-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-08-2 CAPLUS

CN Ethanaminium, 2-[[[[(3Z,7Z)-3,7-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-10-6 CAPLUS

CN Ethanaminium, 2-[[[[(4Z,8Z)-4,8-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-12-8 CAPLUS

CN Ethanaminium, 2-[[[(5Z,9Z)-5,9-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-14-0 CAPLUS

CN Ethanaminium, 2-[[[(6Z,10Z)-6,10-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-16-2 CAPLUS

CN Ethanaminium, 2-[[[(8Z,12Z)-8,12-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-18-4 CAPLUS

CN Ethanaminium, 2-[[[(9Z,13Z)-9,13-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-20-8 CAPLUS

CN Ethanaminium, 2-[[[(10Z,14Z)-10,14-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-22-0 CAPLUS

CN Ethanaminium, 2-[[[(11Z,15Z)-11,15-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-23-1 CAPLUS

CN Ethanaminium, 2-[[[(12Z,16Z)-12,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-24-2 CAPLUS

CN Ethanaminium, 2-[[[(13Z,17Z)-13,17-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-25-3 CAPLUS

CN Ethanaminium, 2-[[[(3Z,8Z)-3,8-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257914-26-4 CAPLUS

CN Ethanaminium, 2-[[[(4Z,9Z)-4,9-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-27-5 CAPLUS

CN Ethanaminium, 2-[[[(5Z,10Z)-5,10-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-28-6 CAPLUS

CN Ethanaminium, 2-[[[(6Z,11Z)-6,11-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-29-7 CAPLUS

CN Ethanaminium, 2-[[[(7Z,12Z)-7,12-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-30-0 CAPLUS

CN Ethanaminium, 2-[[[(8Z,13Z)-8,13-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-31-1 CAPLUS

CN Ethanaminium, 2-[[[(9Z,14Z)-9,14-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-32-2 CAPLUS

CN Ethanaminium, 2-[[[(10Z,15Z)-10,15-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-33-3 CAPLUS

CN Ethanaminium, 2-[[[(11Z,16Z)-11,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-34-4 CAPLUS

CN Ethanaminium, 2-[[[(12Z,17Z)-12,17-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-35-5 CAPLUS

CN Ethanaminium, 2-[[[(3Z,9Z)-3,9-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257914-36-6 CAPLUS

CN Ethanaminium, 2-[[[(4Z,10Z)-4,10-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257914-37-7 CAPLUS

CN Ethanaminium, 2-[[[(5Z,11Z)-5,11-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-38-8 CAPLUS

CN Ethanaminium, 2-[[[(6Z,12Z)-6,12-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-39-9 CAPLUS

CN Ethanaminium, 2-[[[(7Z,13Z)-7,13-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-40-2 CAPLUS

CN Ethanaminium, 2-[[[(8Z,14Z)-8,14-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-41-3 CAPLUS

CN Ethanaminium, 2-[[[(9Z,15Z)-9,15-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-42-4 CAPLUS

CN Ethanaminium, 2-[[[(10Z,16Z)-10,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-43-5 CAPLUS

CN Ethanaminium, 2-[[[(11Z,17Z)-11,17-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-44-6 CAPLUS

CN Ethanaminium, 2-[[[(3Z,10Z)-3,10-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-45-7 CAPLUS

CN Ethanaminium, 2-[[[(4Z,11Z)-4,11-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-46-8 CAPLUS

CN Ethanaminium, 2-[[[(5Z,12Z)-5,12-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-47-9 CAPLUS

CN Ethanaminium, 2-[[[(6Z,13Z)-6,13-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-48-0 CAPLUS

CN Ethanaminium, 2-[[[(7Z,14Z)-7,14-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-49-1 CAPLUS

CN Ethanaminium, 2-[[[(8Z,15Z)-8,15-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-50-4 CAPLUS

CN Ethanaminium, 2-[[[(9Z,16Z)-9,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-51-5 CAPLUS

CN Ethanaminium, 2-[[[(10Z,17Z)-10,17-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-53-7 CAPLUS

CN Ethanaminium, 2-[[[(3Z,11Z)-3,11-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-55-9 CAPLUS

CN Ethanaminium, 2-[[[(4Z,12Z)-4,12-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-57-1 CAPLUS

CN Ethanaminium, 2-[[[(5Z,13Z)-5,13-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-59-3 CAPLUS

CN Ethanaminium, 2-[[[(6Z,14Z)-6,14-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-61-7 CAPLUS

CN Ethanaminium, 2-[[[(7Z,15Z)-7,15-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-63-9 CAPLUS

CN Ethanaminium, 2-[[[(8Z,16Z)-8,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-65-1 CAPLUS

CN Ethanaminium, 2-[[[(9Z,17Z)-9,17-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-67-3 CAPLUS

CN Ethanaminium, 2-[[[(3Z,12Z)-3,12-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-69-5 CAPLUS

CN Ethanaminium, 2-[[[(4Z,13Z)-4,13-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-71-9 CAPLUS

CN Ethanaminium, 2-[[[(5Z,14Z)-5,14-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-73-1 CAPLUS

CN Ethanaminium, 2-[[[(6Z,15Z)-6,15-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-75-3 CAPLUS

CN Ethanaminium, 2-[[[(7Z,16Z)-7,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-77-5 CAPLUS

CN Ethanaminium, 2-[[[(8Z,17Z)-8,17-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-79-7 CAPLUS

CN Ethanaminium, 2-[[[(3Z,13Z)-3,13-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-81-1 CAPLUS

CN Ethanaminium, 2-[[[(4Z,14Z)-4,14-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-83-3 CAPLUS

CN Ethanaminium, 2-[[[(5Z,15Z)-5,15-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-85-5 CAPLUS

CN Ethanaminium, 2-[[[(6Z,16Z)-6,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-87-7 CAPLUS

CN Ethanaminium, 2-[[[(7Z,17Z)-7,17-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-89-9 CAPLUS

CN Ethanaminium, 2-[[[(3Z,14Z)-3,14-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-91-3 CAPLUS

CN Ethanaminium, 2-[[[(4Z,15Z)-4,15-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-93-5 CAPLUS

CN Ethanaminium, 2-[[[(5Z,16Z)-5,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-95-7 CAPLUS

CN Ethanaminium, 2-[[[(6Z,17Z)-6,17-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-96-8 CAPLUS

CN Ethanaminium, 2-[[[(3Z,15Z)-3,15-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257914-97-9 CAPLUS

CN Ethanaminium, 2-[[[(4Z,16Z)-4,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257914-98-0 CAPLUS

CN Ethanaminium, 2-[[[(5Z,17Z)-5,17-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257914-99-1 CAPLUS

CN Ethanaminium, 2-[[[(3Z,17Z)-3,17-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-00-7 CAPLUS

CN Ethanaminium, 2-[[[(3Z,7Z)-3,7-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-01-8 CAPLUS

CN Ethanaminium, 2-[[[(4Z,8Z)-4,8-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-02-9 CAPLUS

CN Ethanaminium, 2-[[[(5Z,9Z)-5,9-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-03-0 CAPLUS

CN Ethanaminium, 2-[[[(6Z,10Z)-6,10-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-04-1 CAPLUS

CN Ethanaminium, 2-[[[(7Z,11Z)-7,11-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-05-2 CAPLUS

CN Ethanaminium, 2-[[[(8Z,12Z)-8,12-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-06-3 CAPLUS

CN Ethanaminium, 2-[[[(9Z,13Z)-9,13-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-07-4 CAPLUS

CN Ethanaminium, 2-[[[(10Z,14Z)-10,14-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-08-5 CAPLUS

CN Ethanaminium, 2-[[[(11Z,15Z)-11,15-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-09-6 CAPLUS

CN Ethanaminium, 2-[[[(12Z,16Z)-12,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-10-9 CAPLUS

CN Ethanaminium, 2-[[[(13Z,17Z)-13,17-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-11-0 CAPLUS

CN Ethanaminium, 2-[[[(14Z,18Z)-14,18-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-12-1 CAPLUS

CN Ethanaminium, 2-[[[(3Z,8Z)-3,8-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257915-13-2 CAPLUS

CN Ethanaminium, 2-[[[(4Z,9Z)-4,9-heneicosadienyloxy]hydroxyphosphinyl]oxy]-

N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-14-3 CAPLUS

CN Ethanaminium, 2-[[[(5Z,10Z)-5,10-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-15-4 CAPLUS

CN Ethanaminium, 2-[[[(6Z,11Z)-6,11-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-16-5 CAPLUS

CN Ethanaminium, 2-[[[(7Z,12Z)-7,12-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-17-6 CAPLUS

CN Ethanaminium, 2-[[[(8Z,13Z)-8,13-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-18-7 CAPLUS

CN Ethanaminium, 2-[[[(9Z,14Z)-9,14-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-19-8 CAPLUS

CN Ethanaminium, 2-[[[(10Z,15Z)-10,15-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-20-1 CAPLUS

CN Ethanaminium, 2-[[[(11Z,16Z)-11,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-21-2 CAPLUS

CN Ethanaminium, 2-[[[(12Z,17Z)-12,17-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-22-3 CAPLUS

CN Ethanaminium, 2-[[[(13Z,18Z)-13,18-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-23-4 CAPLUS

CN Ethanaminium, 2-[[[(3Z,9Z)-3,9-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-24-5 CAPLUS

CN Ethanaminium, 2-[[[(4Z,10Z)-4,10-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-25-6 CAPLUS

CN Ethanaminium, 2-[[[(5Z,11Z)-5,11-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-26-7 CAPLUS

CN Ethanaminium, 2-[[[(6Z,12Z)-6,12-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-27-8 CAPLUS

CN Ethanaminium, 2-[[[(7Z,13Z)-7,13-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-28-9 CAPLUS

CN Ethanaminium, 2-[[[(8Z,14Z)-8,14-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-29-0 CAPLUS

CN Ethanaminium, 2-[[[(9Z,15Z)-9,15-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-30-3 CAPLUS

CN Ethanaminium, 2-[[[(10Z,16Z)-10,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-31-4 CAPLUS

CN Ethanaminium, 2-[[[(11Z,17Z)-11,17-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-32-5 CAPLUS

CN Ethanaminium, 2-[[[(12Z,18Z)-12,18-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-33-6 CAPLUS

CN Ethanaminium, 2-[[[(3Z,10Z)-3,10-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-34-7 CAPLUS

CN Ethanaminium, 2-[[[(4Z,11Z)-4,11-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-35-8 CAPLUS

CN Ethanaminium, 2-[[[(5Z,12Z)-5,12-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-36-9 CAPLUS

CN Ethanaminium, 2-[[[(6Z,13Z)-6,13-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-37-0 CAPLUS

CN Ethanaminium, 2-[[[(7Z,14Z)-7,14-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257915-38-1 CAPLUS

CN Ethanaminium, 2-[[[(8Z,15Z)-8,15-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257915-39-2 CAPLUS

CN Ethanaminium, 2-[[[(9Z,16Z)-9,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-40-5 CAPLUS

CN Ethanaminium, 2-[[[(10Z,17Z)-10,17-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-41-6 CAPLUS

CN Ethanaminium, 2-[[[(11Z,18Z)-11,18-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-42-7 CAPLUS

CN Ethanaminium, 2-[[[(3Z,11Z)-3,11-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-43-8 CAPLUS

CN Ethanaminium, 2-[[[(4Z,12Z)-4,12-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-44-9 CAPLUS

CN Ethanaminium, 2-[[[(5Z,13Z)-5,13-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-45-0 CAPLUS

CN Ethanaminium, 2-[[[(6Z,14Z)-6,14-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-46-1 CAPLUS

CN Ethanaminium, 2-[[[(7Z,15Z)-7,15-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-47-2 CAPLUS

CN Ethanaminium, 2-[[[(8Z,16Z)-8,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-48-3 CAPLUS

CN Ethanaminium, 2-[[[(9Z,17Z)-9,17-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-49-4 CAPLUS

CN Ethanaminium, 2-[[[(10Z,18Z)-10,18-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-50-7 CAPLUS

CN Ethanaminium, 2-[[[(3Z,12Z)-3,12-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-51-8 CAPLUS

CN Ethanaminium, 2-[[[(4Z,13Z)-4,13-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-52-9 CAPLUS

CN Ethanaminium, 2-[[[(5Z,14Z)-5,14-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-53-0 CAPLUS

CN Ethanaminium, 2-[[[(6Z,15Z)-6,15-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-54-1 CAPLUS

CN Ethanaminium, 2-[[[(7Z,16Z)-7,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-55-2 CAPLUS

CN Ethanaminium, 2-[[[(8Z,17Z)-8,17-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-56-3 CAPLUS

CN Ethanaminium, 2-[[[(9Z,18Z)-9,18-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-57-4 CAPLUS

CN Ethanaminium, 2-[[[(3Z,13Z)-3,13-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-58-5 CAPLUS

CN Ethanaminium, 2-[[[(4Z,14Z)-4,14-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-59-6 CAPLUS

CN Ethanaminium, 2-[[[(5Z,15Z)-5,15-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-60-9 CAPLUS

CN Ethanaminium, 2-[[[(6Z,16Z)-6,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-61-0 CAPLUS

CN Ethanaminium, 2-[[[(7Z,17Z)-7,17-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-62-1 CAPLUS

CN Ethanaminium, 2-[[[(8Z,18Z)-8,18-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-63-2 CAPLUS

CN Ethanaminium, 2-[[[(3Z,14Z)-3,14-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-64-3 CAPLUS

CN Ethanaminium, 2-[[[(4Z,15Z)-4,15-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-65-4 CAPLUS

CN Ethanaminium, 2-[[[(5Z,16Z)-5,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-66-5 CAPLUS

CN Ethanaminium, 2-[[[(6Z,17Z)-6,17-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-67-6 CAPLUS

CN Ethanaminium, 2-[[[(7Z,18Z)-7,18-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-68-7 CAPLUS

CN Ethanaminium, 2-[[[(3Z,15Z)-3,15-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-69-8 CAPLUS

CN Ethanaminium, 2-[[[(4Z,16Z)-4,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-70-1 CAPLUS

CN Ethanaminium, 2-[[[(5Z,17Z)-5,17-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-71-2 CAPLUS

CN Ethanaminium, 2-[[[(6Z,18Z)-6,18-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-72-3 CAPLUS

CN Ethanaminium, 2-[[[(3Z,17Z)-3,17-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-73-4 CAPLUS

CN Ethanaminium, 2-[[[(4Z,18Z)-4,18-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-74-5 CAPLUS

CN Ethanaminium, 2-[[[(3Z,7Z)-3,7-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-75-6 CAPLUS

CN Ethanaminium, 2-[[[(4Z,8Z)-4,8-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-76-7 CAPLUS

CN Ethanaminium, 2-[[[(5Z,9Z)-5,9-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-77-8 CAPLUS

CN Ethanaminium, 2-[[[(6Z,10Z)-6,10-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257915-78-9 CAPLUS

CN Ethanaminium, 2-[[[(7Z,11Z)-7,11-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257915-79-0 CAPLUS

CN Ethanaminium, 2-[[[(8Z,12Z)-8,12-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-80-3 CAPLUS

CN Ethanaminium, 2-[[[(9Z,13Z)-9,13-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-81-4 CAPLUS

CN Ethanaminium, 2-[[[(10Z,14Z)-10,14-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-82-5 CAPLUS

CN Ethanaminium, 2-[[[(11Z,15Z)-11,15-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-83-6 CAPLUS

CN Ethanaminium, 2-[[[(12Z,16Z)-12,16-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-84-7 CAPLUS

CN Ethanaminium, 2-[[[(3Z,17Z)-3,17-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-85-8 CAPLUS

CN Ethanaminium, 2-[[[(14Z,18Z)-14,18-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-86-9 CAPLUS

CN Ethanaminium, 2-[[[(15Z,19Z)-15,19-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-87-0 CAPLUS

CN Ethanaminium, 2-[[[(3Z,8Z)-3,8-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257915-88-1 CAPLUS

CN Ethanaminium, 2-[[[(4Z,9Z)-4,9-docosadienyloxy]hydroxyphosphinyl]oxy]-

N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-89-2 CAPLUS

CN Ethanaminium, 2-[[[(5Z,10Z)-5,10-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-90-5 CAPLUS

CN Ethanaminium, 2-[[[(6Z,11Z)-6,11-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-91-6 CAPLUS

CN Ethanaminium, 2-[[[(7Z,12Z)-7,12-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-92-7 CAPLUS

CN Ethanaminium, 2-[[[(8Z,13Z)-8,13-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-93-8 CAPLUS

CN Ethanaminium, 2-[[[(9Z,14Z)-9,14-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-94-9 CAPLUS

CN Ethanaminium, 2-[[[(10Z,15Z)-10,15-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 257915-95-0 257915-96-1 257915-97-2  
257915-98-3 257915-99-4 257916-00-0  
257916-01-1 257916-02-2 257916-03-3  
257916-04-4 257916-05-5 257916-06-6  
257916-07-7 257916-08-8 257916-09-9  
257916-10-2 257916-11-3 257916-12-4  
257916-13-5 257916-14-6 257916-15-7  
257916-16-8 257916-17-9 257916-18-0  
257916-19-1 257916-20-4 257916-21-5  
257916-22-6 257916-23-7 257916-24-8  
257916-25-9 257916-26-0 257916-27-1  
257916-28-2 257916-29-3 257916-30-6  
257916-31-7 257916-32-8 257916-33-9  
257916-34-0 257916-35-1 257916-36-2  
257916-37-3 257916-38-4 257916-39-5  
257916-40-8 257916-41-9 257916-42-0  
257916-43-1 257916-44-2 257916-45-3  
257916-46-4 257916-47-5 257916-48-6  
257916-49-7 257916-50-0 257916-51-1  
257916-52-2 257916-53-3 257916-54-4  
257916-55-5 257916-56-6 257916-57-7  
257916-58-8 257916-59-9 257916-60-2  
257916-61-3 257916-62-4 257916-63-5  
257916-64-6 257916-65-7 257916-66-8  
257916-67-9 257916-68-0 257916-69-1  
257916-70-4 257916-71-5 257916-72-6  
257916-73-7 257916-74-8 257916-75-9  
257916-76-0 257916-77-1 257916-78-2  
257916-79-3 257916-80-6 257916-81-7  
257916-82-8 257916-83-9 257916-84-0  
257916-85-1 257916-86-2 257916-87-3  
257916-88-4 257916-89-5 257916-90-8  
257916-91-9 257916-92-0 257916-93-1  
257916-94-2 257916-95-3 257916-96-4  
257916-97-5 257916-98-6 257916-99-7  
257917-00-3 257917-01-4 257917-02-5  
257917-03-6 257917-04-7 257917-05-8  
257917-06-9 257917-07-0 257917-08-1  
257917-09-2 257917-10-5 257917-11-6  
257917-12-7 257917-13-8 257917-14-9  
257917-15-0 257917-16-1 257917-17-2  
257917-18-3 257917-19-4 257917-20-7  
257917-21-8 257917-22-9 257917-23-0  
257917-24-1 257917-25-2 257917-26-3

257917-27-4 257917-28-5 257917-29-6  
 257917-30-9 257917-31-0 257917-32-1  
 257917-33-2 257917-34-3 257917-35-4  
 257917-36-5 257917-37-6 257917-38-7  
 257917-39-8 257917-40-1 257917-41-2  
 257917-42-3 257917-43-4 257917-44-5  
 257917-45-6 257917-46-7 257917-47-8  
 257917-48-9 257917-49-0 257917-50-3  
 257917-51-4 257917-52-5 257917-53-6  
 257917-54-7 257917-55-8 257917-56-9  
 257917-57-0 257917-58-1 257917-59-2  
 257917-60-5 257917-61-6 257917-62-7  
 257917-63-8 257917-64-9 257917-65-0  
 257917-66-1 257917-67-2 257917-68-3  
 257917-69-4 257917-70-7 257917-71-8  
 257917-72-9 257917-73-0 257917-74-1  
 257917-75-2 257917-76-3 257917-77-4  
 257917-78-5 257917-79-6 257917-80-9  
 257917-81-0 257917-82-1 257917-83-2  
 257917-84-3 257917-85-4 257917-86-5  
 257917-87-6 257917-88-7 257917-89-8  
 257917-90-1 257917-91-2 257917-92-3  
 257917-93-4 257917-94-5 257917-95-6  
 257917-96-7 257917-97-8 257917-98-9  
 257917-99-0 257918-00-6 257918-01-7  
 257918-02-8 257918-03-9 257918-04-0  
 257918-05-1 257918-06-2 257918-07-3  
 257918-08-4 257918-09-5 257918-10-8  
 257918-11-9 257918-12-0 257918-13-1  
 257918-14-2 257918-15-3 257918-16-4  
 257918-17-5 257918-18-6 257918-19-7 25791  
 8-20-0 257918-21-1 257918-22-2  
 257918-23-3 257918-24-4 257918-25-5  
 257918-26-6 257918-27-7 257918-28-8  
 257918-29-9 257918-30-2 257918-31-3  
 257918-32-4 257918-33-5 257918-34-6


RL: PRP (Properties)

(novel phospholipids with synthetic, unsatd. alkyl and acyl chains)

RN 257915-95-0 CAPLUS

CN Ethanaminium, 2-[[[(11Z,16Z)-11,16-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-96-1 CAPLUS

CN Ethanaminium, 2-[[[(12Z,17Z)-12,17-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-97-2 CAPLUS

CN Ethanaminium, 2-[[[(13Z,18Z)-13,18-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-98-3 CAPLUS

CN Ethanaminium, 2-[[[(14Z,19Z)-14,19-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257915-99-4 CAPLUS

CN Ethanaminium, 2-[[[(3Z,9Z)-3,9-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-00-0 CAPLUS

CN Ethanaminium, 2-[[[(4Z,10Z)-4,10-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-01-1 CAPLUS

CN Ethanaminium, 2-[[[(5Z,11Z)-5,11-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-02-2 CAPLUS

CN Ethanaminium, 2-[[[(6Z,12Z)-6,12-docosadienyloxy]hydroxyphosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-03-3 CAPLUS

CN Ethanaminium, 2-[[[(7Z,13Z)-7,13-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-04-4 CAPLUS

CN Ethanaminium, 2-[[[(8Z,14Z)-8,14-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-05-5 CAPLUS

CN Ethanaminium, 2-[[[(9Z,15Z)-9,15-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-06-6 CAPLUS

CN Ethanaminium, 2-[[[(10Z,16Z)-10,16-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-07-7 CAPLUS

CN Ethanaminium, 2-[[[(11Z,17Z)-11,17-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-08-8 CAPLUS

CN Ethanaminium, 2-[[[(12Z,18Z)-12,18-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-09-9 CAPLUS

CN Ethanaminium, 2-[[[(13Z,19Z)-13,19-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-10-2 CAPLUS

CN Ethanaminium, 2-[[[(3Z,10Z)-3,10-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-11-3 CAPLUS

CN Ethanaminium, 2-[[[(4Z,11Z)-4,11-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257916-12-4 CAPLUS

CN Ethanaminium, 2-[[[(5Z,12Z)-5,12-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257916-13-5 CAPLUS

CN Ethanaminium, 2-[[[(6Z,13Z)-6,13-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-14-6 CAPLUS

CN Ethanaminium, 2-[[[(7Z,14Z)-7,14-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-15-7 CAPLUS

CN Ethanaminium, 2-[[[(8Z,15Z)-8,15-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-16-8 CAPLUS

CN Ethanaminium, 2-[[[(9Z,16Z)-9,16-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-17-9 CAPLUS

CN Ethanaminium, 2-[[[(10Z,17Z)-10,17-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-18-0 CAPLUS

CN Ethanaminium, 2-[[[(11Z,18Z)-11,18-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-19-1 CAPLUS

CN Ethanaminium, 2-[[[(12Z,19Z)-12,19-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-20-4 CAPLUS

CN Ethanaminium, 2-[[[(3Z,11Z)-3,11-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-21-5 CAPLUS

CN Ethanaminium, 2-[[[(4Z,12Z)-4,12-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-22-6 CAPLUS

CN Ethanaminium, 2-[[[(5Z,13Z)-5,13-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-23-7 CAPLUS

CN Ethanaminium, 2-[[[(6Z,14Z)-6,14-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-24-8 CAPLUS

CN Ethanaminium, 2-[[[(7Z,15Z)-7,15-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-25-9 CAPLUS

CN Ethanaminium, 2-[[[(8Z,16Z)-8,16-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-26-0 CAPLUS

CN Ethanaminium, 2-[[[(9Z,17Z)-9,17-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-27-1 CAPLUS

CN Ethanaminium, 2-[[[(10Z,18Z)-10,18-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-28-2 CAPLUS

CN Ethanaminium, 2-[[[(11Z,19Z)-11,19-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-29-3 CAPLUS

CN Ethanaminium, 2-[[[(3Z,12Z)-3,12-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-30-6 CAPLUS

CN Ethanaminium, 2-[[[(4Z,13Z)-4,13-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-31-7 CAPLUS

CN Ethanaminium, 2-[[[(5Z,14Z)-5,14-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-32-8 CAPLUS

CN Ethanaminium, 2-[[[(6Z,15Z)-6,15-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-33-9 CAPLUS

CN Ethanaminium, 2-[[[(7Z,16Z)-7,16-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-34-0 CAPLUS

CN Ethanaminium, 2-[[[(8Z,17Z)-8,17-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-35-1 CAPLUS

CN Ethanaminium, 2-[[[(9Z,18Z)-9,18-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-36-2 CAPLUS

CN Ethanaminium, 2-[[[(10Z,19Z)-10,19-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-37-3 CAPLUS

CN Ethanaminium, 2-[[[(13Z,3Z)-3,13-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-38-4 CAPLUS

CN Ethanaminium, 2-[[[(4Z,14Z)-4,14-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-39-5 CAPLUS

CN Ethanaminium, 2-[[[(5Z,15Z)-5,15-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-40-8 CAPLUS

CN Ethanaminium, 2-[[[(6Z,16Z)-6,16-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-41-9 CAPLUS

CN Ethanaminium, 2-[[[(7Z,17Z)-7,17-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-42-0 CAPLUS

CN Ethanaminium, 2-[[[(8Z,18Z)-8,18-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-43-1 CAPLUS

CN Ethanaminium, 2-[[[(9Z,19Z)-9,19-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-44-2 CAPLUS

CN Ethanaminium, 2-[[[(3Z,14Z)-3,14-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-45-3 CAPLUS

CN Ethanaminium, 2-[[[(4Z,15Z)-4,15-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-46-4 CAPLUS

CN Ethanaminium, 2-[[[(5Z,16Z)-5,16-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-47-5 CAPLUS

CN Ethanaminium, 2-[[[(6Z,17Z)-6,17-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-48-6 CAPLUS

CN Ethanaminium, 2-[[[(7Z,18Z)-7,18-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-49-7 CAPLUS

CN Ethanaminium, 2-[[[(8Z,19Z)-8,19-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-50-0 CAPLUS

CN Ethanaminium, 2-[[[(3Z,15Z)-3,15-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-51-1 CAPLUS

CN Ethanaminium, 2-[[[(4Z,16Z)-4,16-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257916-52-2 CAPLUS

CN Ethanaminium, 2-[[[(5Z,17Z)-5,17-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257916-53-3 CAPLUS

CN Ethanaminium, 2-[[[(6Z,18Z)-6,18-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-54-4 CAPLUS

CN Ethanaminium, 2-[[[(7Z,19Z)-7,19-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-55-5 CAPLUS

CN Ethanaminium, 2-[[[(4Z,18Z)-4,18-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-56-6 CAPLUS

CN Ethanaminium, 2-[[[(5Z,19Z)-5,19-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-57-7 CAPLUS

CN Ethanaminium, 2-[[[(3Z,19Z)-3,19-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-58-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,7Z)-3,7-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-59-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,8Z)-4,8-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-60-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,9Z)-5,9-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-61-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,10Z)-6,10-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-62-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,11Z)-7,11-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-63-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,12Z)-8,12-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-64-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,13Z)-9,13-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-65-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,14Z)-10,14-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-66-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,15Z)-11,15-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-67-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,16Z)-12,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-68-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,17Z)-13,17-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-69-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z,18Z)-14,18-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-70-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(15Z,19Z)-15,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-71-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(16Z,20Z)-16,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257916-72-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,8Z)-3,8-tricosadienyloxy]phosphinyl]oxy]-

N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-73-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,9Z)-4,9-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-74-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,10Z)-5,10-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-75-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,11Z)-6,11-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-76-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,12Z)-7,12-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-77-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,13Z)-8,13-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-78-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,14Z)-9,14-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-79-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,15Z)-10,15-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-80-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,16Z)-11,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-81-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,17Z)-12,17-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-82-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,18Z)-13,18-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-83-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z,19Z)-14,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-84-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(15Z,20Z)-15,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-85-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,9Z)-3,9-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-86-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,10Z)-4,10-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-87-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,11Z)-5,11-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-88-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,12Z)-6,12-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-89-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,13Z)-7,13-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-90-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,14Z)-8,14-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-91-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,15Z)-9,15-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257916-92-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,16Z)-10,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257916-93-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,17Z)-11,17-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-94-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,18Z)-12,18-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-95-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,19Z)-13,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-96-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z,20Z)-14,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-97-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,10Z)-3,10-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-98-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,11Z)-4,11-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257916-99-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,12Z)-5,12-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-00-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,13Z)-6,13-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-01-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,14Z)-7,14-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-02-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,15Z)-8,15-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-03-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,16Z)-9,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-04-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,17Z)-10,17-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-05-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,18Z)-11,18-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-06-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,19Z)-12,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-07-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,20Z)-13,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-08-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,11Z)-3,11-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-09-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,12Z)-4,12-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-10-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,13Z)-5,13-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-11-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,14Z)-6,14-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-12-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,15Z)-7,15-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-13-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,16Z)-8,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-14-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,17Z)-9,17-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-15-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,18Z)-10,18-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-16-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,19Z)-11,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-17-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,20Z)-12,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-18-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,12Z)-3,12-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-19-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,13Z)-4,13-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-20-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,14Z)-5,14-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-21-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,15Z)-6,15-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-22-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,16Z)-7,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-23-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,17Z)-8,17-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-24-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,18Z)-9,18-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-25-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,19Z)-10,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-26-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,20Z)-11,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-27-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,22Z)-13,22-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-28-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,14Z)-4,14-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-29-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,15Z)-5,15-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-30-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,16Z)-6,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-31-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,17Z)-7,17-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257917-32-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,18Z)-8,18-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257917-33-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,19Z)-9,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-34-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,20Z)-10,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-35-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,14Z)-3,14-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-36-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,15Z)-4,15-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-37-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,16Z)-5,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-38-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,17Z)-6,17-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-39-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,18Z)-7,18-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-40-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,19Z)-8,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-41-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,20Z)-9,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-42-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,15Z)-3,15-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-43-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,16Z)-4,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-44-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,17Z)-5,17-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-45-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,18Z)-6,18-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-46-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,19Z)-7,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-47-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,20Z)-8,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-48-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,17Z)-3,17-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-49-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,18Z)-4,18-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-50-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,19Z)-5,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-51-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,20Z)-6,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-52-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,19Z)-3,19-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-53-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,20Z)-4,20-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-54-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,7Z)-3,7-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-55-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,8Z)-4,8-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-56-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,9Z)-5,9-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-57-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,10Z)-6,10-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-58-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,11Z)-7,11-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-59-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,12Z)-8,12-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-60-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,13Z)-9,13-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-61-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,14Z)-10,14-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-62-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,15Z)-11,15-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-63-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,16Z)-12,16-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-64-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,17Z)-13,17-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-65-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z,18Z)-14,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-66-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(15Z,19Z)-15,19-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-67-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(16Z,20Z)-16,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-68-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(17Z,21Z)-17,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-69-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,8Z)-3,8-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-70-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,9Z)-4,9-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-71-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,10Z)-5,10-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257917-72-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,11Z)-6,11-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257917-73-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,12Z)-7,12-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-74-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,13Z)-8,13-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-75-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,14Z)-9,14-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-76-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,15Z)-10,15-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-77-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,16Z)-11,16-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-78-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,17Z)-12,17-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-79-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,18Z)-13,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-80-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z,19Z)-14,19-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-81-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(15Z,20Z)-15,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-82-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(16Z,21Z)-16,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-83-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,9Z)-3,9-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-84-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,10Z)-4,10-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-85-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,11Z)-5,11-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-86-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,12Z)-6,12-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-87-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,13Z)-7,13-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-88-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,14Z)-8,14-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-89-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,15Z)-9,15-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-90-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,16Z)-10,16-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-91-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,17Z)-11,17-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-92-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,18Z)-12,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-93-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,19Z)-13,19-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-94-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z,20Z)-14,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-95-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(15Z,21Z)-15,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-96-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,10Z)-3,10-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-97-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,11Z)-4,11-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-98-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,12Z)-5,12-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257917-99-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,13Z)-6,13-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-00-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,14Z)-7,14-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-01-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,15Z)-8,15-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-02-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,16Z)-9,16-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-03-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,17Z)-10,17-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-04-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,18Z)-11,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-05-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,19Z)-12,19-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-06-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,20Z)-13,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-07-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(14Z,21Z)-14,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-08-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,11Z)-3,11-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-09-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,12Z)-4,12-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-10-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,13Z)-5,13-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-11-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,14Z)-6,14-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257918-12-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,15Z)-7,15-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257918-13-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,16Z)-8,16-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-14-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,17Z)-9,17-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-15-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,18Z)-10,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-16-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,19Z)-11,19-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-17-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,20Z)-12,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-18-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,21Z)-13,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-19-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,12Z)-3,12-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-20-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,13Z)-4,13-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-21-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,14Z)-5,14-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-22-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,15Z)-6,15-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-23-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,16Z)-7,16-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-24-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,17Z)-8,17-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-25-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,18Z)-9,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-26-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,19Z)-10,19-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-27-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,20Z)-11,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-28-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z,21Z)-12,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-29-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,13Z)-3,13-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-30-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,14Z)-4,14-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-31-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,15Z)-5,15-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-32-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,16Z)-6,16-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-33-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,17Z)-7,17-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-34-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,18Z)-8,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 257918-35-7 257918-36-8 257918-37-9  
 257918-38-0 257918-39-1 257918-40-4  
 257918-41-5 257918-42-6 257918-43-7  
 257918-44-8 257918-45-9 257918-46-0  
 257918-47-1 257918-48-2 257918-49-3  
 257918-50-6 257918-51-7 257918-52-8  
 257918-53-9 257918-54-0 257918-55-1  
 257918-56-2 257918-57-3 257918-58-4  
 257918-59-5 257918-60-8 257918-61-9  
 257918-62-0 257918-63-1 257918-64-2  
 257918-65-3 257918-66-4 257918-67-5  
 257918-68-6 257918-69-7 257918-70-0  
 257918-71-1 257918-72-2 257918-73-3  
 257918-74-4 257918-75-5 257918-76-6  
 257918-77-7 257918-78-8 257918-79-9  
 257918-80-2 257918-81-3 257918-82-4  
 257918-83-5 257918-84-6 257918-85-7  
 257918-86-8 257918-87-9 257918-88-0  
 257918-89-1 257918-90-4 257918-91-5  
 257918-92-6 257918-93-7 257918-94-8  
 257918-95-9 257918-96-0 257918-97-1  
 257918-98-2 257918-99-3 257919-00-9  
 257919-01-0 257919-02-1 257919-03-2  
 257919-04-3 257919-05-4 257919-06-5  
 257919-07-6 257919-08-7 257919-09-8  
 257919-10-1 257919-11-2 257919-12-3  
 257919-13-4 257919-14-5 257919-15-6  
 257919-16-7 257919-17-8 257919-18-9  
 257919-19-0 257919-20-3 257919-21-4  
 257919-22-5 257919-23-6 257919-24-7  
 257919-25-8 257919-26-9 257919-27-0  
 257919-28-1 257919-29-2 257919-30-5

257919-31-6 257919-32-7 257919-33-8  
257919-34-9 257919-35-0 257919-36-1  
257919-37-2 257919-38-3 257919-39-4  
257919-40-7 257919-41-8 257919-42-9  
257919-43-0 257919-44-1 257919-45-2  
257919-46-3 257919-47-4 257919-48-5  
257919-49-6 257919-50-9 257919-51-0  
257919-52-1 257919-53-2 257919-54-3  
257919-55-4 257919-56-5 257919-57-6  
257919-58-7 257919-59-8 257919-60-1  
257919-61-2 257919-62-3 257919-63-4  
257919-64-5 257919-65-6 257919-66-7  
257919-67-8 257919-68-9 257919-69-0  
257919-70-3 257919-71-4 257919-72-5  
257919-73-6 257919-74-7 257919-75-8  
257919-76-9 257919-78-1 257919-79-2  
257919-80-5 257919-81-6 257919-82-7  
257919-83-8 257919-84-9 257919-85-0  
257919-86-1 257919-87-2 257919-88-3  
257919-89-4 257919-90-7 257919-91-8  
257919-92-9 257919-93-0 257919-94-1  
257919-95-2 257919-96-3 257919-97-4  
257919-98-5 257919-99-6 257920-00-6  
257920-01-7 257920-02-8 257920-03-9  
257920-04-0 257920-05-1 257920-06-2  
257920-07-3 257920-08-4 257920-09-5  
257920-10-8 257920-11-9 257920-12-0  
257920-13-1 257920-14-2 257920-15-3  
257920-16-4 257920-17-5 257920-18-6  
257920-19-7 257920-20-0 257920-21-1  
257920-22-2 257920-23-3 257920-24-4  
257920-25-5 257920-26-6 257920-27-7  
257920-28-8 257920-29-9 257920-30-2  
257920-31-3 257920-32-4 257920-33-5  
257920-34-6 257920-35-7 257920-36-8  
257920-37-9 257920-38-0 257920-39-1  
257920-40-4 257920-41-5 257920-42-6  
257920-43-7 257920-44-8 257920-45-9  
257920-46-0 257920-47-1 257920-48-2  
257920-49-3 257920-50-6 257920-51-7  
257920-52-8 257920-53-9 257920-54-0  
257920-55-1 257920-56-2 257920-57-3  
257920-58-4 257920-59-5 257920-60-8 25792  
0-62-0 257920-64-2 257920-66-4  
257920-68-6 257920-70-0 257920-72-2  
257920-74-4 257920-76-6 257920-78-8  
257920-79-9 257920-80-2 257920-81-3  
257920-82-4 257920-83-5 257920-84-6


RL: PRP (Properties)

(novel phospholipids with synthetic, unsatd. alkyl and acyl chains)

RN 257918-35-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,19Z)-9,19-tetracosadienyloxy]phosphinyl]oxy]-  
N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-36-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,20Z)-10,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-37-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z,21Z)-11,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-38-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,14Z)-3,14-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-39-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,15Z)-4,15-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-40-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,16Z)-5,16-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-41-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,17Z)-6,17-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-42-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,18Z)-7,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-43-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,19Z)-8,19-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-44-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,20Z)-9,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-45-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,21Z)-10,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257918-46-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,15Z)-3,15-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257918-47-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,16Z)-4,16-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-48-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,17Z)-5,17-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-49-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,18Z)-6,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-50-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,19Z)-7,19-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-51-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z,20Z)-8,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-52-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,21Z)-9,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-53-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,17Z)-3,17-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-54-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,18Z)-4,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-55-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,19Z)-5,19-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-56-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,20Z)-6,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-57-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z,21Z)-7,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-58-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(3Z,19Z)-3,19-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-59-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(4Z,20Z)-4,20-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-60-8 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z,21Z)-5,21-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-61-9 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,12Z)-6,12-pentacosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-62-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,15Z)-9,15-pentacosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-63-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z,16Z)-6,16-pentacosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-64-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(9Z,19Z)-9,19-pentacosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-65-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z,20Z)-10,20-pentacosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-66-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z,20Z)-13,20-pentacosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-67-5 CAPLUS

CN Ethanaminium, 2-[[[(6Z,12Z)-6,12-hexacosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-68-6 CAPLUS

CN Ethanaminium, 2-[[[(9Z,15Z)-9,15-hexacosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-69-7 CAPLUS

CN Ethanaminium, 2-[[[(6Z,16Z)-6,16-hexacosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-70-0 CAPLUS

CN Ethanaminium, 2-[[[(9Z,19Z)-9,19-hexacosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-71-1 CAPLUS

CN Ethanaminium, 2-[[[(6Z,20Z)-6,20-hexacosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-72-2 CAPLUS

CN 1-Propanaminium, 3-[[[(5Z,11Z)-5,11-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-73-3 CAPLUS

CN 1-Propanaminium, 3-[[[(5Z,11Z)-5,11-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-74-4 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(5Z,11Z)-5,11-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-75-5 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(6Z,12Z)-6,12-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-76-6 CAPLUS

CN 1-Propanaminium, 3-[[[(10Z,16Z)-10,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-77-7 CAPLUS

CN 1-Propanaminium, 3-[[[10Z,16Z)-10,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-78-8 CAPLUS

CN 1-Propanaminium, 3-[[[10Z,16Z)-10,16-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-79-9 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(10Z,16Z)-10,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-80-2 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(6Z,18Z)-6,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-81-3 CAPLUS

CN 1-Butanaminium, 4-[[[5Z,11Z)-5,11-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-82-4 CAPLUS

CN 1-Butanaminium, 4-[[[(5Z,11Z)-5,11-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-83-5 CAPLUS

CN 1-Butanaminium, 4-[[[hydroxy[(5Z,11Z)-5,11-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-84-6 CAPLUS

CN 1-Butanaminium, 4-[[[hydroxy[(6Z,12Z)-6,12-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-85-7 CAPLUS

CN 1-Butanaminium, 4-[[[[(10Z,16Z)-10,16-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257918-86-8 CAPLUS

CN 1-Butanaminium, 4-[[[[(10Z,16Z)-10,16-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 257918-87-9 CAPLUS

CN 1-Butanaminium, 4-[[[(10Z,16Z)-10,16-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-88-0 CAPLUS

CN 1-Butanaminium, 4-[[[hydroxy[(10Z,16Z)-10,16-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-89-1 CAPLUS

CN 1-Butanaminium, 4-[[[hydroxy[(6Z,18Z)-6,18-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-90-4 CAPLUS

CN Ethanaminium, 2-[[[(11Z)-11,15-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-91-5 CAPLUS

CN Ethanaminium, 2-[[[(11Z)-11,16-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-92-6 CAPLUS

CN Ethanaminium, 2-[[[hydroxy[(11Z)-11,17-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-93-7 CAPLUS

CN Ethanaminium, 2-[[[hydroxy[(11Z)-11,18-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-94-8 CAPLUS

CN Ethanaminium, 2-[[[[(11Z)-11,19-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-95-9 CAPLUS

CN Ethanaminium, 2-[[[[(11Z)-11,20-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-96-0 CAPLUS

CN Ethanaminium, 2-[[[hydroxy[(11Z)-11,22-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-97-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z)-11,23-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-98-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z)-11,24-pentacosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257918-99-3 CAPLUS

CN 1-Propanaminium, 3-[[[(11Z)-11,15-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-00-9 CAPLUS

CN 1-Propanaminium, 3-[[[(11Z)-11,16-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-01-0 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(11Z)-11,17-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-02-1 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(11Z)-11,18-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-03-2 CAPLUS

CN 1-Propanaminium, 3-[[[(11Z)-11,19-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-04-3 CAPLUS

CN 1-Propanaminium, 3-[[[(11Z)-11,20-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-05-4 CAPLUS

CN 1-Propanaminium, 3-[[[(11Z)-11,21-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-06-5 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(11Z)-11,22-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-07-6 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(11Z)-11,23-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-08-7 CAPLUS

CN 1-Propanaminium, 3-[[hydroxy[(11Z)-11,24-pentacosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-09-8 CAPLUS

CN 1-Butanaminium, 4-[[[(11Z)-11,15-hexadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-10-1 CAPLUS

CN 1-Butanaminium, 4-[[[(11Z)-11,16-heptadecadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-11-2 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(11Z)-11,17-octadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-12-3 CAPLUS

CN 1-Butanaminium, 4-[[[hydroxy[(11Z)-11,18-nonadecadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-13-4 CAPLUS

CN 1-Butanaminium, 4-[[[[(11Z)-11,19-eicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-14-5 CAPLUS

CN 1-Butanaminium, 4-[[[[(11Z)-11,20-heneicosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-15-6 CAPLUS

CN 1-Butanaminium, 4-[[[[(11Z)-11,21-docosadienyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-16-7 CAPLUS

CN 1-Butanaminium, 4-[[[hydroxy[(11Z)-11,22-tricosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-17-8 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(11Z)-11,23-tetracosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257919-18-9 CAPLUS

CN 1-Butanaminium, 4-[[hydroxy[(11Z)-11,24-pentacosadienyloxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257919-19-0 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-20-3 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-19-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-21-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-21-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-

trimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-22-5 CAPLUS

CN 3,5,9-Trioxa-4-phosphaoctacos-15-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-23-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphaoctacos-19-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-24-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphaoctacos-21-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257919-25-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphanonacos-15-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Double bond geometry as shown.




RN 257919-26-9 CAPLUS

CN 3,5,9-Trioxa-4-phosphanonacos-19-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-27-0 CAPLUS

CN 3,5,9-Trioxa-4-phosphanonacos-21-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-28-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphatriacont-15-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-29-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphatriacont-19-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-30-5 CAPLUS

CN 3,5,9-Trioxa-4-phosphatriacont-21-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-31-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphahentriacont-15-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-32-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-33-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphahentriacont-21-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 257919-34-9 CAPLUS

CN 3,5,9-Trioxa-4-phosphadotriacont-15-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-35-0 CAPLUS

CN 3,5,9-Trioxa-4-phosphadotriacont-19-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-36-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphadotriacont-21-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-37-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphatritriacont-15-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257919-38-3 CAPLUS

CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-39-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphatritriacont-21-en-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-40-7 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-41-8 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacos-20-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-42-9 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacos-22-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 257919-43-0 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphanonacos-16-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 257919-44-1 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphanonacos-20-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 257919-45-2 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphanonacos-22-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 257919-46-3 CAPLUS

CN 4,6,10-Trioxa-5-phosphatriacont-16-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-47-4 CAPLUS

CN 4,6,10-Trioxa-5-phosphatriacont-20-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-48-5 CAPLUS

CN 4,6,10-Trioxa-5-phosphatriacont-22-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-49-6 CAPLUS

CN 4,6,10-Trioxa-5-phosphahentriacont-16-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-50-9 CAPLUS

CN 4,6,10-Trioxa-5-phosphahentriacont-20-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-51-0 CAPLUS

CN 4,6,10-Trioxa-5-phosphadotriacont-22-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-52-1 CAPLUS

CN 4,6,10-Trioxa-5-phosphadotriacont-16-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-53-2 CAPLUS

CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 257919-54-3 CAPLUS

CN 4,6,10-Trioxa-5-phosphadotriacont-22-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-55-4 CAPLUS

CN 4,6,10-Trioxa-5-phosphatritriacont-16-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-56-5 CAPLUS

CN 4,6,10-Trioxa-5-phosphatritriacont-20-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257919-57-6 CAPLUS

CN 4,6,10-Trioxa-5-phosphatritriacont-22-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.






RN 257919-58-7 CAPLUS

CN 4,6,10-Trioxa-5-phosphatetratratriacont-16-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-59-8 CAPLUS

CN 4,6,10-Trioxa-5-phosphatetratratriacont-20-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-60-1 CAPLUS

CN 4,6,10-Trioxa-5-phosphatetratratriacont-22-en-1-aminium, 5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-61-2 CAPLUS

CN 5,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-62-3 CAPLUS

CN 5,7,11-Trioxa-6-phosphanonacos-21-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-63-4 CAPLUS

CN 5,7,11-Trioxa-6-phosphatriacont-23-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-64-5 CAPLUS

CN 5,7,11-Trioxa-6-phosphatriacont-17-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-65-6 CAPLUS

CN 5,7,11-Trioxa-6-phosphatriacont-21-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-66-7 CAPLUS

CN 5,7,11-Trioxa-6-phosphatriacont-23-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-67-8 CAPLUS

CN 5,7,11-Trioxa-6-phosphahentriacont-17-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-68-9 CAPLUS

CN 5,7,11-Trioxa-6-phosphahentriacont-21-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-69-0 CAPLUS

CN 5,7,11-Trioxa-6-phosphahentriacont-23-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-70-3 CAPLUS

CN 5,7,11-Trioxa-6-phosphadotriacont-17-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-71-4 CAPLUS

CN 5,7,11-Trioxa-6-phosphadotriacont-21-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-72-5 CAPLUS

CN 5,7,11-Trioxa-6-phosphadotriacont-23-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-73-6 CAPLUS

CN 5,7,11-Trioxa-6-phosphatritriacont-17-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 257919-74-7 CAPLUS

CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-75-8 CAPLUS

CN 5,7,11-Trioxa-6-phosphatritriacont-23-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,23Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-76-9 CAPLUS

CN 5,7,11-Trioxa-6-phosphatetratritriacont-17-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-78-1 CAPLUS

CN 5,7,11-Trioxa-6-phosphatetratritriacont-21-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-79-2 CAPLUS

CN 5,7,11-Trioxa-6-phosphatetatriacont-23-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,23Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-80-5 CAPLUS

CN 5,7,11-Trioxa-6-phosphapentatriacont-17-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-81-6 CAPLUS

CN 5,7,11-Trioxa-6-phosphapentatriacont-21-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-82-7 CAPLUS

CN 5,7,11-Trioxa-6-phosphapentatriacont-23-en-1-aminium, 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257919-83-8 CAPLUS

CN 3,5,8-Trioxa-4-phosphahexacos-18-en-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-84-9 CAPLUS

CN 3,5,8-Trioxa-4-phosphaheptacos-14-en-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-85-0 CAPLUS

CN 3,5,8-Trioxa-4-phosphaoctacos-20-en-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-86-1 CAPLUS

CN 3,5,8-Trioxa-4-phosphanonacos-18-en-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-87-2 CAPLUS

CN 3,5,8-Trioxa-4-phosphatriacont-18-en-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,18Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-88-3 CAPLUS

CN 3,5,8-Trioxa-4-phosphatriacont-20-en-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,20Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-89-4 CAPLUS

CN 3,5,8-Trioxa-4-phosphahentriacont-18-en-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,18Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-90-7 CAPLUS




CN 3,5,8-Trioxa-4-phosphadotriacont-18-en-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,18Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257919-91-8 CAPLUS  
CN 4,6,9-Trioxa-5-phosphaheptacos-19-en-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,19Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257919-92-9 CAPLUS  
CN 4,6,9-Trioxa-5-phosphaoctacos-15-en-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 257919-93-0 CAPLUS  
CN 4,6,9-Trioxa-5-phosphanonacos-21-en-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257919-94-1 CAPLUS

CN 4,6,9-Trioxa-5-phosphatriacont-19-en-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,19Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-95-2 CAPLUS

CN 4,6,9-Trioxa-5-phosphahentriacont-19-en-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,19Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-96-3 CAPLUS

CN 4,6,9-Trioxa-5-phosphahentriacont-21-en-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,21Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257919-97-4 CAPLUS

CN 4,6,9-Trioxa-5-phosphadotriacont-19-en-1-aminium, 5-hydroxy-7-


(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,19Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257919-98-5 CAPLUS  
CN 4,6,9-Trioxa-5-phosphatritriacont-19-en-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,19Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257919-99-6 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacos-19-en-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-00-6 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaoctacos-15-en-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-01-7 CAPLUS  
CN 3,5,9-Trioxa-4-phosphanonacos-21-en-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-02-8 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatriacont-19-en-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-03-9 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-04-0 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriacont-21-en-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-05-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphadotriacont-19-en-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-06-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-07-3 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacos-20-en-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-08-4 CAPLUS

CN 4,6,10-Trioxa-5-phosphanonacos-16-en-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257920-09-5 CAPLUS

CN 4,6,10-Trioxa-5-phosphatriacont-22-en-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257920-10-8 CAPLUS

CN 4,6,10-Trioxa-5-phosphahentriacont-20-en-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257920-11-9 CAPLUS

CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 257920-12-0 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriacont-22-en-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-13-1 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatritriacont-20-en-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-14-2 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatetatriacont-20-en-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-15-3 CAPLUS  
CN 3,5,9-Trioxa-4-phosphapentacosa-15,21-dien-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-16-4 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahexacosa-15,21-dien-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-17-5 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacos-15,21-dien-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257920-18-6 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaoctacos-15,21-dien-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257920-19-7 CAPLUS



CN 3,5,9-Trioxa-4-phosphanonacosa-18,24-dien-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,18Z,24Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-20-0 CAPLUS


CN 3,5,9-Trioxa-4-phosphatriaconta-18,24-dien-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,18Z,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A


PAGE 1-B



RN 257920-21-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphahentriaconta-14,26-dien-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,14Z,26Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-22-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphadotriaconta-15,27-dien-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-23-3 CAPLUS


CN 3,5,9-Trioxa-4-phosphatritriaconta-15,27-dien-1-aminium,  
4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z,27Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257920-24-4 CAPLUS


CN 3,5,9-Trioxa-4-phosphatetratritriaconta-15,27-dien-1-aminium,  
4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z,27Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257920-25-5 CAPLUS

CN 4,6,10-Trioxa-5-phosphahexacosa-16,22-dien-1-aminium, 5-hydroxy-8-methoxy-  
N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,22Z)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-26-6 CAPLUS

CN 4,6,10-Trioxa-5-phosphaheptacos-16,22-dien-1-aminium,  
5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,22Z)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-27-7 CAPLUS


CN 4,6,10-Trioxa-5-phosphaoctacos-16,22-dien-1-aminium, 5-hydroxy-8-methoxy-  
N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,22Z)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A

PAGE 1-B




RN 257920-28-8 CAPLUS


CN 4,6,10-Trioxa-5-phosphanonacos-16,22-dien-1-aminium, 5-hydroxy-8-methoxy-  
N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,22Z)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257920-29-9 CAPLUS

CN 4,6,10-Trioxa-5-phosphatriaconta-19,25-dien-1-aminium,  
5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,19Z,25Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-30-2 CAPLUS


CN 4,6,10-Trioxa-5-phosphahentriaconta-19,25-dien-1-aminium,  
5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,19Z,25Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257920-31-3 CAPLUS

CN 4,6,10-Trioxa-5-phosphadotriaconta-15,27-dien-1-aminium,


5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,15Z,27Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.





RN 257920-32-4 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatritriaconta-16,28-dien-1-aminium,  
5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,28Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-33-5 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatettratriaconta-16,28-dien-1-aminium,  
5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,28Z)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-34-6 CAPLUS  
CN 4,6,10-Trioxa-5-phosphapentatriaconta-16,28-dien-1-aminium,  
5-hydroxy-8-methoxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,28Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257920-35-7 CAPLUS

CN 5,7,11-Trioxa-6-phosphaheptacos-17,23-dien-1-aminium,  
6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z,23Z)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-36-8 CAPLUS

CN 5,7,11-Trioxa-6-phosphaoctacos-17,23-dien-1-aminium, 6-hydroxy-9-methoxy-  
N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z,23Z)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-37-9 CAPLUS


CN 5,7,11-Trioxa-6-phosphanonacos-17,23-dien-1-aminium, 6-hydroxy-9-methoxy-  
N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z,23Z)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257920-38-0 CAPLUS


CN 5,7,11-Trioxa-6-phosphatriaconta-17,23-dien-1-aminium,  
6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z,23Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257920-39-1 CAPLUS

CN 5,7,11-Trioxa-6-phosphahentriaconta-20,26-dien-1-aminium,  
6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,20Z,26Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-40-4 CAPLUS

CN 5,7,11-Trioxa-6-phosphadotriaconta-20,26-dien-1-aminium,


6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,20Z,26Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257920-41-5 CAPLUS  
CN 5,7,11-Trioxa-6-phosphatritriaconta-16,28-dien-1-aminium,  
6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,16Z,28Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-42-6 CAPLUS  
CN 5,7,11-Trioxa-6-phosphatetatriaconta-17,29-dien-1-aminium,  
6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z,29Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-43-7 CAPLUS  
CN 5,7,11-Trioxa-6-phosphapentatriaconta-17,29-dien-1-aminium,  
6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z,29Z)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A




PAGE 1-B




RN 257920-44-8 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphahexatriaconta-17,29-dien-1-aminium,  
 6-hydroxy-9-methoxy-N,N,N-trimethyl-, inner salt, 6-oxide, (9R,17Z,29Z)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257920-45-9 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphatetracos-14,20-dien-1-aminium, 4-hydroxy-6-  
 (methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,14Z,20Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 257920-46-0 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphapentacosa-14,20-dien-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,14Z,20Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 257920-47-1 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphahexacosa-14,20-dien-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,14Z,20Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



PAGE 1-A


PAGE 1-B

N<sup>+</sup>Me<sub>3</sub>

RN 257920-48-2 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphaheptacosa-14,20-dien-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,14Z,20Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

N<sup>+</sup>Me<sub>3</sub>

RN 257920-49-3 CAPLUS  
CN 3,5,8-Trioxa-4-phosphaoctacosa-17,23-dien-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,17Z,23Z)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-50-6 CAPLUS  
CN 3,5,8-Trioxa-4-phosphanonacosa-17,23-dien-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,17Z,23Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257920-51-7 CAPLUS  
CN 3,5,8-Trioxa-4-phosphatriaconta-13,25-dien-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,13Z,25Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-52-8 CAPLUS  
CN 3,5,8-Trioxa-4-phosphahentriaconta-14,26-dien-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,14Z,26Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-53-9 CAPLUS  
CN 3,5,8-Trioxa-4-phosphadotriaconta-14,26-dien-1-aminium, 4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (6S,14Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


N<sup>+</sup>Me<sub>3</sub>

RN 257920-54-0 CAPLUS

CN 3,5,8-Trioxa-4-phosphatritriaconta-14,26-dien-1-aminium,  
4-hydroxy-6-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide,  
(6S,14Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

N<sup>+</sup>Me<sub>3</sub>

RN 257920-55-1 CAPLUS

CN 4,6,9-Trioxa-5-phosphapentacos-15,21-dien-1-aminium, 5-hydroxy-7-  
(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,15Z,21Z)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-56-2 CAPLUS

CN 4,6,9-Trioxa-5-phosphahexacos-15,21-dien-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,15Z,21Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-57-3 CAPLUS

CN 4,6,9-Trioxa-5-phosphaheptacos-15,21-dien-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,15Z,21Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


—N<sup>+</sup>Me<sub>3</sub>

RN 257920-58-4 CAPLUS

CN 4,6,9-Trioxa-5-phosphaoctacos-15,21-dien-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,15Z,21Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—N<sup>+</sup>Me<sub>3</sub>

RN 257920-59-5 CAPLUS  
CN 4,6,9-Trioxa-5-phosphanonacosa-18,24-dien-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,18Z,24Z)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-60-8 CAPLUS  
CN 4,6,9-Trioxa-5-phosphatriciaconta-18,24-dien-1-aminium, 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide, (7S,18Z,24Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

 $\text{N}^+\text{Me}_3$ 


RN 257920-62-0 CAPLUS  
CN 4,6,9-Trioxa-5-phosphahentriaconta-14,26-dien-1-aminium,  
5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide,  
(7S,14Z,26Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-64-2 CAPLUS  
CN 4,6,9-Trioxa-5-phosphadotriaconta-15,27-dien-1-aminium,  
5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide,  
(7S,15Z,27Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-66-4 CAPLUS  
CN 4,6,9-Trioxa-5-phosphatritriaconta-15,27-dien-1-aminium,  
5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide,  
(7S,15Z,27Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A




PAGE 1-B

—N<sup>+</sup>Me<sub>3</sub>

RN 257920-68-6 CAPLUS  
 CN 4,6,9-Trioxa-5-phosphatetratrisaconta-15,27-dien-1-aminium,  
 5-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 5-oxide,  
 (7S,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—N<sup>+</sup>Me<sub>3</sub>

RN 257920-70-0 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentacos-15,21-dien-1-aminium, 7-(1,1-  
 dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide,  
 (7R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 257920-72-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphahexacos-15,21-dien-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257920-74-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-15,21-dien-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257920-76-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphaoctacos-15,21-dien-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257920-78-8 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphanonacosa-18,24-dien-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,18Z,24Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.




RN 257920-79-9 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatriaconta-18,24-dien-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,18Z,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257920-80-2 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahentriaconta-14,26-dien-1-aminium, 7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (7R,14Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-81-3 CAPLUS  
CN 3,5,9-Trioxa-4-phosphadotriaconta-15,27-dien-1-aminium,  
7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide,  
(7R,15Z,27Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-82-4 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatritriaconta-15,27-dien-1-aminium,  
7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide,  
(7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257920-83-5 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatettratriaconta-15,27-dien-1-aminium,  
7-(1,1-dimethylethoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide,  
(7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257920-84-6 CAPLUS

CN 4,6,10-Trioxa-5-phosphahexacos-16,22-dien-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,22Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



IT 257920-85-7 257920-86-8 257920-87-9  
257920-88-0 257920-89-1 257920-90-4  
257920-91-5 257920-92-6 257920-93-7  
257920-94-8 257920-95-9 257920-96-0  
257920-97-1 257920-98-2 257920-99-3  
257921-00-9 257921-01-0 257921-02-1  
257921-03-2 257921-04-3 257921-05-4  
257921-06-5 257921-07-6 257921-08-7  
257921-09-8 257921-26-9 257921-27-0  
257921-28-1 257921-29-2 257921-30-5  
257921-31-6 257921-32-7 257921-33-8  
257921-34-9 257921-35-0 257921-36-1  
257921-37-2 257921-38-3 257921-39-4  
257921-40-7 257921-41-8 257921-42-9  
257921-43-0 257921-44-1 257921-45-2  
257921-66-7 257921-67-8 257921-68-9  
257921-69-0 257921-70-3 257921-71-4  
257921-72-5 257921-73-6 257921-75-8  
257921-77-0 257921-79-2 257921-80-5  
257921-81-6 257921-82-7 257921-83-8  
257921-84-9 257921-85-0 257921-86-1  
257921-87-2 257921-88-3 257921-89-4  
257921-90-7 257921-91-8 257921-92-9  
257921-93-0 257921-94-1 257921-95-2  
257921-96-3 257921-97-4 257921-98-5  
257921-99-6 257922-00-2 257922-01-3  
257922-02-4 257922-03-5 257922-04-6  
257922-05-7 257922-06-8 257922-07-9  
257922-08-0 257922-09-1 257922-10-4

257922-11-5 257922-12-6 257922-13-7  
257922-14-8 257922-15-9 257922-16-0  
257922-17-1 257922-18-2 257922-19-3  
257922-20-6 257922-21-7 257922-22-8  
257922-23-9 257922-24-0 257922-25-1  
257922-26-2 257922-27-3 257922-28-4  
257922-29-5 257922-30-8 257922-31-9  
257922-32-0 257922-33-1 257922-34-2  
257922-35-3 257922-36-4 257922-37-5  
257922-38-6 257922-39-7 257922-40-0  
257922-41-1 257922-42-2 257922-43-3  
257922-44-4 257922-45-5 257922-46-6  
257922-47-7 257922-48-8 257922-49-9  
257922-50-2 257922-51-3 257922-52-4  
257922-53-5 257922-54-6 257922-55-7  
257922-56-8 257922-57-9 257922-58-0  
257922-59-1 257922-60-4 257922-61-5  
257922-62-6 257922-63-7 257922-64-8  
257922-65-9 257922-66-0 257922-67-1  
257922-68-2 257922-69-3 257922-70-6  
257922-71-7 257922-72-8 257922-73-9  
257922-74-0 257922-75-1 257922-76-2  
257922-77-3 257922-78-4 257922-79-5  
257922-80-8 257922-81-9 257922-82-0  
257922-83-1 257922-84-2 257922-85-3  
257922-86-4 257922-87-5 257922-88-6  
257922-89-7 257922-90-0 257922-91-1  
257922-92-2 257922-93-3 257922-94-4  
257922-95-5 257922-96-6 257922-97-7  
257922-98-8 257922-99-9 257923-00-5  
257923-01-6 257923-02-7 257923-03-8  
257923-04-9 257923-05-0 257923-06-1  
257923-07-2 257923-08-3 257923-09-4  
257923-10-7 257923-11-8 257923-12-9  
257923-13-0 257923-15-2 257923-16-3  
257923-17-4 257923-18-5 257923-19-6  
257923-20-9 257923-21-0 257923-22-1  
257923-23-2 257923-25-4 257923-27-6  
257923-29-8 257923-30-1 257923-31-2  
257923-32-3 257923-33-4 257923-34-5  
257923-35-6 257923-36-7 257923-37-8  
257923-45-8 257923-46-9 257923-47-0  
257923-48-1 257923-49-2 257923-50-5  
257923-51-6 257923-52-7 257923-53-8  
257923-57-2 257923-58-3 257923-59-4  
257923-60-7 257923-61-8 257923-62-9 25792  
3-63-0 257923-64-1 257923-65-2  
257923-66-3 257923-67-4 257923-68-5  
257923-69-6 257923-70-9 257923-71-0  
257923-72-1 257923-73-2 257923-74-3  
257923-75-4 257923-76-5 257923-77-6

RL: PRP (Properties)


(novel phospholipids with synthetic, unsatd. alkyl and acyl chains)

RN 257920-85-7 CAPLUS

CN 4,6,10-Trioxa-5-phosphaheptacos-16,22-dien-1-aminium,  
8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide,  
(8R,16Z,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257920-86-8 CAPLUS


CN 4,6,10-Trioxa-5-phosphaoctacos-16,22-dien-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257920-87-9 CAPLUS


CN 4,6,10-Trioxa-5-phosphanonacos-16,22-dien-1-aminium, 8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257920-88-0 CAPLUS

CN 4,6,10-Trioxa-5-phosphatriaconta-19,25-dien-1-aminium,


8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide,  
(8R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257920-89-1 CAPLUS  
CN 4,6,10-Trioxa-5-phosphahentriaconta-19,25-dien-1-aminium,  
8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide,  
(8R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




PAGE 1-A

PAGE 1-B



RN 257920-90-4 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriaconta-15,27-dien-1-aminium,  
8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide,  
(8R,15Z,27Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257920-91-5 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatritriaconta-16,28-dien-1-aminium,  
8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide,  
(8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.






RN 257920-92-6 CAPLUS


CN 4,6,10-Trioxa-5-phosphatetatriaconta-16,28-dien-1-aminium,  
8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide,  
(8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257920-93-7 CAPLUS


CN 4,6,10-Trioxa-5-phosphapentatriaconta-16,28-dien-1-aminium,  
8-(1,1-dimethylethoxy)-5-hydroxy-N,N,N-trimethyl-, inner salt, 5-oxide,  
(8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257920-94-8 CAPLUS

CN 3,5,8-Trioxa-4-phosphahexacos-18-en-1-aminium, 4-hydroxy-N,N,N,6-

tetramethyl-, inner salt, 4-oxide, (18Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257920-95-9 CAPLUS

CN 3,5,8-Trioxa-4-phosphaheptacos-14-en-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (14Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257920-96-0 CAPLUS

CN 3,5,8-Trioxa-4-phosphaoctacos-20-en-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (20Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257920-97-1 CAPLUS

CN 3,5,8-Trioxa-4-phosphanonacos-18-en-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (18Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257920-98-2 CAPLUS

CN 3,5,8-Trioxa-4-phosphatriacont-18-en-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (18Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257920-99-3 CAPLUS

CN 3,5,8-Trioxa-4-phosphatriacont-20-en-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (20Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-00-9 CAPLUS

CN 3,5,8-Trioxa-4-phosphahentriacont-18-en-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (18Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-01-0 CAPLUS

CN 3,5,8-Trioxa-4-phosphadotriacont-18-en-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (18Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-02-1 CAPLUS

CN 4,6,9-Trioxa-5-phosphaheptacos-19-en-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (19Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-03-2 CAPLUS

CN 4,6,9-Trioxa-5-phosphaoctacos-15-en-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (15Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-04-3 CAPLUS

CN 4,6,9-Trioxa-5-phosphanonacos-21-en-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (21Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-05-4 CAPLUS

CN 4,6,9-Trioxa-5-phosphatriacont-19-en-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (19Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-06-5 CAPLUS

CN 4,6,9-Trioxa-5-phosphahentriacont-19-en-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (19Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-07-6 CAPLUS

CN 4,6,9-Trioxa-5-phosphahentriacont-21-en-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (21Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-08-7 CAPLUS

CN 4,6,9-Trioxa-5-phosphadotriacont-19-en-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (19Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-09-8 CAPLUS

CN 4,6,9-Trioxa-5-phosphatritriacont-19-en-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (19Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-26-9 CAPLUS

CN 3,5,8-Trioxa-4-phosphatetracos-14,20-dien-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (14Z,20Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-27-0 CAPLUS

CN 3,5,8-Trioxa-4-phosphapentacos-14,20-dien-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (14Z,20Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-28-1 CAPLUS

CN 3,5,8-Trioxa-4-phosphahexacos-14,20-dien-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (14Z,20Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-29-2 CAPLUS


CN 3,5,8-Trioxa-4-phosphaheptacos-14,20-dien-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (14Z,20Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-A


PAGE 1-B



RN 257921-30-5 CAPLUS

CN 3,5,8-Trioxa-4-phosphaoctacosa-17,23-dien-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (17Z,23Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257921-31-6 CAPLUS


CN 3,5,8-Trioxa-4-phosphanonacosa-17,23-dien-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (17Z,23Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257921-32-7 CAPLUS

CN 3,5,8-Trioxa-4-phosphatriaconta-13,25-dien-1-aminium, 4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (13Z,25Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-33-8 CAPLUS

CN 3,5,8-Trioxa-4-phosphahentriaconta-14,26-dien-1-aminium,  
4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (14Z,26Z)- (9CI) (CA  
INDEX NAME)


Double bond geometry as shown.



RN 257921-34-9 CAPLUS


CN 3,5,8-Trioxa-4-phosphadotriaconta-14,26-dien-1-aminium,  
4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (14Z,26Z)- (9CI) (CA  
INDEX NAME)

Double bond geometry as shown.



PAGE 1-A

PAGE 1-B




RN 257921-35-0 CAPLUS

CN 3,5,8-Trioxa-4-phosphatritriaconta-14,26-dien-1-aminium,  
4-hydroxy-N,N,N,6-tetramethyl-, inner salt, 4-oxide, (14Z,26Z)- (9CI) (CA  
INDEX NAME)



Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

$\text{N}^+\text{Me}_3$


RN 257921-36-1 CAPLUS  
CN 4,6,9-Trioxa-5-phosphapentacos-15,21-dien-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (15Z,21Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257921-37-2 CAPLUS  
CN 4,6,9-Trioxa-5-phosphahexacos-15,21-dien-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (15Z,21Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 257921-38-3 CAPLUS  
CN 4,6,9-Trioxa-5-phosphaheptacos-15,21-dien-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (15Z,21Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-39-4 CAPLUS


CN 4,6,9-Trioxa-5-phosphaoctacos-15,21-dien-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (15Z,21Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257921-40-7 CAPLUS

CN 4,6,9-Trioxa-5-phosphanonacos-18,24-dien-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (18Z,24Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257921-41-8 CAPLUS


CN 4,6,9-Trioxa-5-phosphatriaconta-18,24-dien-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (18Z,24Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257921-42-9 CAPLUS

CN 4,6,9-Trioxa-5-phosphahentriaconta-14,26-dien-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (14Z,26Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257921-43-0 CAPLUS

CN 4,6,9-Trioxa-5-phosphadotriaconta-15,27-dien-1-aminium, 5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (15Z,27Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257921-44-1 CAPLUS


CN 4,6,9-Trioxa-5-phosphatritriaconta-15,27-dien-1-aminium,  
5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (15Z,27Z)- (9CI) (CA  
INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-45-2 CAPLUS


CN 4,6,9-Trioxa-5-phosphatetratriaconta-15,27-dien-1-aminium,  
5-hydroxy-N,N,N,7-tetramethyl-, inner salt, 5-oxide, (15Z,27Z)- (9CI) (CA  
INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-66-7 CAPLUS  
CN 3,5,9-Trioxa-4-phosphapentacos-15-en-1-aminium, N-(2,3-dihydroxypropyl)-  
4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,15Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-67-8 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahexacos-19-en-1-aminium, N-(2,3-dihydroxypropyl)-4,7-  
dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-68-9 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-69-0 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaoctacos-15-en-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-70-3 CAPLUS  
CN 3,5,9-Trioxa-4-phosphanonacos-21-en-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-71-4 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-  
4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-72-5 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-  
4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-73-6 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriacont-21-en-1-aminium, N-(2,3-dihydroxypropyl)-  
4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,21Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-75-8 CAPLUS  
CN 3,5,9-Trioxa-4-phosphadotriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-  
4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-77-0 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-  
4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z)- (9CI)




(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-79-2 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatetatriacont-24-en-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-80-5 CAPLUS  
CN 3,5,9-Trioxa-4-phosphapentatriacont-25-en-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-81-6 CAPLUS


3,5,9-Trioxa-4-phosphapentacos-14,20-dien-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-82-7 CAPLUS


3,5,9-Trioxa-4-phosphahexacos-14,20-dien-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-83-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-14,20-dien-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-84-9 CAPLUS


CN 3,5,9-Trioxa-4-phosphaoctacos-15,21-dien-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-85-0 CAPLUS  
CN 3,5,9-Trioxa-4-phosphanonacosa-19,25-dien-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-86-1 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatriaconta-19,25-dien-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-87-2 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-88-3 CAPLUS


CN 3,5,9-Trioxa-4-phosphadotriaconta-19,25-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt,  
4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-89-4 CAPLUS


CN 3,5,9-Trioxa-4-phosphatritriaconta-15,27-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt,  
4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-90-7 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatetratratriaconta-19,25-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt,  
4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-91-8 CAPLUS  
CN 3,5,9-Trioxa-4-phosphapentatratratriaconta-15,27-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt,  
4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-92-9 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentacos-15-en-1-aminium, N-(2,3-dihydroxypropyl)-  
 4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257921-93-0 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentacos-15-en-1-aminium, N-(2,3-dihydroxypropyl)-  
 4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-94-1 CAPLUS


CN 3,5,9-Trioxa-4-phosphanonacos-21-en-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-95-2 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-96-3 CAPLUS

CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A



PAGE 1-B




RN 257921-97-4 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentatriacont-25-en-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-98-5 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentacos-14,20-dien-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257921-99-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosa-14,20-dien-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-00-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphanonacosa-19,25-dien-1-aminium, N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-01-3 CAPLUS

CN 3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium,


N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide,  
(7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-02-4 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatritriaconta-15,27-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide,  
(7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-03-5 CAPLUS  
CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide,  
(7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-04-6 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexacos-16-en-1-aminium, N-(2,3-dihydroxypropyl)-  
5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,16Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-05-7 CAPLUS


CN 4,6,10-Trioxa-5-phosphaheptacos-20-en-1-aminium, N-(2,3-dihydroxypropyl)-  
5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-06-8 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, N-(2,3-dihydroxypropyl)-  
 5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,16Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-07-9 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatriacont-22-en-1-aminium, N-(2,3-dihydroxypropyl)-  
 5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,22Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-08-0 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-(2,3-dihydroxypropyl)-


5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-09-1 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriacont-22-en-1-aminium, N-(2,3-dihydroxypropyl)-  
5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,22Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-10-4 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatritriacont-20-en-1-aminium, N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide,  
(8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-11-5 CAPLUS


CN 4,6,10-Trioxa-5-phosphatetatriacont-20-en-1-aminium, N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-12-6 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexacosa-15,21-dien-1-aminium, N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-13-7 CAPLUS


CN 4,6,10-Trioxa-5-phosphaoctacos-15,21-dien-1-aminium, N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-14-8 CAPLUS


CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium, N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B







RN 257922-15-9 CAPLUS  
CN 4,6,10-Trioxa-5-phosphahentriaconta-20,26-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt,  
5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-16-0 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriaconta-20,26-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt,  
5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-17-1 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatetratriaconta-16,28-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt,  
5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-18-2 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt,  
5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-19-3 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexacos-16-en-1-aminium, N-(2,3-dihydroxypropyl)-  
5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-20-6 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, N-(2,3-dihydroxypropyl)-  
5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-21-7 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatriacont-22-en-1-aminium, N-(2,3-dihydroxypropyl)-  
5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-22-8 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-(2,3-dihydroxypropyl)-  
5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA


INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-23-9 CAPLUS


CN 4,6,10-Trioxa-5-phosphatetatriacont-20-en-1-aminium, N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-24-0 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexacosa-15,21-dien-1-aminium, N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-25-1 CAPLUS


CN 4,6,10-Trioxa-5-phosphaoctacosa-15,21-dien-1-aminium, N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-26-2 CAPLUS


CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium, N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-27-3 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriaconta-20,26-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide,  
 (8R,20Z,26Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-28-4 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatetratriaconta-16,28-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide,  
 (8R,16Z,28Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-29-5 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide,  
 (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-30-8 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, N-(2,3-dihydroxypropyl)-  
 6,9-dihydroxy-N,N-dimethyl-12-oxo-, inner salt, 6-oxide, (9R,17Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-31-9 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-(2,3-  
 dihydroxypropyl)-6,9-dihydroxy-N,N-dimethyl-12-oxo-, inner salt, 6-oxide,  
 (9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-32-0 CAPLUS


CN 5,7,11-Trioxa-6-phosphaheptacos-16,22-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-6,9-dihydroxy-N,N-dimethyl-12-oxo-, inner salt,  
6-oxide, (9R,16Z,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-33-1 CAPLUS

CN 5,7,11-Trioxa-6-phosphatritriaconta-21,27-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-6,9-dihydroxy-N,N-dimethyl-12-oxo-, inner salt,  
6-oxide, (9R,21Z,27Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A






PAGE 1-B




RN 257922-34-2 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphaheptatriaconta-17,29-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-6,9-dihydroxy-N,N-dimethyl-12-oxo-, inner salt,  
 6-oxide, (9R,17Z,29Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-35-3 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, N-(2,3-dihydroxypropyl)-  
 6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-36-4 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-(2,3-  
 dihydroxypropyl)-6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide,


(9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-37-5 CAPLUS


CN 5,7,11-Trioxa-6-phosphanacosa-16,22-dien-1-aminium, N-(2,3-dihydroxypropyl)-6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide, (9R,16Z,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-38-6 CAPLUS


CN 5,7,11-Trioxa-6-phosphahentriacont-23-en-1-aminium, N-(2,3-dihydroxypropyl)-6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide, (9R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-39-7 CAPLUS

CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-40-0 CAPLUS

CN 7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, N-(2,3-dihydroxypropyl)-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,23Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-41-1 CAPLUS


CN 7,9,13-Trioxa-8-phosphanonacosa-18,24-dien-1-aminium, N-(2,3-dihydroxypropyl)-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,18Z,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-42-2 CAPLUS


CN 7,9,13-Trioxa-8-phosphapentatriaconta-23,29-dien-1-aminium, N-(2,3-dihydroxypropyl)-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,23Z,29Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-43-3 CAPLUS


CN 7,9,13-Trioxa-8-phosphanonatriaconta-19,31-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt,  
8-oxide, (11R,19Z,31Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-44-4 CAPLUS  
CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, N-(2,3-  
dihydroxypropyl)-8,11-dihydroxy-N,N-dimethyl-, inner salt, 8-oxide,  
(11R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-45-5 CAPLUS  
CN 7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, N-(2,3-  
dihydroxypropyl)-8,11-dihydroxy-N,N-dimethyl-, inner salt, 8-oxide,  
(11R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-46-6 CAPLUS


CN 7,9,13-Trioxa-8-phosphahentriaconta-18,24-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-8,11-dihydroxy-N,N-dimethyl-, inner salt, 8-oxide,  
(11R,18Z,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-47-7 CAPLUS


CN 7,9,13-Trioxa-8-phosphatritriacont-25-en-1-aminium, N-(2,3-  
dihydroxypropyl)-8,11-dihydroxy-N,N-dimethyl-, inner salt, 8-oxide,  
(11R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-48-8 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentacos-15-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-49-9 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphaoctacos-15-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-50-2 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-51-3 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacont-21-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-52-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A



PAGE 1-B




RN 257922-53-5 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentatriacont-25-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-54-6 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentacosa-14,20-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-55-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-14,20-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-56-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphatriaconta-19,25-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-57-9 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-58-0 CAPLUS  
CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-  
oxo-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-59-1 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, N-[3-(2,3-  
dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner  
salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-60-4 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphanonacos-21-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-61-5 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-62-6 CAPLUS


CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-63-7 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentatriacont-25-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-64-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-14,20-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-65-9 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatritriaconta-15,27-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-,  
 inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-66-0 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, N-[3-(2,3-  
 dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-oxo-,  
 inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-67-1 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatriacont-22-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-68-2 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-69-3 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriacont-22-en-1-aminium, N-[3-(2,3-


dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-oxo-,  
inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-70-6 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatetatriacont-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-oxo-,  
inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-71-7 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacosa-15,21-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-oxo-,  
inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A



PAGE 1-B




RN 257922-72-8 CAPLUS


CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-  
 oxo-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-73-9 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriaconta-20,26-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-  
 oxo-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-74-0 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatetatriaconta-16,28-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-  
 oxo-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-75-1 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-  
 oxo-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-76-2 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexacos-16-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-77-3 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-78-4 CAPLUS


CN 4,6,10-Trioxa-5-phosphatetratriacont-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-79-5 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexacos-15,21-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-80-8 CAPLUS


CN 4,6,10-Trioxa-5-phosphaoctacos-15,21-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-81-9 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatriciaconta-20,26-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-,  
 inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-82-0 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatetratriciaconta-16,28-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-,  
 inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-83-1 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-,  
 inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-84-2 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, N-[3-(2,3-  
 dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-12-oxo-,  
 inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-85-3 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-[3-(2,3-  
 dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-12-oxo-,  
 inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-86-4 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphaheptacos-16,22-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-12-  
 oxo-, inner salt, 6-oxide, (9R,16Z,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-87-5 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphatritriaconta-21,27-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-12-  
 oxo-, inner salt, 6-oxide, (9R,21Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-88-6 CAPLUS


CN 5,7,11-Trioxa-6-phosphaheptatriaconta-17,29-dien-1-aminium,  
N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-12-  
oxo-, inner salt, 6-oxide, (9R,17Z,29Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-89-7 CAPLUS


CN 5,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, N-[3-(2,3-  
dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-, inner  
salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 257922-90-0 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-[3-(2,3-




dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-91-1 CAPLUS  
CN 5,7,11-Trioxa-6-phosphanonacosa-16,22-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide, (9R,16Z,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257922-92-2 CAPLUS  
CN 5,7,11-Trioxa-6-phosphahentriacont-23-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide, (9R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-93-3 CAPLUS


CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-94-4 CAPLUS


CN 7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-95-5 CAPLUS


CN 7,9,13-Trioxa-8-phosphanonacosa-18,24-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,18Z,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-96-6 CAPLUS


CN 7,9,13-Trioxa-8-phosphapentatriaconta-23,29-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,23Z,29Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-97-7 CAPLUS


CN 7,9,13-Trioxa-8-phosphanonatriaconta-19,31-dien-1-aminium,  
N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-  
14-oxo-, inner salt, 8-oxide, (11R,19Z,31Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-98-8 CAPLUS


CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, N-[3-(2,3-  
dihydroxypropoxy)-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-, inner  
salt, 8-oxide, (11R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257922-99-9 CAPLUS


CN 7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, N-[3-(2,3-  
dihydroxypropoxy)-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-, inner  
salt, 8-oxide, (11R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-00-5 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphahentriaconta-18,24-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-,  
 inner salt, 8-oxide, (11R,18Z,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-01-6 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphatritriacont-25-en-1-aminium, N-[3-(2,3-  
 dihydroxypropoxy)-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-, inner  
 salt, 8-oxide, (11R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-02-7 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, 5,8-dihydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257923-03-8 CAPLUS

CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, 5,8-dihydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257923-04-9 CAPLUS

CN 4,6,10-Trioxa-5-phosphatetratriacont-20-en-1-aminium, 5,8-dihydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 257923-05-0 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacos-15,21-dien-1-aminium, 5,8-dihydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-06-1 CAPLUS


CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium,  
5,8-dihydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z,26Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-07-2 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriaconta-20,26-dien-1-aminium,  
5,8-dihydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z,26Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-08-3 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
 5,8-dihydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (8R,16Z,28Z)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257923-09-4 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, 5,8-dihydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 257923-10-7 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatetratratriacont-20-en-1-aminium, 5,8-dihydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.






RN 257923-11-8 CAPLUS

CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium,  
5,8-dihydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257923-12-9 CAPLUS


CN 4,6,10-Trioxa-5-phosphatetriaconta-16,28-dien-1-aminium,  
5,8-dihydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-13-0 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
5,8-dihydroxy-N,N,N-trimethyl-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-15-2 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (15Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-16-3 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (19Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-17-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-


4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (19Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-18-5 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-14,20-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (14Z,20Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-19-6 CAPLUS


CN 3,5,9-Trioxa-4-phosphanonacos-19,25-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (19Z,25Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-20-9 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt,  
 4-oxide, (19Z,25Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-21-0 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt,  
 4-oxide, (15Z,27Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-22-1 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-(2,3-dihydroxypropyl)-  
 5-hydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (20Z)- (9CI) (CA  
 INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-23-2 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-(2,3-dihydroxypropyl)-6-hydroxy-N,N-dimethyl-12-oxo-, inner salt, 6-oxide, (21Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257923-25-4 CAPLUS

CN 3,5,8-Trioxa-4-phosphatriacont-18-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N,6-trimethyl-9-oxo-, inner salt, 4-oxide, (18Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257923-27-6 CAPLUS


CN 5,7,10-Trioxa-6-phosphadotriacont-20-en-1-aminium, N-(2,3-dihydroxypropyl)-6-hydroxy-N,N,8-trimethyl-11-oxo-, inner salt, 6-oxide, (20Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-29-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (15Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-30-1 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (19Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-31-2 CAPLUS


CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (19Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-32-3 CAPLUS


CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (14Z,20Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-33-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (14Z,20Z)- (9CI) (CA INDEX NAME)


salt, 4-oxide, (19Z,25Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-34-5 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium,  
N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-  
, inner salt, 4-oxide, (19Z,25Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-35-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-  
, inner salt, 4-oxide, (15Z,27Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

PAGE 1-A





PAGE 1-B




RN 257923-36-7 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (20Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-37-8 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-, inner salt, 6-oxide, (21Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257923-45-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (15Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257923-46-9 CAPLUS

CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (19Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257923-47-0 CAPLUS

CN 4,6,10-Trioxa-5-phosphatetratritriacont-20-en-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (20Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257923-48-1 CAPLUS


CN 4,6,10-Trioxa-5-phosphaoctacos-15,21-dien-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (15Z,21Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257923-49-2 CAPLUS

CN 4,6,10-Trioxa-5-phosphatriacenta-20,26-dien-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (20Z,26Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257923-50-5 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriaconta-20,26-dien-1-aminium,  
5-hydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (20Z,26Z)- (9CI)  
(CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-51-6 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
5-hydroxy-N,N,N-trimethyl-11-oxo-, inner salt, 5-oxide, (16Z,28Z)- (9CI)  
(CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257923-52-7 CAPLUS

CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, 5-hydroxy-N,N,N-  
trimethyl-11-oxo-, inner salt, 5-oxide, (20Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257923-53-8 CAPLUS

CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, 6-hydroxy-N,N,N-trimethyl-12-oxo-, inner salt, 6-oxide, (21Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 257923-57-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacos-15-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(6Z)-1-oxo-6-hexadecenyl]oxy-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-58-3 CAPLUS

CN 3,5,9-Trioxa-4-phosphahexacos-19-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(10Z)-1-oxo-10-heptadecenyl]oxy-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-59-4 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(6Z)-1-oxo-6-octadecenyl]oxy-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-60-7 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphaoctacos-15-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(6Z)-1-oxo-6-nonadecenyl]oxy-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-61-8 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphanonacos-21-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(12Z)-1-oxo-12-eicosenyl]oxy-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-62-9 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(10Z)-1-oxo-10-heneicosenyl]oxy-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-63-0 CAPLUS

CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(10Z)-1-oxo-10-docosenyl]oxy-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-64-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphahentriacont-21-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(12Z)-12-docosenyl]oxy-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-65-2 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphadotriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-  
 4-hydroxy-N,N-dimethyl-10-oxo-7-[[1-oxo-10-tricosenyl]oxy]-, inner salt,  
 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-66-3 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-  
 4-hydroxy-N,N-dimethyl-10-oxo-7-[[10Z]-1-oxo-10-tetracosenyl]oxy]-, inner  
 salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



PAGE 1-A




PAGE 1-B




RN 257923-67-4 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatetriacont-24-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(15Z)-1-oxo-15-pentacosenyl]oxy-, inner salt, 4-oxide, (7R,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-68-5 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriacont-25-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(16Z)-1-oxo-16-hexacosenyl]oxy-, inner salt, 4-oxide, (7R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-69-6 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentacos-14,20-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[{(5Z,11Z)-1-oxo-6,11-hexadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-70-9 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahexacos-14,20-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[{(5Z,11Z)-1-oxo-5,11-heptadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-71-0 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacos-14,20-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (5Z,11Z)-1-oxo-5,11-octadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-72-1 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaoctacos-15,21-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z,12Z)-1-oxo-6,12-nonadecadienyl]oxy]-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-73-2 CAPLUS  
CN 3,5,9-Trioxa-4-phosphanonacosa-19,25-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z,16Z)-1-oxo-10,16-eicosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-74-3 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatriaconta-19,25-dien-1-aminium, N-(2,3-


dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(10Z,16Z)-1-oxo-10,16-heneicosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN	257923-75-4	CAPLUS
CN	3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-76-5 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphadotriaconta-19,25-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z,16Z)-1-oxo-  
 10,16-tricosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-77-6 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatritriaconta-15,27-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z,18Z)-6,18-  
 tetracosadienyl]oxy]-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IT 257923-78-7 257923-79-8 257923-80-1  
257923-81-2 257923-82-3 257923-83-4  
257923-84-5 257923-85-6 257923-86-7  
257923-87-8 257923-88-9 257923-89-0  
257923-90-3 257923-91-4 257923-92-5  
257923-93-6 257923-94-7 257923-95-8  
257923-96-9 257923-97-0 257923-98-1  
257923-99-2 257924-00-8 257924-01-9  
257924-02-0 257924-03-1 257924-04-2  
257924-05-3 257924-06-4 257924-07-5  
257924-08-6 257924-09-7 257924-10-0  
257924-11-1 257924-12-2 257924-13-3  
257924-14-4 257924-15-5 257924-16-6  
257924-17-7 257924-18-8 257924-19-9  
257924-20-2 257924-21-3 257924-23-5  
257924-24-6 257924-25-7 257924-26-8  
257924-27-9 257924-28-0 257924-29-1  
257924-30-4 257924-31-5 257924-32-6  
257924-33-7 257924-34-8 257924-35-9  
257924-36-0 257924-37-1 257924-38-2  
257924-39-3 257924-40-6 257924-42-8  
257924-44-0 257924-45-1 257924-46-2  
257924-47-3 257924-48-4 257924-50-8  
257924-51-9 257924-52-0 257924-53-1  
257924-54-2 257924-55-3 257924-56-4  
257924-57-5 257924-58-6 257924-59-7  
257924-60-0 257924-61-1 257924-62-2  
257924-63-3 257924-64-4 257924-65-5  
257924-66-6 257924-67-7 257924-68-8  
257924-69-9 257924-70-2 257924-71-3  
257924-72-4 257924-73-5 257924-74-6  
257924-75-7 257924-76-8 257924-77-9  
257924-78-0 257924-79-1 257924-80-4  
257924-81-5 257924-82-6 257924-83-7  
257924-84-8 257924-85-9 257924-86-0  
257924-87-1 257924-88-2 257924-89-3  
257924-90-6 257924-91-7 257924-92-8  
257924-93-9 257924-94-0 257924-95-1  
257924-96-2 257924-97-3 257924-98-4  
257924-99-5 257925-00-1 257925-01-2  
257925-02-3 257925-03-4 257925-04-5  
257925-05-6 257925-06-7 257925-07-8  
257925-08-9 257925-09-0 257925-10-3  
257925-11-4 257925-12-5 257925-13-6  
257925-14-7 257925-15-8 257925-16-9  
257925-17-0 257925-18-1 257925-19-2  
257925-20-5 257925-21-6 257925-22-7  
257925-23-8 257925-25-0 257925-27-2  
257925-29-4 257925-31-8 257925-32-9  
257925-33-0 257925-34-1 257925-35-2  
257925-36-3 257925-37-4 257925-38-5  
257925-39-6 257925-40-9 257925-41-0

257925-42-1 257925-43-2 257925-44-3  
257925-45-4 257925-46-5 257925-47-6  
257925-48-7 257933-68-9 257933-69-0  
258274-24-7 258274-25-8 258274-26-9  
258274-27-0 258274-28-1 258274-29-2  
258274-30-5 258274-31-6 258274-32-7  
258274-33-8 258274-34-9 258274-35-0  
258274-36-1 258274-37-2 258274-38-3  
258274-39-4 258274-40-7 258274-41-8  
258274-42-9 258274-43-0 258274-44-1  
258274-45-2 258274-46-3 258274-47-4  
258274-48-5 258274-49-6 258274-50-9  
258274-51-0 258274-52-1 258274-53-2  
258274-54-3 258274-55-4 258274-56-5  
258274-57-6 258274-58-7 258274-59-8  
258274-60-1 258274-61-2 258274-62-3  
258274-63-4 258274-64-5 258274-65-6  
258274-66-7 258274-68-9 258274-70-3  
258274-75-8 258274-76-9 258274-77-0  
258274-78-1 258274-79-2 258274-80-5  
258274-81-6 258274-82-7 258274-83-8  
258274-87-2 258274-88-3 258274-89-4  
258274-90-7 258274-91-8 258274-92-9 25827  
4-93-0 258274-94-1 258274-95-2  
258274-96-3 258274-97-4 258274-98-5  
258274-99-6 258275-00-2 258275-01-3  
258275-02-4 258275-03-5 258275-04-6  
258275-05-7 258275-06-8 258275-07-9


RL: PRP (Properties)

(novel phospholipids with synthetic, unsatd. alkyl and acyl chains)


RN 257923-78-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphatetatriaconta-19,25-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[{(10Z,16Z)-1-oxo-  
10,16-pentacosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-B




RN 257923-79-8 CAPLUS




CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z,18Z)-1-oxo-  
6,18-hexacosadienyl]oxy]-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257923-80-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-(2,3-dihydroxypropyl)-4-  
hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z)-1-oxo-6-hexadecenyl]oxy]-, inner  
salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257923-81-2 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-(2,3-dihydroxypropyl)-4-  
hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z)-1-oxo-10-octadecenyl]oxy]-, inner  
salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-82-3 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphaoctacos-18-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-9-oxo-7-[[1-oxooctadecyl]oxy]methyl-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-83-4 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahentriacontan-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-84-5 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(6Z,12Z)-1-oxo-6,12-hexadecadienyl]oxy-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-85-6 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphatriaconta-18,24-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-9-oxo-7-[(1-oxooctadecyl)oxy]methyl-, inner salt, 4-oxide, (7R,18Z,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-86-7 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphadotriaconta-14,26-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-9-oxo-7-[[1-oxooctadecyl]oxy]methyl-, inner salt, 4-oxide, (7R,14Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257923-87-8 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[[1-oxooctadecyl]oxy]-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 257923-88-9 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentacos-5,17-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R,5Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-89-0 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium, N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-10-oxo-7-[(6Z)-1-oxo-6-hexadecenyl]oxy]-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-90-3 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphapentatriaconta-14,27-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-9-oxo-7-[[[(6Z)-1-oxo-6-  
 hexadecenyl]oxy]methyl]-, inner salt, 4-oxide, (7R,14Z,27Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-91-4 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexacos-16-en-1-aminium, N-(2,3-dihydroxypropyl)-5-  
 hydroxy-N,N-dimethyl-11-oxo-8-[[[(6Z)-1-oxo-6-hexadecenyl]oxy]-, inner  
 salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-92-5 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaheptacos-20-en-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-heptadecenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-93-6 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257923-94-7 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatriciacont-22-en-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(12Z)-1-oxo-12-eicosenyl]oxy]-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-95-8 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



PAGE 1-A



PAGE 1-B




RN 257923-96-9 CAPLUS


4,6,10-Trioxa-5-phosphadotriacont-22-en-1-aminium, N-(2,3-dihydroxypropyl)-  
5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (12Z)-1-oxo-12-docosenyl]oxy]-, inner  
salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-97-0 CAPLUS


CN 4,6,10-Trioxa-5-phosphatritriacont-20-en-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (10Z)-1-oxo-10-tricosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-98-1 CAPLUS


CN 4,6,10-Trioxa-5-phosphatetatriacont-20-en-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (10Z)-1-oxo-10-tetracosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257923-99-2 CAPLUS


CN 4,6,10-Trioxa-5-phosphaoctacos-15,21-dien-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (5Z,11Z)-1-oxo-5,11-octadecadienyl]oxy]-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-00-8 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatriciaconta-20,26-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (10Z,16Z)-1-oxo-  
 10,16-eicosadienyl]oxy]-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-01-9 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriaconta-20,26-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (10Z,16Z)-1-oxo-  
 10,16-docosadienyl]oxy]-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-02-0 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (6Z,18Z)-1-oxo-  
 6,18-hexacosadienyl]oxy]-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-03-1 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (6Z)-1-oxo-6-hexadecenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-04-2 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-(2,3-dihydroxypropyl)-5-


hydroxy-N,N-dimethyl-11-oxo-8-[[{(10Z)-1-oxo-10-octadecenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-05-3 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriacontan-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[{(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-06-4 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[[{(6Z,12Z)-1-oxo-6,12-hexadecadienyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257924-07-5 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacos-20-en-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[(1-oxooctadecyl)oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.




RN 257924-08-6 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium, N-(2,3-dihydroxypropyl)-5-hydroxy-N,N-dimethyl-11-oxo-8-[(1-oxooctadecyl)oxy]-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-09-7 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, N-(2,3-dihydroxypropyl)-6-hydroxy-N,N-dimethyl-12-oxo-9-[[ (6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-10-0 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-(2,3-dihydroxypropyl)-6-hydroxy-N,N-dimethyl-12-oxo-9-[[ (10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



PAGE 1-A




PAGE 1-B




RN 257924-11-1 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphaheptacos-16,22-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-6-hydroxy-N,N-dimethyl-12-oxo-9-[[ (5Z,11Z)-1-oxo-  
 5,11-hexadecadienyl]oxy]-, inner salt, 6-oxide, (9R,16Z,22Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-12-2 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriaconta-21,27-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-6-hydroxy-N,N-dimethyl-12-oxo-9-[[ (10Z,16Z)-1-oxo-  
10,16-docosadienyl]oxy]-, inner salt, 6-oxide, (9R,21Z,27Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-13-3 CAPLUS  
CN 5,7,11-Trioxa-6-phosphaheptatriaconta-17,29-dien-1-aminium,  
N-(2,3-dihydroxypropyl)-4-hydroxy-N,N-dimethyl-12-oxo-9-[[ (6Z,18Z)-1-oxo-  
6,18-hexacosadienyl]oxy]-, inner salt, 6-oxide, (9R,17Z,29Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-14-4 CAPLUS


CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, N-(2,3-dihydroxypropyl)-8-hydroxy-N,N-dimethyl-14-oxo-11-[[ (6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 8-oxide, (11R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-15-5 CAPLUS


CN 7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, N-(2,3-dihydroxypropyl)-8-hydroxy-N,N-dimethyl-14-oxo-11-[[ (10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 8-oxide, (11R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-16-6 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphapentatriaconta-23,29-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-8-hydroxy-N,N-dimethyl-14-oxo-11-[[[(10Z,16Z)-1-oxo-  
 10,16-docosadienyl]oxy]-, inner salt, 8-oxide, (11R,23Z,29Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-17-7 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphanonatriaconta-19,31-dien-1-aminium,  
 N-(2,3-dihydroxypropyl)-8-hydroxy-N,N-dimethyl-14-oxo-11-[[[(6Z,17Z)-1-oxo-  
 6,17-pentacosadienyl]oxy]-, inner salt, 8-oxide, (11R,19Z,31Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-18-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentacos-15-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z)-1-oxo-6-hexadecenyl]oxy]-], inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-19-9 CAPLUS

CN 3,5,9-Trioxa-4-phosphahexacos-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z)-1-oxo-10-


heptadecenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-20-2 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-21-3 CAPLUS

CN 3,5,9-Trioxa-4-phosphaoctacos-15-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z)-1-oxo-6-


nonadecenyl]oxy]-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-23-5 CAPLUS


CN 3,5,9-Trioxa-4-phosphanonacos-10-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(12Z)-1-oxo-12-eicosenyl]oxy]-, inner salt, 4-oxide, (7R,10Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-24-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphatriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(10Z)-1-oxo-10-heneicosenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-25-7 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-26-8 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriacont-21-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(12Z)-1-oxo-12-docosenyl]oxy]-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)




1-oxo-12-docosenyl]oxy]-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-27-9 CAPLUS  
CN 3,5,9-Trioxa-4-phosphadotriacont-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z)-1-oxo-10-tricosenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-28-0 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-[3-(2,3-


dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z)-1-oxo-10-tetracosenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-29-1 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatetatriacont-24-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (15Z)-1-oxo-15-pentacosenyl]oxy]-, inner salt, 4-oxide, (7R,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-30-4 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentatriacont-25-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (16Z)-1-oxo-16-hexacosenyl]oxy]-, inner salt, 4-oxide, (7R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-31-5 CAPLUS  
CN 3,5,9-Trioxa-4-phosphapentacosa-14,20-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (5Z,11Z)-1-oxo-5,11-hexadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-32-6 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahexacos-14,20-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(5Z,11Z)-1-oxo-5,11-heptadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-33-7 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahexacos-14,20-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(5Z,11Z)-1-oxo-5,11-octadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-34-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphaoctacosyl-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z,12Z)-1-oxo-6,12-nonadecadienyl]oxy]-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-35-9 CAPLUS

CN 3,5,9-Trioxa-4-phosphanonacosyl-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z,16Z)-1-oxo-10,16-eicosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-36-0 CAPLUS


CN 3,5,9-Trioxa-4-phosphatriaconta-19,25-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z,16Z)-1-oxo-10,16-heneicosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-37-1 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-  
 7-[[[(10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-, inner salt, 4-oxide,  
 (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-38-2 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphadotriaconta-19,25-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-  
 7-[[[(10Z,16Z)-1-oxo-10,16-tricosadienyl]oxy]-, inner salt, 4-oxide,  
 (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-39-3 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatritriaconta-15,27-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-  
 7-[[ (6Z,18Z)-1-oxo-6,18-tetracosadienyl]oxy]-, inner salt, 4-oxide,  
 (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-40-6 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatettratriaconta-19,25-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-  
 7-[[ (10Z,16Z)-1-oxo-10,16-pentacosadienyl]oxy]-, inner salt, 4-oxide,  
 (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-42-8 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-  
 7-[[[(6Z,18Z)-1-oxo-6,18-hexacosadienyl]oxy]-, inner salt, 4-oxide,  
 (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-44-0 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-  
 hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z)-1-oxo-6-  
 hexadecenyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-45-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[10Z)-1-oxo-10-octadecenyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-46-2 CAPLUS


CN 3,5,8-Trioxa-4-phosphaoctacos-18-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[1-oxooctadecyl]oxy]methyl]-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-47-3 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacontan-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-48-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z,12Z)-1-oxo-6,12-hexadecadienyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-50-8 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphatriciaconta-18,24-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[1-oxooctadecyl)oxy]methyl]-, inner salt, 4-oxide, (7R,18Z,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-51-9 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphadotriaconta-14,26-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[1-oxooctadecyl)oxy]methyl]-, inner salt, 4-oxide, (7R,14Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257924-52-0 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacos-19-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.




RN 257924-53-1 CAPLUS  
CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-54-2 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-  
 7-[[[(6Z)-1-oxo-6-hexadecenyl]oxy]-, inner salt, 4-oxide, (7R,15Z,27Z)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-55-3 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphatetratratriaconta-14,26-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-  
 7-[[[(6Z)-1-oxo-6-hexadecenyl]oxy]methyl]-, inner salt, 4-oxide,  
 (7R,14Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-56-4 CAPLUS  
CN 4,6,10-Trioxa-5-phosphahexacos-16-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[6Z]-1-oxo-6-hexadecenyl]oxy]-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-57-5 CAPLUS  
CN 4,6,10-Trioxa-5-phosphahexacos-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[10Z]-1-oxo-10-heptadecenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-58-6 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-59-7 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatriacont-22-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[12Z)-1-oxo-12-eicosenyl]oxy]-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A



PAGE 1-B




RN 257924-60-0 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-61-1 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriacont-22-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[12Z)-1-oxo-12-docosenyl]oxy]-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-62-2 CAPLUS


CN 4,6,10-Trioxa-5-phosphatritriacont-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[{(10Z)-1-oxo-10-tricosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-63-3 CAPLUS


CN 4,6,10-Trioxa-5-phosphatetatriacont-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[{(10Z)-1-oxo-10-tetracosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-64-4 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacosa-15,21-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(5Z,11Z)-1-oxo-5,11-octadecadienyl]oxy]-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-65-5 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z,16Z)-1-oxo-10,16-eicosadienyl]oxy]-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-66-6 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriaconta-20,26-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-  
 8-[[10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-, inner salt, 5-oxide,  
 (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-67-7 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-  
 8-[[6Z,18Z)-1-oxo-6,18-hexacosadienyl]oxy]-, inner salt, 5-oxide,  
 (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-68-8 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[6Z]-1-oxo-6-hexadecenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-69-9 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[10Z]-1-oxo-10-octadecenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-70-2 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriacontan-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[10Z]-1-oxo-10-docosenyl]oxy]-, inner salt, 5-oxide, (8R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-71-3 CAPLUS


CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[6Z,12Z]-1-oxo-6,12-hexadecadienyl]oxy]-, inner salt, 5-oxide, (8R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-72-4 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacos-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[(1-oxooctadecyl)oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-73-5 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[(1-oxooctadecyl)oxy]-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-74-6 CAPLUS


CN 5,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-9-[[ (6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-75-7 CAPLUS

CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-9-[[ (10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A



PAGE 1-B




RN 257924-76-8 CAPLUS


CN 5,7,11-Trioxa-6-phosphaheptacos-16,22-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-  
 9-[[5Z,11Z)-1-oxo-5,11-hexadecadienyl]oxy]-, inner salt, 6-oxide,  
 (9R,16Z,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-77-9 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriaconta-21,27-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-  
 9-[[10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-, inner salt, 6-oxide,  
 (9R,21Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-78-0 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphaheptatriaconta-17,29-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-  
 9-[[[(6Z,18Z)-1-oxo-6,18-hexacosadienyl]oxy]-, inner salt, 6-oxide,  
 (9R,17Z,29Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-79-1 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, N-[3-(2,3-  
 dihydroxypropoxy)-2-hydroxypropyl]-8-hydroxy-N,N-dimethyl-14-oxo-11-[[[(6Z)-  
 1-oxo-6-octadecenyl]oxy]-, inner salt, 8-oxide, (11R,19Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN	257924-80-4	CAPLUS
CN	7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-8-hydroxy-N,N-dimethyl-14-oxo-11-[[ (10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 8-oxide, (11R,23Z)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN	257924-81-5	CAPLUS
CN	7,9,13-Trioxa-8-phosphapentatriaconta-23,29-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-8-hydroxy-N,N-dimethyl-14-oxo- 11-[[[(10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-, inner salt, 8-oxide, (11R,23Z,29Z)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-82-6 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphanonatriaconta-19,31-dien-1-aminium,  
 N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-8-hydroxy-N,N-dimethyl-14-oxo-  
 11-[[[(6Z,18Z)-1-oxo-6,18-hexacosadienyl]oxy]-, inner salt, 8-oxide,  
 (11R,19Z,31Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 257924-83-7 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexacos-16-en-1-aminium, 5-hydroxy-N,N,N-trimethyl-  
 11-oxo-8-[[[(6Z)-1-oxo-6-hexadecenyl]oxy]-, inner salt, 5-oxide, (8R,16Z)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Me

RN 257924-84-8 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaheptacos-20-en-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-heptadecenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Me


RN 257924-85-9 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[[(6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-86-0 CAPLUS


CN 4,6,10-Trioxa-5-phosphatriacont-22-en-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[12Z]-1-oxo-12-eicosenyl]oxy]-, inner salt, 5-oxide, (8R,22Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-87-1 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[10Z]-1-oxo-10-docosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-88-2 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriacont-22-en-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[{(12Z)-1-oxo-12-docosenyl]oxy]-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-89-3 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatritriacont-20-en-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[{(10Z)-1-oxo-10-tricosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-90-6 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatetatriacont-20-en-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-tetracosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257924-91-7 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacosa-15,21-dien-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[[(5Z,11Z)-1-oxo-5,11-octadecadienyl]oxy]-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



PAGE 1-A




PAGE 1-B




RN 257924-92-8 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium,  
 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[ (10Z,16Z)-1-oxo-10,16-  
 eicosadienyl]oxy]-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-93-9 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriaconta-20,26-dien-1-aminium,  
 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[ (10Z,16Z)-1-oxo-10,16-  
 docosadienyl]oxy]-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-94-0 CAPLUS  
CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[ (6Z,18Z)-1-oxo-6,18-  
hexacosadienyl]oxy]-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257924-95-1 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-  
oxo-8-[[ (6Z)-1-oxo-6-hexadecenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257924-96-2 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[10Z)-1-oxo-10-octadecenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257924-97-3 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriacontan-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 257924-98-4 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[[6Z,12Z)-1-oxo-6,12-hexadecadienyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 257924-99-5 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacos-20-en-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[(1-oxooctadecyl)oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 257925-00-1 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium, 5-hydroxy-N,N,N-trimethyl-11-oxo-8-[(1-oxooctadecyl)oxy]-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257925-01-2 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, 6-hydroxy-N,N,N-trimethyl-12-oxo-9-[[6Z]-1-oxo-6-octadecenyl]oxy]-, inner salt, 6-oxide, (9R,17Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257925-02-3 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, 6-hydroxy-N,N,N-trimethyl-12-oxo-9-[[10Z]-1-oxo-10-docosenyl]oxy]-, inner salt, 6-oxide, (9R,21Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257925-03-4 CAPLUS


CN 5,7,11-Trioxa-6-phosphaheptacos-16,22-dien-1-aminium,  
6-hydroxy-N,N,N-trimethyl-12-oxo-9-[[ (5Z,11Z)-1-oxo-5,11-  
hexadecadienyl]oxy]-, inner salt, 6-oxide, (9R,16Z,22Z)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257925-04-5 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriaconta-21,27-dien-1-aminium,  
6-hydroxy-N,N,N-trimethyl-12-oxo-9-[(10Z,16Z)-1-oxo-10,16-  
docosadienyl]oxy]-, inner salt, 6-oxide, (9R,21Z,27Z)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257925-05-6 CAPLUS


CN 5,7,11-Trioxa-6-phosphaheptatriaconta-17,29-dien-1-aminium,  
6-hydroxy-N,N,N-trimethyl-12-oxo-9-[[ (6Z,18Z)-1-oxo-6,18-  
hexacosadienyl]oxy]-, inner salt, 6-oxide, (9R,17Z,29Z)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257925-06-7 CAPLUS


CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, 8-hydroxy-N,N,N-  
trimethyl-14-oxo-11-[[ (6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 8-oxide,  
(11R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257925-07-8 CAPLUS


CN 7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, 8-hydroxy-N,N,N-trimethyl-14-oxo-11-[[[(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 8-oxide, (11R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 257925-08-9 CAPLUS

CN 7,9,13-Trioxa-8-phosphapentatriaconta-23,29-dien-1-aminium, 8-hydroxy-N,N,N-trimethyl-14-oxo-11-[[[(10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-, inner salt, 8-oxide, (11R,23Z,29Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A






PAGE 1-B




RN 257925-09-0 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphanonatriaconta-19,31-dien-1-aminium,  
 8-hydroxy-N,N,N-trimethyl-14-oxo-11-[[ (6Z,18Z)-1-oxo-6,18-  
 hexacosadienyl]oxy]-, inner salt, 8-oxide, (11R,19Z,31Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 257925-10-3 CAPLUS  
 CN Ethanaminium, 2-[[[(3Z)-3-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-  
 trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257925-11-4 CAPLUS  
 CN Ethanaminium, 2-[[[(4Z)-4-hexadecenyloxy]hydroxyphosphinyl]oxy]-N,N,N-  
 trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-12-5 CAPLUS

CN Ethanaminium, 2-[[[(5Z)-5-hexadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-13-6 CAPLUS

CN Ethanaminium, 2-[[[(6Z)-6-hexadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-14-7 CAPLUS

CN Ethanaminium, 2-[[[(8Z)-8-hexadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-15-8 CAPLUS

CN Ethanaminium, 2-[[[(9Z)-9-hexadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-16-9 CAPLUS

CN Ethanaminium, 2-[[[(10Z)-10-hexadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-17-0 CAPLUS

CN Ethanaminium, 2-[[[12Z]-12-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-18-1 CAPLUS

CN Ethanaminium, 2-[[[13Z]-13-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-19-2 CAPLUS


CN Ethanaminium, 2-[[[14Z]-14-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257925-20-5 CAPLUS


CN Ethanaminium, 2-[[[15Z]-15-hexadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257925-21-6 CAPLUS

CN Ethanaminium, 2-[[[3Z]-3-heptadecenyl]oxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-22-7 CAPLUS

CN Ethanaminium, 2-[[[(4Z)-4-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-23-8 CAPLUS

CN Ethanaminium, 2-[[[(5Z)-5-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-25-0 CAPLUS

CN Ethanaminium, 2-[[[(6Z)-6-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-27-2 CAPLUS

CN Ethanaminium, 2-[[[(7Z)-7-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-29-4 CAPLUS

CN Ethanaminium, 2-[[[(8Z)-8-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-31-8 CAPLUS

CN Ethanaminium, 2-[[[(9Z)-9-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-32-9 CAPLUS

CN Ethanaminium, 2-[[[(10Z)-10-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-33-0 CAPLUS

CN Ethanaminium, 2-[[[(11Z)-11-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-34-1 CAPLUS

CN Ethanaminium, 2-[[[(12Z)-12-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-35-2 CAPLUS

CN Ethanaminium, 2-[[[(13Z)-13-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-36-3 CAPLUS

CN Ethanaminium, 2-[[[(14Z)-14-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-37-4 CAPLUS


CN Ethanaminium, 2-[[[(15Z)-15-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257925-38-5 CAPLUS


CN Ethanaminium, 2-[[[(16Z)-16-heptadecen-1-yl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 257925-39-6 CAPLUS

CN Ethanaminium, 2-[[[hydroxy[(3Z)-3-octadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-40-9 CAPLUS

CN Ethanaminium, 2-[[[hydroxy[(4Z)-4-octadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-41-0 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(5Z)-5-octadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-42-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(6Z)-6-octadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-43-2 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(7Z)-7-octadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-44-3 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(8Z)-8-octadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-45-4 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(10Z)-10-octadecen-1-yl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-46-5 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(11Z)-11-octadecenyl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-47-6 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(12Z)-12-octadecenyl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257925-48-7 CAPLUS

CN Ethanaminium, 2-[[hydroxy[(13Z)-13-octadecenyl]oxy]phosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 257933-68-9 CAPLUS

CN Ethanaminium, 2-[[[[(7Z,11Z)-7,11-eicosadienyl]oxy]hydroxyphosphoryl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 257933-69-0 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



PAGE 1-A



PAGE 1-B




RN 258274-24-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacos-15-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-25-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphaoctacos-15-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-26-9 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-27-0 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacont-21-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-28-1 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriacont-25-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-29-2 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentacos-14,20-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-30-5 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentacos-14,20-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-31-6 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-  
 dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-32-7 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-  
 dihydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-33-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-34-9 CAPLUS


CN 3,5,9-Trioxa-4-phosphanonacos-21-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-35-0 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-36-1 CAPLUS


CN 3,5,9-Trioxa-4-phosphapentatriacont-25-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-37-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosa-14,20-dien-1-aminium, N-[3-[3-(2,3-


dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-38-3 CAPLUS  
CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4,7-  
dihydroxy-N,N-dimethyl-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-39-4 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, N-[3-[3-(2,3-  
dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-dihydroxy-N,N-  
dimethyl-11-oxo-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-40-7 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-41-8 CAPLUS

CN 4,6,10-Trioxa-5-phosphatetriacont-20-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B




RN 258274-42-9 CAPLUS


CN 4,6,10-Trioxa-5-phosphaooctacosa-15,21-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-43-0 CAPLUS


CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium,  
N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-  
dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-44-1 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriaconta-20,26-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-  
 dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-45-2 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-  
 dihydroxy-N,N-dimethyl-11-oxo-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-46-3 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-[3-[3-(2,3-  
 dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-dihydroxy-N,N-  
 dimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-47-4 CAPLUS


CN 4,6,10-Trioxa-5-phosphatetatriacont-20-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-48-5 CAPLUS


CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-49-6 CAPLUS


CN 4,6,10-Trioxa-5-phosphatetatriaconta-16,28-dien-1-aminium,  
N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-  
dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-50-9 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5,8-  
dihydroxy-N,N-dimethyl-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-51-0 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-12-oxo-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-52-1 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriaconta-21,27-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-12-oxo-, inner salt, 6-oxide, (9R,21Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-53-2 CAPLUS


CN 5,7,11-Trioxa-6-phosphaheptatriaconta-17,29-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-12-oxo-, inner salt, 6-oxide, (9R,17Z,29Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-54-3 CAPLUS


CN 5,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-55-4 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-56-5 CAPLUS

CN 5,7,11-Trioxa-6-phosphanonacosa-16,22-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide, (9R,16Z,22Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-57-6 CAPLUS

CN 5,7,11-Trioxa-6-phosphahentriacont-23-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6,9-dihydroxy-N,N-dimethyl-, inner salt, 6-oxide, (9R,23Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-58-7 CAPLUS

CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8,11-dihydroxy-N,N-


dimethyl-14-oxo-, inner salt, 8-oxide, (11R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-59-8 CAPLUS  
CN 7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-60-1 CAPLUS  
CN 7,9,13-Trioxa-8-phosphanonacosa-18,24-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,18Z,24Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A




PAGE 1-B




RN 258274-61-2 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphapentatriaconta-23,29-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8,11-  
 dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,23Z,29Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-62-3 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphanonatriaconta-19,31-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8,11-  
 dihydroxy-N,N-dimethyl-14-oxo-, inner salt, 8-oxide, (11R,19Z,31Z)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-63-4 CAPLUS


CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-, inner salt, 8-oxide, (11R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-64-5 CAPLUS


CN 7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8,11-dihydroxy-N,N-dimethyl-, inner salt, 8-oxide, (11R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-65-6 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphahentriaconta-18,24-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8,11-  
 dihydroxy-N,N-dimethyl-, inner salt, 8-oxide, (11R,18Z,24Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-66-7 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphatritriacont-25-en-1-aminium, N-[3-[3-(2,3-  
 dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8,11-dihydroxy-N,N-  
 dimethyl-, inner salt, 8-oxide, (11R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-68-9 CAPLUS  
CN 3,5,8-Trioxa-4-phosphatriacont-18-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-4-hydroxy-N,N,6-trimethyl-9-oxo-, inner salt, 4-oxide, (18Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-70-3 CAPLUS  
CN 5,7,10-Trioxa-6-phosphadotriacont-20-en-1-aminium, N-[3-(2,3-dihydroxypropoxy)-2-hydroxypropyl]-5-hydroxy-N,N,8-trimethyl-11-oxo-, inner salt, 6-oxide, (20Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-75-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (15Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-76-9 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (19Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-77-0 CAPLUS


CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (19Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-78-1 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-14,20-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (14Z,20Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-79-2 CAPLUS


CN 3,5,9-Trioxa-4-phosphanonacos-19,25-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (19Z,25Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-80-5 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (19Z,25Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-81-6 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-  
 hydroxy-N,N-dimethyl-10-oxo-, inner salt, 4-oxide, (15tal.,27Z)- (9CI)  
 (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-82-7 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatritriacont-21-en-1-aminium, N-[3-[3-(2,3-  
 dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-  
 dimethyl-11-oxo-, inner salt, 5-oxide, (20Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-83-8 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-, inner salt, 6-oxide, (21Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-87-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacos-15-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z)-1-oxo-6-hexadecenyl]oxy]-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-88-3 CAPLUS

CN 3,5,9-Trioxa-4-phosphahexacos-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z)-1-oxo-10-heptadecenyl]oxy]-, inner salt, 4-oxide, (7R,10Z)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-89-4 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-90-7 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaoctacos-15-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z)-1-oxo-6-nonadecenyl]oxy]-, inner salt, 4-oxide,


(7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-91-8 CAPLUS  
CN 3,5,9-Trioxa-4-phosphanacos-21-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(12Z)-1-oxo-12-eicosenyl]oxy]-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-92-9 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatriacont-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-


dimethyl-10-oxo-7-[[[(10Z)-1-oxo-10-heneicosenyl]oxy]-, inner salt,  
4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-93-0 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-94-1 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriacont-21-en-1-aminium, N-[3-[3-(2,3-


dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(12Z)-1-oxo-12-docosenyl]oxy]-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-95-2 CAPLUS  
CN 3,5,9-Trioxa-4-phosphadotriacont-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z)-1-oxo-10-tricosenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-96-3 CAPLUS


CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z)-1-oxo-10-tetracosenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258274-97-4 CAPLUS


CN 3,5,9-Trioxa-4-phosphatetratriacont-24-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (15Z)-1-oxo-15-pentacosenyl]oxy]-, inner salt, 4-oxide, (7R,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-98-5 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriacont-25-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (16Z)-1-oxo-16-hexacosenyl]oxy]-, inner salt, 4-oxide, (7R,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258274-99-6 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentacos-14,20-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (5Z,11Z)-1-oxo-5,11-hexadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-00-2 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahexacos-14,20-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (5Z,11Z)-1-oxo-5,11-heptadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-01-3 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphaheptacos-14,20-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (5Z,11Z)-1-oxo-5,11-octadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-02-4 CAPLUS


CN 3,5,9-Trioxa-4-phosphaoctacosyl-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z,12Z)-1-oxo-6,12-nonadecadienyl]oxy]-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 258275-03-5 CAPLUS


CN 3,5,9-Trioxa-4-phosphanonacosyl-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z,16Z)-1-oxo-10,16-eicosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-04-6 CAPLUS


CN 3,5,9-Trioxa-4-phosphatriaconta-19,25-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z,16Z)-1-oxo-10,16-heneicosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-05-7 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-  
 hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-,  
 inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-06-8 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphadotriaconta-19,25-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-  
 hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z,16Z)-1-oxo-10,16-tricosadienyl]oxy]-,  
 inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-07-9 CAPLUS

CN 3,5,9-Trioxa-4-phosphatritriaconta-15,27-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-  
 hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z,18Z)-1-oxo-6,18-tetracosadienyl]oxy]-,  
 inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IT 258275-08-0 258275-09-1 258275-10-4  
 258275-11-5 258275-12-6 258275-13-7  
 258275-14-8 258275-15-9 258275-16-0  
 258275-17-1 258275-18-2 258275-19-3  
 258275-20-6 258275-21-7 258275-22-8  
 258275-23-9 258275-24-0 258275-25-1  
 258275-26-2 258275-27-3 258275-28-4

258275-29-5 258275-30-8 258275-31-9  
258275-32-0 258275-33-1 258275-34-2  
258275-35-3 258275-36-4 258275-37-5  
258275-38-6 258275-39-7 258275-40-0  
258275-41-1 258275-42-2 258275-43-3  
258275-44-4 258275-45-5 258275-46-6  
258275-47-7 258275-48-8 258275-49-9  
258275-50-2 258275-51-3 258275-52-4  
258275-53-5 258275-54-6 258275-55-7  
258275-56-8 258275-57-9 258275-58-0  
258275-59-1 258275-60-4 258275-61-5  
258275-62-6 258275-63-7 258275-64-8  
258275-65-9 258275-66-0 258275-67-1  
258275-68-2 258275-69-3 258275-70-6  
258275-71-7 258275-72-8 258275-73-9  
258275-74-0 258275-75-1 258275-76-2  
258275-77-3 258275-78-4 258275-79-5  
258275-80-8 258275-81-9 258275-82-0  
258275-83-1 258275-84-2 258275-85-3  
258275-86-4 258275-87-5 258275-88-6  
258275-89-7 258275-90-0 258275-91-1  
258275-92-2 258275-93-3 258275-94-4  
258275-95-5 258275-96-6 258275-97-7  
258275-98-8 258275-99-9 258276-00-5  
258276-01-6 258276-02-7 258276-03-8  
258276-04-9 258276-05-0 258276-06-1  
258276-07-2 258276-08-3

RL: PRP (Properties)

(novel phospholipids with synthetic, unsatd. alkyl and acyl chains)


RN 258275-08-0 CAPLUS

CN 3,5,9-Trioxa-4-phosphatetatriaconta-19,25-dien-1-aminium,  
N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-  
hydroxy-N,N-dimethyl-10-oxo-7-[[{(10Z,16Z)-1-oxo-10,16-pentacosadienyl]oxy]-  
, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-09-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,


N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z,18Z)-1-oxo-6,18-hexacosadienyl]oxy]-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-10-4 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z)-1-oxo-6-hexadecenyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-11-5 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-3-oxo-7-[[{(10Z)-1-oxo-10-octadecenyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-12-6 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphaoctacos-18-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[{(1-oxooctadecyl)oxy]methyl]-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-13-7 CAPLUS


CN 3,5,9-Trioxa-4-phosphahentriacontan-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-14-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z,12Z)-1-oxo-6,12-hexadecadienyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-15-9 CAPLUS


CN 3,5,8-Trioxa-4-phosphatriaconta-18,24-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[[1-oxooctadecyl)oxy)methyl]-, inner salt, 4-oxide, (7R,18Z,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-16-0 CAPLUS

CN 3,5,8-Trioxa-4-phosphadotriaconta-14,26-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[[1-oxooctadecyl)oxy)methyl]-, inner salt, 4-oxide, (7R,14Z,26Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A



PAGE 1-B




RN 258275-17-1 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-19-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R,19Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-18-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphahexatriaconta-15,28-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R,15Z,28Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-19-3 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-  
 hydroxy-N,N-dimethyl-10-oxo-7-[(6Z)-1-oxo-6-hexadecenyl]oxy-, inner  
 salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-20-6 CAPLUS  
 CN 3,5,8-Trioxa-4-phosphatetratratriaconta-14,26-dien-1-aminium,


N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[[(6Z)-1-oxo-6-hexadecenyl]oxy]methyl]-, inner salt, 4-oxide, (7R,14Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-21-7 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaheptacos-16-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(6Z)-1-oxo-6-hexadecenyl]oxy]-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-22-8 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaheptacos-20-en-1-aminium, N-[3-[3-(2,3-


dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-heptadecenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-23-9 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-24-0 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatriacont-22-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-


dimethyl-11-oxo-8-[[ (12Z)-1-oxo-12-eicosenyl]oxy]-, inner salt, 5-oxide,  
(8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-25-1 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 5-oxide,  
(8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-26-2 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriacont-22-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (12Z)-1-oxo-12-docosenyl]oxy]-, inner salt, 5-oxide,


(8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-27-3 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatritriacont-20-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[(10Z)-10-tetracosenyl]oxy-, inner salt, 5-oxide, (8R,10Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-28-4 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatettratriacont-20-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[(10Z)-1-oxo-10-tetracosenyl]oxy-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-29-5 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacos-15,21-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(5Z,11Z)-1-oxo-5,11-octadecadienyl]oxy]-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-30-8 CAPLUS  
CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z,16Z)-1-oxo-10,16-eicosadienyl]oxy]-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-31-9 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriaconta-21,26-dien-1-aminium,  
N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-  
hydroxy-N,N-dimethyl-11-oxo-8-[[ (10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-,  
inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-32-0 CAPLUS  
CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-  
hydroxy-N,N-dimethyl-11-oxo-8-[[ (6Z,18Z)-1-oxo-6,18-hexacosadienyl]oxy]-,  
inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-33-1 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(6Z)-1-oxo-6-hexadecenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-34-2 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-octadecenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)


NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-35-3 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriacontan-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-36-4 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(6Z,12Z)-1-oxo-6,12-hexadecadienyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-37-5 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacos-20-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[(1-oxooctadecyl)oxy]-, inner salt, 5-oxide, (8R,20Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-38-6 CAPLUS  
CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[(1-oxooctadecyl)oxy]-, inner salt, 5-oxide,


(8R,16Z,28Z) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN	258275-39-7	CAPLUS
CN	45,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-8-[[[(6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN	258275-40-0	CAPLUS
CN	5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-8-[[[(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-41-1 CAPLUS


CN 5,7,11-Trioxa-6-phosphaheptacos-16,22-dien-1-aminium,  
N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6-  
hydroxy-N,N-dimethyl-12-oxo-8-[[[(5Z,11Z)-1-oxo-5,11-hexadecadienyl]oxy]-,  
inner salt, 6-oxide, (9R,16Z,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-42-2 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriaconta-21,27-dien-1-aminium,  
N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6-  
hydroxy-N,N-dimethyl-12-oxo-8-[[[(10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-,  
inner salt, 6-oxide, (9R,21Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-43-3 CAPLUS  
CN 5,7,11-Trioxa-6-phosphaheptatriaconta-17,29-dien-1-aminium,  
N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-6-  
hydroxy-N,N-dimethyl-12-oxo-8-[[ (6Z,18Z)-1-oxo-6,18-hexadocosadienyl]oxy]-  
, inner salt, 6-oxide, (9R,17Z,29Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-44-4 CAPLUS  
CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, N-[3-[3-(2,3-  
dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8-hydroxy-N,N-  
dimethyl-14-oxo-11-[[ (6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 8-oxide,  
(11R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-45-5 CAPLUS  
CN 7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8-hydroxy-N,N-dimethyl-14-oxo-11-[[[(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 8-oxide, (11R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-46-6 CAPLUS  
CN 7,9,13-Trioxa-8-phosphapentatriaconta-23,29-dien-1-aminium, N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8-hydroxy-N,N-dimethyl-14-oxo-11-[[[(10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-, inner salt, 8-oxide, (11R,23Z,29Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-47-7 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphonanatriacenta-19,31-dien-1-aminium,  
 N-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-8-  
 hydroxy-N,N-dimethyl-14-oxo-11-[[ (6Z,18Z)-1-oxo-6,18-hexacosadienyl]oxy]-,  
 inner salt, 8-oxide, (11R,19Z,31Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-48-8 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentacos-15-en-1-aminium, N-[3-[3-[3-(2,3-  
 dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-  
 hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z)-1-oxo-6-hexadecenyl]oxy]-, inner  
 salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



PAGE 1-A



PAGE 1-B





RN 258275-49-9 CAPLUS

CN 3,5,9-Trioxa-4-phosphahectacos-19-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z)-1-oxo-10-heptadecenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-50-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-15-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-51-3 CAPLUS


CN 3,5,9-Trioxa-4-phosphaoctacos-15-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z)-1-oxo-6-nonadecenyl]oxy]-, inner salt, 4-oxide, (7R,15Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-52-4 CAPLUS


CN 3,5,9-Trioxa-4-phosphanonacos-21-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (12Z)-1-oxo-12-eicosenyl]oxy]-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B




RN 258275-53-5 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatriacont-19-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z)-1-oxo-10-heneicosenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B




RN 258275-54-6 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriacont-19-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B




RN 258275-55-7 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahentriacont-21-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(12Z)-1-oxo-12-docosenyl]oxy]-, inner salt, 4-oxide, (7R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-56-8 CAPLUS  
CN 3,5,9-Trioxa-4-phosphadotriacont-19-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z)-1-oxo-10-tricosenyl]oxy]-, inner


salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B




RN 258275-57-9 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatritriacont-19-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z)-1-oxo-10-tetracosenyl]oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-58-0 CAPLUS  
CN 3,5,9-Trioxa-4-phosphatettratriacont-24-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-


hydroxy-N,N-dimethyl-10-oxo-7-[(15Z)-1-oxo-15-pentacosenyl]oxy-, inner salt, 4-oxide, (7R,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B




RN	258275-59-1	CAPLUS
CN	3,5,9-Trioxa-4-phosphapentatriacont-25-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[16Z)-1-oxo-16-hexacosenyl]oxy]-, inner salt, 4-oxide, (7R,25Z)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-60-4 CAPLUS  
CN 3,5,9-Trioxa-4-phosphapentacosa-14,20-dien-1-aminium, N-[3-[3-[3-(2,3-


dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(5Z,11Z)-1-oxo-5,11-hexadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-61-5 CAPLUS  
CN 3,5,9-Trioxa-4-phosphahexacosa-14,20-dien-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(5Z,11Z)-1-oxo-5,11-heptadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-62-6 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-14,20-dien-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (5Z,11Z)-1-oxo-5,11-octadecadienyl]oxy]-, inner salt, 4-oxide, (7R,14Z,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-63-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphaoctacos-15,21-dien-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z,12Z)-1-oxo-6,12-nonadecadienyl]oxy]-, inner salt, 4-oxide, (7R,15Z,21Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B




RN 258275-64-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphanonacosa-19,25-dien-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z,16Z)-1-oxo-10,16-eicosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-65-9 CAPLUS


CN 3,5,9-Trioxa-4-phosphatriaconta-19,25-dien-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z,16Z)-1-oxo-10,16-heneicosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-66-0 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphahentriaconta-19,25-dien-1-aminium,  
 N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
 hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(10Z,16Z)-1-oxo-10,16-  
 docosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-67-1 CAPLUS


CN 3,5,9-Trioxa-4-phosphadotriaconta-19,25-dien-1-aminium,  
N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(10Z,16Z)-1-oxo-10,16-tricosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-68-2 CAPLUS


CN 3,5,9-Trioxa-4-phosphatritriaconta-15,27-dien-1-aminium,  
N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(6Z,18Z)-1-oxo-6,18-tetracosadienyl]oxy]-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-69-3 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatetratriciaconta-19,25-dien-1-aminium,  
 N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
 hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z,16Z)-1-oxo-10,16-  
 pentacosadienyl]oxy]-, inner salt, 4-oxide, (7R,19Z,25Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A





PAGE 1-B




RN 258275-70-6 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriciaconta-15,27-dien-1-aminium,  
 N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
 hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(6Z,18Z)-1-oxo-6,18-  
 hexacosadienyl]oxy]-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-71-7 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z)-1-oxo-6-hexadecenyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 258275-72-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-[3-[3-[3-(2,3-

dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[[(10Z)-1-oxo-10-octadecenyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A

Me (CH<sub>2</sub>)<sub>16</sub>.



PAGE 1-B




RN 258275-73-9 CAPLUS  
CN 3,5,8-Trioxa-4-phosphaoctacos-18-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[[(1-oxooctadecyl)oxy]methyl]-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A

Me (CH<sub>2</sub>)<sub>16</sub>.



PAGE 1-B




RN 258275-74-0 CAPLUS

CN 3,5,9-Trioxa-4-phosphahentriacontan-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A

Me (CH<sub>2</sub>)<sub>20</sub>



PAGE 1-B




RN 258275-75-1 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[[ (6Z,12Z)-1-oxo-6,12-hexadecadienyl]oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-76-2 CAPLUS


CN 3,5,8-Trioxa-4-phosphatriaconta-18,24-dien-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[1-oxooctadecyl)oxy]methyl]-, inner salt, 4-oxide, (7R,18Z,24Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-77-3 CAPLUS

CN 3,5,8-Trioxa-4-phosphadotriaconta-14,26-dien-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[1-oxooctadecyl)oxy]methyl]-, inner salt, 4-oxide, (7R,14Z,26Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A



PAGE 1-B





RN 258275-78-4 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-19-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-79-5 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-,  
inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-80-8 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentatriaconta-15,27-dien-1-aminium,  
 N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
 hydroxypropyl]-4-hydroxy-N,N-dimethyl-10-oxo-7-[(6Z)-1-oxo-6-  
 hexadecenyl]oxy]-, inner salt, 4-oxide, (7R,15Z,27Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 258275-81-9 CAPLUS


CN 3,5,8-Trioxa-4-phosphatetratriciaconta-14,26-dien-1-aminium,  
N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
hydroxypropyl]-4-hydroxy-N,N-dimethyl-9-oxo-7-[[[(6Z)-1-oxo-6-  
hexadecenyl]oxy]methyl]-, inner salt, 4-oxide, (7R,14Z,26Z)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-82-0 CAPLUS


CN 4,6,10-Trioxa-5-phosphahexacos-16-en-1-aminium, N-[3-[3-[3-(2,3-  
dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-  
hydroxy-N,N-dimethyl-11-oxo-8-[[[(6Z)-1-oxo-6-hexadecenyl]oxy]-, inner  
salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-83-1 CAPLUS


CN 4,6,10-Trioxa-5-phosphaheptacos-20-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[10Z)-1-oxo-10-heptadecenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-84-2 CAPLUS


CN 4,6,10-Trioxa-5-phosphaoctacos-16-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 5-oxide, (8R,16Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-85-3 CAPLUS


CN 4,6,10-Trioxa-5-phosphatriacont-22-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(12Z)-1-oxo-12-eicosenyl]oxy]-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-86-4 CAPLUS

CN 4,6,10-Trioxa-5-phosphadotriacont-20-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(12Z)-1-oxo-12-eicosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)


hydroxy-N,N-dimethyl-11-oxo-8-[[ (10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-87-5 CAPLUS  
CN 4,6,10-Trioxa-5-phosphadotriacont-22-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (12Z)-1-oxo-12-docosenyl]oxy]-, inner salt, 5-oxide, (8R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-88-6 CAPLUS


CN 4,6,10-Trioxa-5-phosphatritriacont-20-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-tricosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-89-7 CAPLUS


CN 4,6,10-Trioxa-5-phosphatetratriacont-20-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-tetracosenyl]oxy]-, inner salt, 5-oxide, (8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-90-0 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacosa-15,21-dien-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[{(5Z,11Z)-1-oxo-5,11-octadecadienyl}oxy]-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 258275-91-1 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphatriaconta-20,26-dien-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[{(5Z,11Z)-1-oxo-5,11-octadecadienyl}oxy]-, inner salt, 5-oxide, (8R,15Z,21Z)- (9CI) (CA INDEX NAME)




hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (10Z,16Z)-1-oxo-10,16-eicosadienyl]oxy]-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-92-2 CAPLUS

CN 4,6,10-Trioxa-5-phosphadotriaconta-20,26-dien-1-aminium,  
N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (10Z,16Z)-1-oxo-10,16-docosadienyl]oxy]-, inner salt, 5-oxide, (8R,20Z,26Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-93-3 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
 N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
 hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[{(6Z,18Z)-1-oxo-6,18-  
 hexacosadienyl]oxy]-, inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-94-4 CAPLUS  
 CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-[3-[3-[3-(2,3-  
 dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-  
 hydroxy-N,N-dimethyl-11-oxo-8-[[{(6Z)-1-oxo-6-hexadecenyl]oxy]-, inner  
 salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-95-5 CAPLUS

CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-octadecenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-96-6 CAPLUS


CN 4,6,10-Trioxa-5-phosphadotriacontan-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[[(10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 5-oxide, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-97-7 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacosan-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[[ (6Z,12Z)-1-oxo-6,12-hexadecadienyl]oxy]-, inner salt, 5-oxide, (8R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258275-98-8 CAPLUS  
CN 4,6,10-Trioxa-5-phosphaoctacos-20-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[(1-oxooctadecyl)oxy]-, inner salt, 5-oxide,


(8R,20Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258275-99-9 CAPLUS  
CN 4,6,10-Trioxa-5-phosphahexatriaconta-16,28-dien-1-aminium,  
N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
hydroxypropyl]-5-hydroxy-N,N-dimethyl-11-oxo-8-[(1-oxooctadecyl)oxy]-,  
inner salt, 5-oxide, (8R,16Z,28Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258276-00-5 CAPLUS


CN 5,7,11-Trioxa-6-phosphanonacos-17-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-9-[[6Z]-1-oxo-6-octadecenyl]oxy]-, inner salt, 6-oxide, (9R,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258276-01-6 CAPLUS


CN 5,7,11-Trioxa-6-phosphatritriacont-21-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-9-[[10Z]-1-oxo-10-docosenyl]oxy]-, inner salt, 6-oxide, (9R,21Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258276-02-7 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphaheptacos-16,22-dien-1-aminium,  
 N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-9-[[5Z,11Z]-1-oxo-5,11-hexadecadienyl]oxy]-, inner salt, 6-oxide, (9R,16Z,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258276-03-8 CAPLUS  
 CN 5,7,11-Trioxa-6-phosphatritriaconta-21,27-dien-1-aminium,  
 N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-9-[[10Z,16Z]-1-oxo-10,16-docosadienyl]oxy]-, inner salt, 6-oxide, (9R,21Z,27Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 258276-04-9 CAPLUS


CN 5,7,11-Trioxa-6-phosphaheptatriaconta-17,29-dien-1-aminium,  
N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
hydroxypropyl]-6-hydroxy-N,N-dimethyl-12-oxo-9-[[6Z,18Z)-1-oxo-6,18-  
hexacosadienyl]oxy]-, inner salt, 6-oxide, (9R,17Z,29Z)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 258276-05-0 CAPLUS


CN 7,9,13-Trioxa-8-phosphahentriacont-19-en-1-aminium, N-[3-[3-[3-(2,3-




dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-8-hydroxy-N,N-dimethyl-14-oxo-11-[[ (6Z)-1-oxo-6-octadecenyl]oxy]-, inner salt, 8-oxide, (11R,19Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258276-06-1 CAPLUS  
CN 7,9,13-Trioxa-8-phosphapentatriacont-23-en-1-aminium, N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl]-8-hydroxy-N,N-dimethyl-14-oxo-11-[[ (10Z)-1-oxo-10-docosenyl]oxy]-, inner salt, 8-oxide, (11R,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258276-07-2 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphapentatriaconta-23,29-dien-1-aminium,  
 N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
 hydroxypropyl]-8-hydroxy-N,N-dimethyl-14-oxo-11-[[10Z,16Z)-1-oxo-10,16-  
 docosadienyl]oxy]-, inner salt, 8-oxide, (11R,23Z,29Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 258276-08-3 CAPLUS  
 CN 7,9,13-Trioxa-8-phosphanonacontriaconta-19,31-dien-1-aminium,  
 N-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-  
 hydroxypropyl]-8-hydroxy-N,N-dimethyl-14-oxo-11-[[6Z,18Z)-1-oxo-6,18-  
 hexacosadienyl]oxy]-, inner salt, 8-oxide, (11R,19Z,31Z)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L57 ANSWER 24 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:763878 CAPLUS

DOCUMENT NUMBER: 132:6370

TITLE: Process for producing composite preparation containing nucleic acid

INVENTOR(S): Sugihara, Katsuhiko; Seki, Junzo; Hirabayashi, Kazuko

PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961032	A1	19991202	WO 1999-JP2713	19990524
W: CA, CN, JP, KR, RU, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2333162	AA	19991202	CA 1999-2333162	19990524
EP 1086699	A1	20010328	EP 1999-921242	19990524
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.:	JP 1998-142763	A	19980525
	WO 1999-JP2713	W	19990524

AB A process for producing a homogeneous nucleic-acid-contg. composite prepn. of good quality which is capable of sterilization by filtration and is characterized by contg. no coarse particles having a size of .gtoreq. 7 .mu.m, which are regarded as unsafe for the human body. The process for producing the prepn., contg. a composite of a cationic carrier with a nucleic acid polymer, is characterized in that two single-stranded nucleic acid polymers capable of at least partly forming a double-stranded state are sep. added, each in the single-stranded state, to either a cationic carrier or a material from which the cationic carrier is to be formed, and all these ingredients are subjected to a dispersing treatment. A

freeze-dried compn. was prepd. from 2-O-(2-diethylaminoethyl)-carbamoyl-1,3-O-dioleoylglycerol, egg lecithin, water, poly(I) (polyinosinic acid), and poly(C) (polycytidylic acid). The av. particle size of the composite particles after dissolved in injection water was 140 nm.

IT 128835-92-7, Lipofectin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compn. contg. two single-stranded **nucleic acid**  
polymers and cationic carrier)

RN 128835-92-7 CAPLUS


CN 1-Propanaminium, N,N,N-trimethyl-2,3-bis[(9Z)-9-octadecenyl]oxy-,  
chloride, mixt. with 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-  
ethanediyl di-(9Z)-9-octadecenoate (9CI) (CA INDEX NAME)

CM 1

CRN 104162-48-3

CMF C42 H84 N O2 . Cl

Double bond geometry as shown.



● Cl<sup>-</sup>


CM 2

CRN 2462-63-7

CMF C41 H78 N O8 P

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

REFERENCE COUNT:

18

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS

Searched by Barb O'Bryen, STIC 308-4291

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 25 OF 59 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1999:691195 CAPLUS  
DOCUMENT NUMBER: 131:307093  
TITLE: Combination therapy using nucleic acids and  
conventional drugs  
INVENTOR(S): Joshi, Phalgun B.; Mortimer, Ian C.; Tam, Patrick M.  
S.; MacLachlan, Ian; Graham, Roger W.  
PATENT ASSIGNEE(S): Inex Pharmaceuticals Corporation, Can.  
SOURCE: PCT Int. Appl., 83 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954445	A2	19991028	WO 1999-CA371	19990422
WO 9954445	A3	19991209		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2325561	AA	19991028	CA 1999-2325561	19990422
AU 9935912	A1	19991108	AU 1999-35912	19990422
EP 1082419	A2	20010314	EP 1999-917711	19990422
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002512258	T2	20020423	JP 2000-544777	19990422
PRIORITY APPLN. INFO.:			US 1998-82665P P	19980422
			US 1998-111635P P	19981209
			US 1999-295663 A	19990421
			WO 1999-CA371 W	19990422
AB	Methods for increasing the efficiency of transformation of cycling cells comprise synchronizing cells at a first stage of the cell cycle, and transforming the cells at a second stage of the cell cycle within about one cell cycle of the first stage with a genetically engineered nucleic acid that encodes a desired gene product. The invention further relates to cancer therapy and, in particular, to methods of efficiently transforming cancer cells with nucleic acids that encode gene products that inhibit the growth of cancer cells.			
IT	2462-63-7			
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination therapy using nucleic acids and conventional drugs)			
RN	2462-63-7 CAPLUS			
CN	9-Octadecenoic acid (9Z)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)			

Double bond geometry as shown.



WO 1999-CA372 W 19990422

AB Methods are provided for increasing the efficiency of transformation of cycling cells, the methods comprising synchronizing cells at a first stage of the cell cycle, and transforming the cells at a second stage of the cell cycle within about one cell cycle of the first stage with a genetically engineered nucleic acid that encodes a desired gene product. The invention further relates to cancer therapy and, in particular, to methods of efficiently transforming cancer cells with nucleic acids that encode gene products that inhibit the growth of cancer cells.

IT 2462-63-7


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination therapy using **nucleic acids** and  
radiotherapy)

RN 2462-63-7 CAPLUS

CN 9-Octadecenoic acid (9Z)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—Me

L57 ANSWER 27 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:659214 CAPLUS

DOCUMENT NUMBER: 131:291286

TITLE: Cationic lipid formulation for delivering nucleic acids to peritoneal tumors

INVENTOR(S): Smith, Janet G.; Niven, Ralph W.; Zhang, Yilin

PATENT ASSIGNEE(S): Megabios Corporation, USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951206	A1	19991014	WO 1999-US7413	19990402
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				

Searched by Barb O'Bryen, STIC 308-4291

TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,  
RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
US 2001008772 A1 20010719 US 1999-283543 19990401  
US 6271209 B2 20010807  
CA 2326130 AA 19991014 CA 1999-2326130 19990402  
AU 9933815 A1 19991025 AU 1999-33815 19990402  
EP 1067909 A1 20010117 EP 1999-915259 19990402  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI  
JP 2002510615 T2 20020409 JP 2000-541978 19990402  
PRIORITY APPLN. INFO.: US 1998-80450P P 19980403  
WO 1999-US7413 W 19990402

OTHER SOURCE(S): MARPAT 131:291286

AB Methods of transfecting cells in vivo, including tumor cells in the peritoneal cavity, are provided. Related lipid/nucleic acid formulations adapted to transfecting cells in the peritoneal cavity are provided. Assays, including high-throughput assays for screening lipid/nucleic acids are also provided.

IT 2462-63-7, Dope 183283-19-4, EDMPC 246044-55-3  
, DiPPE


RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(cationic lipid formulation for delivering nucleic acids to peritoneal tumors)

RN 2462-63-7 CAPLUS

CN 9-Octadecenoic acid (9Z)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


Me

RN 183283-19-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-ethoxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, 4-oxide, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 246044-55-3 CAPLUS

CN Cyclopentanoctanoic acid, 2-pentyl-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 28 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:388071 CAPLUS

DOCUMENT NUMBER: 131:35880

TITLE: Nasal pharmaceutical compositions containing hydrophilic particles for delivering active agents to the central nervous system

INVENTOR(S): Betbeder, Didier; Sperandio, Sandrine

PATENT ASSIGNEE(S): Biovector Therapeutics (S.A.), Fr.

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9929295	A1	19990617	WO 1998-FR2674	19981209
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2771929	A1	19990611	FR 1997-15565	19971209
FR 2771929	B1	20010223		
AU 9915661	A1	19990628	AU 1999-15661	19981209
PRIORITY APPLN. INFO.:			FR 1997-15565	A 19971209

WO 1998-FR2674 W 19981209


AB The use in a pharmaceutical compn. to be administered through the nose, of a hydrophilic particle whether or not bearing ionic ligands and optionally coated with a layer of amphiphilic compds., having a size ranging between about 20 and 200 nm and advantageously between 50 and 100 nm to ensure and/or enhance the passage of an active agent administered through the nose up to the central nervous system. Supramol. biovectors comprising polysaccharide 12.7, dipalmitoylphosphatidylcholine 2.3, cholesterol 0.67 mg/mL, and  $^{111}\text{InCl}_3$  0.39 MBq/dose were prepd. Twelve h after the administration of the compn. to volunteers nose 20% of the radioactivity was detected.

IT 63-89-8, Dipalmitoylphosphatidylcholine  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nasal pharmaceutical compns. contg. hydrophilic particles for delivering active agents to central nervous system)

RN 63-89-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 29 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:350607 CAPLUS

DOCUMENT NUMBER: 131:14825

TITLE: A method of increasing nucleic acid synthesis with ultrasound

INVENTOR(S): Unger, Evan C.; McCreery, Thomas; Sadewasser, David

PATENT ASSIGNEE(S): ImaRx Pharmaceutical Corp., USA

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925385	A1	19990527	WO 1998-US23843	19981111
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9913906	A1	19990607	AU 1999-13906	19981111
PRIORITY APPLN. INFO.:			US 1997-971540	19971117
			WO 1998-US23843	19981111

OTHER SOURCE(S): MARPAT 131:14825

AB The present invention is directed to a method of increasing nucleic acid synthesis in a cell comprising administering to the cell a therapeutically effective amt. of ultrasound for a therapeutically effective time such

that said administration of said ultrasound results in said increased nucleic acid synthesis. The nucleic acid sequence may comprise an endogenous sequence or an exogenous sequence. In particular, the invention is directed to increasing the expression of stress proteins and repair proteins.


IT 2644-64-6, Dipalmitoylphosphatidylcholine 4235-95-4,  
DOPC 4539-70-2, Distearoylphosphatidylcholine 18656-38-7  
, Dimyristoylphosphatidylcholine 18656-40-1,  
Dilauroylphosphatidylcholine 67896-63-3,  
Dipentadecanoylphosphatidylcholine 68737-67-7,  
Dioleoylphosphatidylcholine 183283-19-4, EDMPC  
225940-35-2 225940-43-2

RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(carrier; method of increasing nucleic acid synthesis with ultrasound)

RN 2644-64-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)




RN 4235-95-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Me


RN 4539-70-2 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)




RN 18656-38-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)




RN 18656-40-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxododecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 67896-63-3 CAPLUS


CN 3,5,9-Trioxa-4-phosphatetracosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxopentadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 68737-67-7 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[ (9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (18Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B


Me

RN 183283-19-4 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-ethoxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 225940-35-2 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphaundecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 225940-43-2 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, mixt. with .alpha.-[7-hydroxy-7-oxido-13-oxo-10-[(1-oxo-9-hexadecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphaoctacos-1-yl]-.omega.-hydroxypoly(oxy-1,2-

ethanediyl) and 1-[(phosphonooxy)methyl]-1,2-ethanediyl dihexadecanoate  
(9CI) (CA INDEX NAME)


CM 1

CRN 145035-97-8


CMF (C2 H4 O)<sub>n</sub> C39 H78 N O9 P

CCI PMS

PAGE 1-A




PAGE 1-B



CM 2

CRN 19698-29-4


CMF C35 H69 O8 P



CM 3

CRN 2644-64-6

CMF C40 H80 N O8 P



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 30 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:262163 CAPLUS

DOCUMENT NUMBER: 130:301682

TITLE: Methods for encapsulating nucleic acids in lipid bilayers

INVENTOR(S): Saravolac, Edward G.; Zhang, Yuan-Peng; Wheeler, Jeffery J.; Cullis, Pieter R.; Scherrer, Peter; Kojic, Ljiljana D.; Ludkovski, Olga

PATENT ASSIGNEE(S): Inex Pharmaceuticals Corporation, Can.

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918933	A2	19990422	WO 1998-US21500	19981009
WO 9918933	A3	19990701		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2309727	AA	19990422	CA 1998-2309727	19981009
AU 9913604	A1	19990503	AU 1999-13604	19981009
EP 1023048	A1	20000802	EP 1998-957320	19981009
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1997-63473P P 19971010  
WO 1998-US21500 W 19981009

AB The present invention relates to lipid-based formulations for nucleic acid delivery to cells, methods for the prepn. of such formulations and, in particular, to lipid-encapsulated plasmids. The compns. are safe and practical for clin. use. In addn., the present invention provides methods for introducing nucleic acids into cells and for inhibiting tumor growth in cells using such lipid-nucleic acid formulations.

IT 2462-63-7, Dope

RL: MOA (Modifier or additive use); NUU (Other use, unclassified); USES (Uses)


(methods for encapsulating nucleic acids in lipid bilayers)

RN 2462-63-7 CAPLUS

CN 9-Octadecenoic acid (9Z)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

L57 ANSWER 31 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:220014 CAPLUS

DOCUMENT NUMBER: 130:249137

TITLE: Novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use

INVENTOR(S): Unger, Evan C.; Fritz, Thomas A.; Gertz, Edward W.

PATENT ASSIGNEE(S): ImarRx Pharmaceutical Corp., USA

SOURCE: PCT Int. Appl., 223 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913919	A1	19990325	WO 1998-US18858	19980909
W: AU, CA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6139819	A	20001031	US 1997-932273	19970917
AU 9893830	A1	19990405	AU 1998-93830	19980909
EP 959908	A1	19991201	EP 1998-946919	19980909

R: DE, FR, GB, IT

PRIORITY APPLN. INFO.:

US 1997-932273	A	19970917
US 1995-497684	B2	19950607
US 1996-640464	B2	19960501
US 1996-660032	B2	19960606
US 1996-666129	A2	19960619
WO 1998-US18858	W	19980909

AB This invention describes novel contrast agents which may be used for diagnostic and therapeutic use. The compns. may comprise a lipid, a protein, polymer and/or surfactant, and a gas, in combination with a targeting ligand. In preferred embodiments, the targeting ligand targets coagula, including emboli and/or thrombi, particularly in patients suffering from an arrhythmic disorder. The contrast media can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.

IT 63-89-8, Dipalmitoylphosphatidylcholine 816-94-4,



Distearoylphosphatidylcholine 4235-95-4 18194-24-6,  
Dimyristoylphosphatidylcholine


RL: ARU (Analytical role, unclassified); BUU (Biological use,  
unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL  
(Biological study); USES (Uses)

(contrast agent; novel targeted ultrasound imaging contrast agents for  
diagnostic and therapeutic use)

RN 63-89-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-  
oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry. Rotation (+).



RN 816-94-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-  
oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 4235-95-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-  
10-oxo-7-[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.




PAGE 1-A

PAGE 1-B

—Me

RN 18194-24-6 CAPLUS  
 CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 79481-27-9P  
 RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)


RN 79481-27-9 CAPLUS  
 CN 3,5,8,21-Tetraoxa-4-phosphatetracos-23-en-1-aminium, 4-hydroxy-N,N,N,23-tetramethyl-9,22-dioxo-7-[[[(1-oxohexadecyl)oxy]methyl]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 28319-77-9, L-.alpha.-Glycerophosphocholine  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)  
 RN 28319-77-9 CAPLUS  
 CN Ethanaminium, 2-[[[(2R)-2,3-dihydroxypropoxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




## IT 79605-84-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)

RN 79605-84-8 CAPLUS

CN 3,5,9,22-Tetraoxa-4-phosphapentacos-24-en-1-aminium, 4-hydroxy-N,N,N,24-tetramethyl-7-[[12-[(2-methyl-1-oxo-2-propenyl)oxy]-1-oxododecyl]oxy]-10,23-dioxo-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




## IT 80294-15-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)

RN 80294-15-1 CAPLUS

CN 3,5,9,22-Tetraoxa-4-phosphapentacos-24-en-1-aminium, 4-hydroxy-N,N,N,24-tetramethyl-10,23-dioxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 32 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:194050 CAPLUS

DOCUMENT NUMBER: 130:254460

TITLE: Coated particles for delivery or uptake of materials

INVENTOR(S): Anderson, David M.

PATENT ASSIGNEE(S): Select Release, L. L.C., USA


Searched by Barb O'Bryen, STIC 308-4291

SOURCE: PCT Int. Appl., 116 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912640	A1	19990318	WO 1998-US18639	19980908
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9896614	A1	19990329	AU 1998-96614	19980908
AU 747252	B2	20020509		
EP 942780	A1	19990922	EP 1998-950618	19980908
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001506541	T2	20010522	JP 1999-515708	19980908
US 6482517	B1	20021119	US 2000-297997	20000816
PRIORITY APPLN. INFO.:			US 1997-58309P P	19970909
			WO 1998-US18639 W	19980908
AB	Coated particles comprising an internal core matrix and an exterior coating are prepd. by solubilizing the internal core material (e.g., active material) in soln. contg. a coating compd. precursor, mixing the soln. with a second liq. contg. components to form a liq. dispersion in which the (active) material becomes insolubilized and coated, followed by reducing the size of the resulting coated particles. The matrix consists essentially of a nanostructured liq. phase or liq. cryst. phase or a combination of the two and the exterior coating comprising a nonlamellar cryst. material. The coated particles are used for release of materials into the environment or adsorption/absorption of materials from the environment in which the coating dissolves, is fractured, or is porous. The particles have applications for delivery of rodent toxins, polymer additives, dyes and drugs. In an example, Me paraben coated particles with increased soly. in acidic media were prepd. contg. salicylic acid, vinblastine sulfate, thymidine, thyrotropic hormone, anti 3',5'-cAMP antibody, or L-thyroxine for gastrointestinal drug delivery.			
IT	68737-67-7 RL: NUU (Other use, unclassified); USES (Uses) (coated particles for delivery or uptake of materials)			
RN	68737-67-7 CAPLUS			
CN	3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[ (9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (18Z)-(9CI) (CA INDEX NAME)			

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 33 OF 59 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1999:193980 CAPLUS  
 DOCUMENT NUMBER: 130:227746  
 TITLE: Modulation of drug loading in multivesicular liposomes  
 INVENTOR(S): Ye, Qiang; Katre, Nandini; Sankaram, Mantripragada  
 PATENT ASSIGNEE(S): Depotech Corporation, USA  
 SOURCE: PCT Int. Appl., 54 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912523	A1	19990318	WO 1998-US18739	19980908
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6106858	A	20000822	US 1997-925532	19970908
CA 2303432	AA	19990318	CA 1998-2303432	19980908
AU 9893101	A1	19990329	AU 1998-93101	19980908
AU 741784	B2	20011206		
EP 1011637	A1	20000628	EP 1998-945975	19980908
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001515853	T2	20010925	JP 2000-510422	19980908
NO 2000001179	A	20000404	NO 2000-1179	20000307
PRIORITY APPLN. INFO.:			US 1997-925532 A1	19970908
			WO 1998-US18739 W	19980908

AB Disclosed is a method for making liposomes, for example multivesicular liposomes (MVLs), contg. one or more biol. active agents, wherein the

loading of the active agents into the liposomes is modulated by adjusting the osmolarity of the aq. component into which the agents are dissolved prior to encapsulation. To increase the loading of the active agent, the osmolarity of the aq. component is reduced, and to decrease the loading of the active agent, the osmolarity of the aq. component is increased. In the making of MVLs, the process involves dissolving the active agent and an optimal osmotic excipient in a first aq. component encapsulated within the liposomes. For any given concn. of drug, the osmolarity of the first aq. component can be adjusted by increasing or decreasing the concn. or mol. wt. of the osmotic excipients used therein. The rate of release of the active agent into the surrounding environment in which the liposomes are introduced can be simultaneously controlled by incorporating into the lipid component used in the formulation at least one long chain amphipathic lipid. For example the amphipathic lipid can have from about 13 to about 28 carbons for example, from about 18 to about 22 carbons, in its carbon chain. Use of the long chain amphipathic lipid in the lipid component is particularly helpful in controlling the release rate and encapsulation efficiency for high drug load formulations. A water-in-oil prepn. was prepd. by mixing a lipid component comprising 1,2-dioleoyl-sn-glycero-3-phosphocholine 13.20, cholesterol 19.88, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 2.79, and triolein 2.44 mM in chloroform with an aq. component comprising cytarabine 40 mg/mL, sucrose 8.0%, and citric acid 20 mM. The drug loading of the final liposome suspension was 21.0%.


IT 63-89-8 4235-95-4 51779-95-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(modulation of drug loading in multivesicular liposomes)

RN 63-89-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 4235-95-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.

INVENTOR(S): Zhang, Yuan-Peng; Scherrer, Peter; Hope, Michael  
 PATENT ASSIGNEE(S): Inex Pharmaceuticals Corporation, Can.  
 SOURCE: PCT Int. Appl., 53 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9905303	A1	19990204	WO 1998-CA710	19980723
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9884289	A1	19990216	AU 1998-84289	19980723
PRIORITY APPLN. INFO.:			US 1997-72656	19970724
			WO 1998-CA710	19980723

AB This invention relates to a novel Solvent Extn. and Direct Hydration (SEDH) method for prepg. lipid-nucleic acid particles which are useful for the introduction of nucleic acids (e.g., plasmid DNA, antisense mols., ribozymes, etc.) into cells. The SEDH method comprises (1) contacting the nucleic acid with a soln. contg. a non-cationic lipid and a cationic lipid to form a lipid-nucleic acid mixt., said soln. contg. 15-35% water and 65-85% org. solvent; (2) removing the water; (3) removing the org. solvent to form the a lipid-nucleic acid complex; then (4) hydrating the complex to form the lipid-nucleic acid particle. The lipid-nucleic acid particles prepd. using the methods of the present invention have enhanced circulation characteristics and serum stability and, thus, they are extremely effective as nucleic acid delivery vehicles. The sizes of the lipid-nucleic acid particles are in the range of 200-500 nm, but can be reduced to about 50-150 nm by, for example, brief sonication. The SEDH method is simple and time-efficient. The disclosed method provides high encapsulation efficiency (60-100%) with relatively low lipid:nucleic acid ratios.


IT 2644-64-6, Dipalmitoylphosphatidylcholine 6542-05-8, Dilinoleoylphosphatidylcholine 68737-67-7, Dioleoylphosphatidylcholine

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of lipid-nucleic acid particles by solvent extn. and direct hydration and their use in cell transfection and gene therapy)

RN 2644-64-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



**THIS PAGE BLANK (USPTO)**




RN 6542-05-8 CAPLUS


CN 3,5,9-Trioxa-4-phosphaheptacos-18,21-dien-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[ (9Z,12Z)-1-oxo-9,12-octadecadienyl]oxy]-, inner salt, 4-oxide, (18Z,21Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 68737-67-7 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[ (9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (18Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 35 OF 59 CAPLUS COPYRIGHT 2003 ACS

Searched by Barb O'Bryen, STIC 308-4291

**THIS PAGE BLANK (USPTO)**

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 36 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:789045 CAPLUS

DOCUMENT NUMBER: 130:24103

TITLE: An influenza enveloped DNA vaccine

INVENTOR(S): Cusi, Maria Grazia; Gluck, Reinhard; Walti, Ernst

PATENT ASSIGNEE(S): Schweiz. Serum- & Impfinstitut Bern, Switz.

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852603	A2	19981126	WO 1998-EP3050	19980522
WO 9852603	A3	19990514		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9879153	A1	19981211	AU 1998-79153	19980522
EP 988052	A2	20000329	EP 1998-929369	19980522
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

PRIORITY APPLN. INFO.:

EP 1997-108390 19970523

WO 1998-EP3050 19980522

AB Described are virosomes comprising cationic lipids, biol. active influenza hemagglutinin protein or biol. active derivs. thereof and nucleic acids encoding antigens from pathogenic sources in their insides, preferably antigens from mumps virus wherein said antigens are derived from conserved external and internal proteins of said virus. Provided are virosomes which may advantageously be formulated as vaccines capable of inducing strong neutralizing antibody and cytotoxic T cell responses as well as protection to pathogenic sources such as a mumps virus. Furthermore, vaccines comprising recombinant DNA derived from DNA encoding conserved external and internal proteins from mumps virus are described. Mol. cloning of hemagglutinin gene, F gene, and nucleocapsid gene of mumps virus, N gene of respiratory syncytial virus, and S or Pre-S1 or Pre-S2 or S ORF gene of hepatitis B virus was described. Also described were prepn. of DOTAP-PC virosomes and DOTAP-PC-PE virosomes, incorporation of plasmids expressing mumps genes into DOTAP virosomes, humoral and cellular immune response to viral mumps-antigens induced by genetic immunization.


IT 124076-29-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(virosomes comprising cationic lipids, influenza hemagglutinin, and antigen gene of pathogen as DNA vaccine for infectious diseases)

RN 124076-29-5 CAPLUS

CN Hexadecanoic acid, 1-[16-amino-9-[(3-aminopropyl)amino]-3-hydroxy-3-oxido-8-oxo-2,4-dioxa-7,13-diaza-3-phosphahexadec-1-yl]-1,2-ethanediyl ester  
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— (CH<sub>2</sub>)<sub>14</sub>—Me

L57 ANSWER 37 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:766505 CAPLUS

DOCUMENT NUMBER: 130:29197

TITLE: High efficiency encapsulation of charged therapeutic agents in lipid vesicles

INVENTOR(S): Semple, Sean C.; Klimuk, Sandra K.; Harasym, Troy; Hope, Michael J.; Ansell, Steven M.; Cullis, Pieter; Scherrer, Peter; Debeyer, Dan

PATENT ASSIGNEE(S): Inex Pharmaceuticals Corporation, Can.

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851278	A2	19981119	WO 1998-CA485	19980514
WO 9851278	A3	20000615		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9874221	A1	19981208	AU 1998-74221	19980514
AU 733310	B2	20010510		
EP 1027033	A2	20000816	EP 1998-921310	19980514
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002501511	T2	20020115	JP 1998-548646	19980514
PRIORITY APPLN. INFO.:			US 1997-856374 A	19970514
			WO 1998-CA485 W	19980514

AB Methods for the prepn. of a lipid-nucleic acid compn. are provided. According to the methods, a mixt. of lipids contg. a protonatable or

deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or polyamide oligomer-modified lipid is combined with a buffered aq. soln. of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated comps. of the therapeutic agents. The method permits the prepn. of comps. with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50 %.

IT 816-94-4, DSPC 74936-61-1, POPC


RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(high-efficiency encapsulation of charged therapeutic agents in lipid vesicles)

RN 816-94-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74936-61-1 CAPLUS

CN Ethanaminium, 2-[[hydroxy[[[(1-oxohexadecyl)oxy] [(9Z)-1-oxo-9-octadecenyl]oxy]propoxy]phosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)

CM 1

CRN 563-24-6

CMF C8 H20 N O6 P




CM 2

CRN 112-80-1

CMF C18 H34 O2

Double bond geometry as shown.



CM 3

CRN 57-10-3  
CMF C16 H32 O2HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>14</sub>-Me

L57 ANSWER 38 OF 59 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1998:548562 CAPLUS  
DOCUMENT NUMBER: 129:193718  
TITLE: Formulation of stabilized cationic transfection agents  
complexed with nucleic acid particles  
INVENTOR(S): Crouzet, Joel; Pitard, Bruno  
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Fr.  
SOURCE: PCT Int. Appl., 52 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834648	A1	19980813	WO 1998-FR222	19980206
W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
FR 2759298	A1	19980814	FR 1997-1467	19970210
FR 2759298	B1	19990409		
AU 9862987	A1	19980826	AU 1998-62987	19980206
AU 737720	B2	20010830		
BR 9807563	A	20000201	BR 1998-7563	19980206
EP 1007097	A1	20000614	EP 1998-906986	19980206
EP 1007097	B1	20011017		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI			
JP 2001511171	T2	20010807	JP 1998-533881	19980206
AT 206932	E	20011115	AT 1998-906986	19980206
ES 2166146	T3	20020401	ES 1998-906986	19980206
ZA 9801034	A	19980811	ZA 1998-1034	19980209
NO 9903825	A	19990809	NO 1999-3825	19990809
PRIORITY APPLN. INFO.:			FR 1997-1467 A	19970210
			WO 1998-FR222 W	19980206
OTHER SOURCE(S):	MARPAT 129:193718			
AB	The invention concerns a compn. contg. stabilized particles of cationic transfection agent(s)/nucleic acid complexes characterized in that it includes besides said transfection agent and nucleic acid at least a non-ionic surfactant in sufficient amt. for preventing the aggregation of the particles in course of time. In a preferred embodiment, the surfactant is a polyoxyalkylene or a deriv. thereof.			
IT	2462-63-7, Dope 4537-76-2, Distearoylphosphatidylethanolamine 4537-76-2D, Distearoylphosphatidylethanolamine, N-Me derivs. 5681-36-7, Dipalmitoylphosphatidylethanolamine 5681-36-7D, Dipalmitoylphosphatidylethanolamine, N-Me derivs.			

10015-88-0, Pope 20255-95-2,  
 Dimyristoylphosphatidylethanolamine 20255-95-2D,  
 Dimyristoylphosphatidylethanolamine, N-Me derivs. 158571-62-1,  
 Lipofectamine

RL: DEV (Device component use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)


(formulation of stabilized cationic transfection agents complexed with nucleic acid particles)

RN 2462-63-7 CAPLUS

CN 9-Octadecenoic acid (9Z)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Me


RN 4537-76-2 CAPLUS

CN Octadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 4537-76-2 CAPLUS

CN Octadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)




RN 5681-36-7 CAPLUS

CN Hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 5681-36-7 CAPLUS


CN Hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 10015-88-0 CAPLUS

CN 9-Octadecenoic acid (9Z)-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 20255-95-2 CAPLUS

CN Tetradecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-




ethanediyl ester (9CI) (CA INDEX NAME)



RN 20255-95-2 CAPLUS

CN Tetradecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 158571-62-1 CAPLUS

CN 1-Propanaminium, N-[3-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-3-oxopropyl]-N,N-dimethyl-2,3-bis[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, salt with trifluoroacetic acid (1:1), mixt. with 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl di-(9Z)-9-octadecenoate (9CI) (CA INDEX NAME)


CM 1

CRN 2462-63-7

CMF C41 H78 N O8 P

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—Me

CM 2

CRN 185097-43-2

CMF C54 H106 N5 O5 . C2 F3 O2


CM 3

CRN 181508-68-9


CMF C54 H106 N5 O5

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



CM 4

CRN 14477-72-6

CMF C2 F3 O2



IT 124076-29-5


RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(formulation of stabilized cationic transfection agents complexed with nucleic acid particles)

RN 124076-29-5 CAPLUS

CN Hexadecanoic acid, 1-[16-amino-9-[(3-aminopropyl)amino]-3-hydroxy-3-oxido-8-oxo-2,4-dioxo-7,13-diaza-3-phosphahexadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— (CH<sub>2</sub>)<sub>14</sub>—Me

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 39 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:484928 CAPLUS

DOCUMENT NUMBER: 129:113548

TITLE: Pharmaceutical or cosmetic compositions containing homogeneously charged particulate vector

INVENTOR(S): Betbeder, Didier; Major, Michel

PATENT ASSIGNEE(S): Biovector Therapeutics S.A., Fr.

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9829102	A1	19980709	WO 1997-FR2397	19971223
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			

FR 2757768 A1 19980703 FR 1996-16146 19961227  
 FR 2757768 B1 19990402  
 AU 9856688 A1 19980731 AU 1998-56688 19971223  
 EP 946153 A1 19991006 EP 1997-952990 19971223

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI

JP 2001508425 T2 20010626 JP 1998-529682 19971223

PRIORITY APPLN. INFO.:

FR 1996-16146 A 19961227

WO 1997-FR2397 W 19971223

AB The invention concerns a particulate carrier comprising a non-liq. hydrophilic nucleus; an amphiphilic lamella characterized in that the nucleus carries a global cationic, anionic or neutral charge and that the amphiphilic lamella carries a global charge of same polarity as that carried by the nucleus. The invention also concerns a pharmaceutical or cosmetic compn. or a nutrient additive contg. such a vector. Thus, maltodextrin (500 g) was treated with 7 g NaBH<sub>4</sub> followed by the reaction with NaOH, 30.25 mL epichlorohydrin and 382.3 g glycidyltrimethylammonium chloride. The resulting gel was dild. with water and neutralized with HOAc. Nanoparticle carriers were prepd. by using the above polysaccharide and a phospholipid.

IT 63-89-8, DPPC 137720-22-0D, 1-acylated


RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical or cosmetic compns. contg. homogeneously charged particulate vector)

RN 63-89-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 137720-22-0 CAPLUS

CN 3,5,8-Trioxa-4-phosphaeicosan-1-aminium, 4-hydroxy-7-(hydroxymethyl)-N,N,N-trimethyl-20-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-9-oxo-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 40 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:251030 CAPLUS

DOCUMENT NUMBER: 128:326492

TITLE: N-acyl phosphatidylethanolamine-mediated liposomal drug delivery

INVENTOR(S): Meers, Paul R.; Shangguan, Tong; Ali, Shaukat; Janoff, Andrew S.; Pak, Charles

PATENT ASSIGNEE(S): Liposome Company, Inc., USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9816199	A1	19980423	WO 1997-US18112	19971015
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9746723	A1	19980511	AU 1997-46723	19971015
AU 725257	B2	20001012		
EP 966267	A1	19991229	EP 1997-945550	19971015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6120797	A	20000919	US 1997-951056	19971015
NO 9903257	A	19990728	NO 1999-3257	19990630
US 6294191	B1	20010925	US 2000-487053	20000119
PRIORITY APPLN. INFO.:			US 1996-28557P	P 19961015
			US 1997-951056	A1 19971015
			WO 1997-US18112	W 19971015

OTHER SOURCE(S): MARPAT 128:326492

AB This invention provides liposomes contg. one or more N-acylated phosphatidylethanolamines, such liposomes being useful for localizing the delivery of bioactive agents to cells. N-dodecanoyldioleoylphosphatidylethanolamine was prepd. and liposomes were prepd. from this compd. and dioleoylphosphatidylcholine.

IT 4235-95-4

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic


use); BIOL (Biological study); PROC (Process); USES (Uses)  
(N-acyl phosphatidylethanolamine-mediated liposomal drug delivery)

RN 4235-95-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

L57 ANSWER 41 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:147190 CAPLUS

DOCUMENT NUMBER: 128:208915

TITLE: Methods for the production of protein particles useful for delivery of pharmacological agents

INVENTOR(S): Magdassi, Shlomo; Desai, Neil; Ferreri, Kevin; Soon-Shiong, Patrick

PATENT ASSIGNEE(S): Vivorx Pharmaceuticals, Inc., USA; Magdassi, Shlomo; Desai, Neil; Ferreri, Kevin; Soon-Shiong, Patrick

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807410	A1	19980226	WO 1997-US14661	19970819
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9739169	A1	19980306	AU 1997-39169	19970819
EP 938299	A1	19990901	EP 1997-936517	19970819
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

Searched by Barb O'Bryen, STIC 308-4291

IE, FI

PRIORITY APPLN. INFO.:

US 1996-23968P P 19960819

WO 1997-US14661 W 19970819


AB A method has been developed for the formation of submicron particles (nanoparticles) by heat-denaturation of proteins (such as human serum albumin) in the presence of multivalent ions (such as calcium). Also provided are novel products produced by the invention method. An appropriate concn. of multivalent ions, within a relatively narrow range of concns., induces the pptn. of protein in the form of colloidal particles, at a temp. which is well below the heat denaturation temp. of the protein (as low as 60 .degree.C for serum albumin). Temps. at which invention method operates are sufficiently low to permit incorporation of other mols. (e.g., by co-pptn.), into submicron particles according to the invention, including compds. which cannot withstand high temps. Invention methods facilitate the prodn. of protein nanoparticles and microparticles contg. various mols. (such as nucleic acids, oligonucleotides, polynucleotides, DNA, RNA, polysaccharides, ribozymes, pharmacol. active compds., and the like) useful for therapeutic, diagnostic and other purposes. The addn. of multivalent cations serves both to induce pptn., and to allow linking of neg. charged mols., such as DNA, to the neg. charged protein. Microparticles and nanoparticles were formed from albumin in the presence of CaCL2.

IT 70641-51-9, Edelfosine

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(prodn. of protein particles useful for delivery of pharmacol. agents)

RN 70641-51-9 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L57 ANSWER 42 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:89344 CAPLUS

DOCUMENT NUMBER: 128:184675

TITLE: Transdermal transport of pharmaceuticals

INVENTOR(S): Crandall, Wilson T.

PATENT ASSIGNEE(S): Crandall, Wilson T., USA

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803641	A1	19980129	WO 1997-US12970	19970723
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,			

CA 1997-2262009	19970723
AU 1997-40450	19970723
EP 1997-938029	19970723

US 1996-685235	19960723
WO 1997-US12970	19970723

3,5,9-Trioxa-4-phosphapentadecan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 43 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:287437 CAPLUS

DOCUMENT NUMBER: 129:45331

TITLE: Drug carriers comprising tranexamic acid derivatives

INVENTOR(S): Isozaki, Masashi; Koiwai, Kazumichi; Uchiyama, Hideki

PATENT ASSIGNEE(S): Terumo Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10120595	A2	19980512	JP 1996-273425	19961016

PRIORITY APPLN. INFO.: JP 1996-273425 19961016

OTHER SOURCE(S): MARPAT 129:45331

GI





AB The carriers, useful for including agents for diagnosis and/or treatment in them, comprise tranexamic acid derivs. I (R1, R2 = H, C10-25 alkyl, alkenyl). Condensation of trans-4-[N-(benzyloxycarbonyl)-aminomethyl]cyclohexanecarboxylic acid with dioctadecylamine followed by deprotection gave N,N-dioctadecyl-trans-4-(aminomethyl)cyclohexanecarboxamide (II). II showed LD50 of .gtoreq.320 mg/kg i.v. in mice. Liposomes were prepd. from I 3, dipalmitoylphosphatidylcholine 21, and cholesterol 6 .mu.M as membrane constituents and 0.5 .mu.M calcein. Incorporation of calcein into the liposomes was 45.47%.


IT 63-89-8, Dipalmitoylphosphatidylcholine 4004-05-1,  
Dioleoylphosphatidylethanolamine 18194-25-7,  
Dilauroylphosphatidylcholine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prepn. of tranexamic acid derivs. as drug carriers for disease  
diagnosis and treatment)

RN 63-89-8 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 4004-05-1 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

— Me

RN 18194-25-7 CAPLUS  
CN 3,5,9-Trioxa-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxododecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 44 OF 59 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1997:90523 CAPLUS  
DOCUMENT NUMBER: 126:99297  
TITLE: Composition and methods for creating syngeneic recombinant virus-producing cells  
INVENTOR(S): Garver, Robert I.; Curiel, David T.  
PATENT ASSIGNEE(S): University of Alabama, At Birmingham Research Foundation, USA; Garver, Robert I.; Curiel, David T.  
SOURCE: PCT Int. Appl., 67 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9639036	A1	19961212	WO 1996-US8885	19960605
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9660433	A1	19961224	AU 1996-60433	19960605
PRIORITY APPLN. INFO.:		US 1995-465417	A	19950605
		WO 1996-US8885	W	19960605

AB Replication-defective viruses and means for intracellular replication thereof are described which are useful for gene therapy. Human cells can be changed into recombinant replication-defective virus particle-producing cells by the simultaneous delivery to those cells of two different nucleic acids: the first being a replication-defective viral genome, the second being a nucleic acid that complements the viral sequences deleted from the first nucleic acid so as to result in the prodn. of new infective virus. The first nucleic acid can be delivered by the replication-defective virus itself or, as a nucleic acid that is not part of the virus. In a preferred embodiment, the replication-defective virus includes elements to maintain the two nucleic acids in combination during transduction. Co-delivery of a replication-defective adenovirus (with E1A region deleted

from the viral genome) and an E1A region-contg. replication-enabling plasmid is described. Results are also presented which indicate that RNA transcripts can replace plasmids as vectors for delivery of replication-enabling functions.

IT 4004-05-1

RL: BPR (Biological process); BSU (Biological study, unclassified);

THU (Therapeutic use); BIOL (Biological study); PROC (Process);

USES (Uses)

(plasmid complex with lipid mixt. contg.; recombinant virus-producing cell using replication-defective virus and means for intracellular replication, and use for gene therapy)


RN 4004-05-1 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

L57 ANSWER 45 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:590320 CAPLUS

DOCUMENT NUMBER: 125:212664

TITLE: Combined therapeutic treatment of hyperproliferative diseases using oncogenic cell-signaling pathway-inhibiting nucleic acids and anticancer agents

INVENTOR(S): Tocque, Bruno

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Fr.

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9622101	A1	19960725	WO 1996-FR56	19960112
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,				

Searched by Barb O'Bryen, STIC 308-4291

BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

FR 2729295	A1	19960719	FR 1995-436	19950117
FR 2729295	B1	19970228		
CA 2209771	AA	19960725	CA 1996-2209771	19960112
AU 9645429	A1	19960807	AU 1996-45429	19960112
AU 716364	B2	20000224		
EP 800399	A1	19971015	EP 1996-901387	19960112
EP 800399	B1	20020814		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI				
BR 9606969	A	19971104	BR 1996-6969	19960112
JP 10512559	T2	19981202	JP 1996-522078	19960112
AT 222109	E	20020815	AT 1996-901387	19960112
NO 9703197	A	19970709	NO 1997-3197	19970709
FI 9703023	A	19970716	FI 1997-3023	19970716
US 6262032	B1	20010717	US 1997-875222	19970717
US 2001021395	A1	20010913	US 2001-816144	20010326
PRIORITY APPLN. INFO.:			FR 1995-436	A 19950117
			WO 1996-FR56	W 19960112
			US 1997-875222	A1 19970717

OTHER SOURCE(S): MARPAT 125:212664

AB Hyperproliferative diseases are treated with a medicinal combination of .gtoreq.1 nucleic acids that at least partially inhibit oncogenic cell signaling pathways, and a therapeutic anticancer agent. The nucleic acid is e.g. a DNA coding for a tumor suppressor protein. The anticancer agent may be a taxoid, vinca alkaloid, etc.

IT 158571-62-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hyperproliferative disease combined therapeutic treatment with  
oncogenic cell-signaling pathway-inhibiting **nucleic  
acids** and anticancer agents)

RN 158571-62-1 CAPLUS

CN 1-Propanaminium, N-[3-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]ami  
no]-3-oxopropyl]-N,N-dimethyl-2,3-bis[[[(9Z)-1-oxo-9-octadecenyl]oxy]-,  
salt with trifluoroacetic acid (1:1), mixt. with 1-[[[(2-  
aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl  
di-(9Z)-9-octadecenoate (9CI) (CA INDEX NAME)


CM 1

CRN 2462-63-7

CMF C41 H78 N O8 P

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

CM 2

CRN 185097-43-2

CMF C54 H106 N5 O5 . C2 F3 O2


CM 3

CRN 181508-68-9


CMF C54 H106 N5 O5

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



CM 4

CRN 14477-72-6

CMF C2 F3 O2



L57 ANSWER 46 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:369786 CAPLUS

DOCUMENT NUMBER: 125:41790

TITLE: Preparation of multivesicular liposomes for controlled release of active agents

INVENTOR(S): Sankaram, Mantripragada B.; Kim, Sinil

PATENT ASSIGNEE(S): Depotech Corporation, USA

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9608235	A1	19960321	WO 1995-US11609	19950913
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5993850	A	19991130	US 1994-305158	19940913
CA 2199004	AA	19960321	CA 1995-2199004	19950913
AU 9535115	A1	19960329	AU 1995-35115	19950913
AU 697484	B2	19981008		
EP 781123	A1	19970702	EP 1995-931820	19950913
R:	DE, GB			
CN 1166136	A	19971126	CN 1995-196186	19950913
BR 9508913	A	19971230	BR 1995-8913	19950913
JP 3026271	B2	20000327	JP 1996-510312	19950913
JP 10502667	T2	19980310		
FI 9701037	A	19970512	FI 1997-1037	19970312
NO 9701149	A	19970513	NO 1997-1149	19970312
PRIORITY APPLN. INFO.:			US 1994-305158 A	19940913
			WO 1995-US11609 W	19950913
AB	A process for producing multivesicular liposomes (MVL's) for controlled release of biol. active substances comprise (1) forming a water-in-oil emulsion from two immiscible components, a lipid component contg. org. solvent, an amphiphilic lipid and a neutral lipid, and a first aq. component contg. an active substance, (2) dispersing the emulsion into a second aq. component to form solvent spherules, and (3) removing the org. solvent from the solvent spherules to form the multivesicular liposomes. The osmolarity of the first aq. component is chosen to modulate the rate of release from multivesicular liposomes into a physiol. aq. environment. The rate of release of the active substance can be decreased by increasing the osmolarity of the first aq. component or increased by decreasing the osmolarity.			
IT	10015-85-7, Dioleoyl phosphatidylcholine			
RL:	THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(prepn. of multivesicular liposomes for controlled release of active agents)			
RN	10015-85-7 CAPLUS			

L57 ANSWER 47 OF 59 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:274951 CAPLUS

DOCUMENT NUMBER: 122:64335

TITLE: antitumor compositions containing nucleic acid copolymer and lipid device

INVENTOR(S): Yano, Junichi; Ohgi, Tadaaki

PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 85 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9418987	A1	19940901	WO 1994-JP238	19940217
W: AU, BR, CA, CN, FI, HU, JP, KR, NO, NZ, RU, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2156288	AA	19940901	CA 1994-2156288	19940217
CA 2156289	AA	19940901	CA 1994-2156289	19940217
AU 9460450	A1	19940914	AU 1994-60450	19940217
EP 685234	A1	19951206	EP 1994-907061	19940217
EP 685234	B1	20000510		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE				
RU 2143903	C1	20000110	RU 1995-121696	19940217
ES 2142934	T3	20000501	ES 1994-907060	19940217
AT 192657	E	20000515	AT 1994-907061	19940217
JP 3189279	B2	20010716	JP 1994-518815	19940217
US 5705188	A	19980106	US 1995-507269	19951010
PRIORITY APPLN. INFO.:			JP 1993-54939	A 19930219
			WO 1994-JP238	W 19940217

OTHER SOURCE(S): MARPAT 122:64335

AB Pharmaceutical comps. comprise a single-stranded nucleic acid copolymer, esp. poly(adenylic acid-uridylic acid), and a lipid device [such as lipofecting (com. product) on a mixt. contg. phospholipid and glycerol derivs. such as 3-O-(4-dimethylaminobutanoyl)-1,2-O-dioleoylglycerol]. The lipid device promoted the entrance of single-stranded nucleic acid into tumor cells to induce interferon activity. As a result, the nucleic acid copolymer acted as neoplasm inhibitor. An injection was formulated contg. poly(adenylic acid-uridylic acid) and the lipid device is saline.

IT **128835-92-7, Lipofectin**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antitumor comps. contg. **nucleic acid** copolymer and lipid device)

RN 128835-92-7 CAPLUS


CN 1-Propanaminium, N,N,N-trimethyl-2,3-bis[(9Z)-9-octadecenyl]oxy]-, chloride, mixt. with 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl di-(9Z)-9-octadecenoate (9CI) (CA INDEX NAME)

CM 1

CRN 104162-48-3

CMF C42 H84 N O2 . Cl

Double bond geometry as shown.




CM 2

CRN 2462-63-7

CMF C41 H78 N O8 P

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me


IT 160005-30-1P 160005-32-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (antitumor comps. contg. **nucleic acid** copolymer and lipid device)

RN 160005-30-1 CAPLUS


CN 9-Octadecenoic acid (9Z)-, 2-[[[2-(dimethylamino)ethoxy]methylphosphinyl]oxy]-1,3-propanediyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 1-B




RN 160005-32-3 CAPLUS  
 CN 9-Octadecenoic acid (9Z)-, 2-[[[2-(diethylamino)ethoxy]methylphosphinyl]oxy]-1,3-propanediyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L57 ANSWER 48 OF 59 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1991:687225 CAPLUS  
 DOCUMENT NUMBER: 115:287225  
 TITLE: Heterovesicular liposomes  
 INVENTOR(S): Kim, Sinil  
 PATENT ASSIGNEE(S): Research Development Foundation, USA  
 SOURCE: PCT Int. Appl., 23 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9114445	A1	19911003	WO 1991-US1849	19910320
W: AU, CA, FI, JP, KR, NO, SU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
ZA 9101974	A	19940822	ZA 1991-1974	19910318
CA 2078666	AA	19910922	CA 1991-2078666	19910320
AU 9175806	A1	19911021	AU 1991-75806	19910320
AU 655177	B2	19941208		
EP 524968	A1	19930203	EP 1991-906733	19910320
EP 524968	B1	19950607		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				


JP 05507680 T2 19931104 JP 1991-507280 19910320  
 IL 97615 A1 19950629 IL 1991-97615 19910320  
 ES 2073164 T3 19950801 ES 1991-906733 19910320  
 CN 1055663 A 19911030 CN 1991-102478 19910321  
 CN 1053101 B 20000607  
 RU 2120795 C1 19981027 RU 1991-5053129 19910321  
 NO 9203624 A 19920917 NO 1992-3624 19920917  
 PRIORITY APPLN. INFO.: US 1990-496846 A 19900321  
 WO 1991-US1849 A 19910320

AB A heterovesicular lipid vesicle or liposome contains .gtoreq.2 different substances (.gtoreq.1 biol. active substance), encapsulated in sep. chambers of the same liposome. The prepn. process includes the addn. of compn. to 1st lipid component in the vial to obtain an emulsion, the addn. of compn. to 2nd lipid component in the vial to obtain a 2nd emulsion, and mixing these emulsions to form a chimeric emulsion. Thus, heterovesicular liposomes contg. dideoxycytidine soln. as the 1st aq. substance and glucose soln. as the 2nd aq. substance were prepd. The liposomes were more stable than nonheterovesicular liposomes.

IT 2644-64-6, Dipalmitoyl phosphatidylcholine 10015-85-7,  
 Dioleoyl phosphatidylcholine  
 RL: BIOL (Biological study)  
 (pharmaceutical liposomes manuf. with heterovesicular)

RN 2644-64-6 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 10015-85-7 CAPLUS

L57 ANSWER 49 OF 59 USPATFULL

ACCESSION NUMBER: 2002:329426 USPATFULL

TITLE: Polymer combinations that result in stabilized aerosols for gene delivery to the lungs

INVENTOR(S): Zou, Yiyu, Bronx, NY, UNITED STATES  
 Perez-Soler, Roman, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002187105	A1	20021212
APPLICATION INFO.:	US 2002-61444	A1	20020201 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-266174P	20010201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FULBRIGHT & JAWORSKI L.L.P., A REGISTERED LIMITED LIABILITY PARTNERSHIP, SUITE 2400, 600 CONGRESS AVENUE, AUSTIN, TX, 78701	
NUMBER OF CLAIMS:	126	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	

LINE COUNT: 5666

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of non-viral delivery of therapeutically effective compositions through aerosol for therapy or research purpose has been limited by the low efficiency mainly caused by an inefficient delivery system and destruction of formulation (gene and/or delivery system) by aerosol shearing power. This invention develops formulations that are established polymer combination formulations. The formulations are highly efficient in delivering genes in vivo through aerosol and are able to protect the delivered gene from the destruction by aerosol shearing power.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 216165-62-7

(polymer combinations that result in stabilized aerosols for gene delivery to the lungs)

RN 216165-62-7 USPATFULL

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-ethoxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, 4-oxide (9CI) (CA INDEX NAME)



L57 ANSWER 50 OF 59 USPATFULL

ACCESSION NUMBER: 2002:322479 USPATFULL

TITLE: Methods of high-throughput screening for internalizing antibodies

INVENTOR(S): Marks, James D., Kensington, CA, UNITED STATES  
Nielsen, Ulrik B., Brookline, MA, UNITED STATES  
Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002182643	A1	20021205
APPLICATION INFO.:	US 2001-981636	A1	20011016 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-241279P	20001018 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501	
NUMBER OF CLAIMS:	72	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	2405	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter

within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 26662-91-9, 1-Palmitoyl-2-oleoylphosphatidylcholine  
(liposomes contg.; methods of high-throughput screening for  
internalizing ligands or antibodies and receptors)  
RN 26662-91-9 USPATFULL  
CN 3,5,8-Trioxa-4-phosphaheacos-17-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-  
oxo-7-[[1-oxohexadecyl]oxy]methyl]-, inner salt, 4-oxide, (17Z)- (9CI)  
(CA INDEX NAME)

Double bond geometry as shown.



IT 4539-70-2, Distearoylphosphatidylcholine  
(liposomes contg.; methods of high-throughput screening for  
internalizing ligands or antibodies and receptors)  
RN 4539-70-2 USPATFULL  
CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-  
oxo-7-[[1-oxooctadecyl]oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L57 ANSWER 51 OF 59 USPATFULL  
ACCESSION NUMBER: 2002:259486 USPATFULL  
TITLE: Method to incorporate N-(4-hydroxyphenyl) retinamide in  
liposomes  
INVENTOR(S): Lopez-Berestein, Gabriel, Bellaire, TX, UNITED STATES  
Tari, Ana M., Houston, TX, UNITED STATES  
Lim, Soo-Jeong, Seoul, KOREA, REPUBLIC OF  
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002143062	A1	20021003
APPLICATION INFO.:	US 2001-982113	A1	20011017 (9)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: US 2000-241445P 20001017 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI L.L.P., A REGISTERED LIMITED  
LIABILITY PARTNERSHIP, Suite 2400, 600 Congress Avenue,  
Austin, TX, 78701

NUMBER OF CLAIMS: 130

EXEMPLARY CLAIM: 1

LINE COUNT: 3985

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are simple and unique methods of methods of preparing liposomal compositions of N-(4-hydroxyphenyl) retinamide (4HPR) and/or other retinoids. Also disclosed are liposomal 4HPR compositions prepared by such methods, and use of such compositions in the treatment of diseases, such as breast cancer. This invention further provides methods for improving the efficacy of N-(4-hydroxyphenyl) retinamide (4HPR) as a chemopreventive agent in the presence of agents that potentiates its ability increase the expression of inducible nitric oxide synthase (iNOS, and NO production in cells.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 18194-24-6, Dimyristoylphosphatidylcholine  
(incorporation of N-(4-hydroxyphenyl)retinamide in liposomes)

RN 18194-24-6 USPATFULL

CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 52 OF 59 USPATFULL

ACCESSION NUMBER: 2002:43574 USPATFULL

TITLE: Combination product intended for carrying out a  
**cytotoxic** treatment, in particular an  
antitumour treatment, in a mammal  
INVENTOR(S): Meyer, Olivier, Kirchheim, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002025941	A1	20020228
APPLICATION INFO.:	US 2001-880038	A1	20010614 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2000-7604	20000614
	US 2000-246090P	20001107 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Norman H. Stepno, BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404	
NUMBER OF CLAIMS:	26	

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 6 Drawing Page(s)  
LINE COUNT: 1400  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a combination product comprising at least one nucleic acid containing a sequence encoding a polypeptide or interest and at least one phospholipid of interest, for use which is simultaneous, consecutive or spread out over time, characterized in that said polypeptide and phospholipid of interest have **cytotoxic** activity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 58066-85-6, Hexadecylphosphocholine

(combination product for **cytotoxic** treatment in particular antitumor treatment in a mammal comprising nucleic acid encoding a polypeptide and phospholipid used with adjuvants)

RN 58066-85-6 USPATEFULL

CN Ethanaminium, 2-[[ (hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



L57 ANSWER 53 OF 59 USPATEFULL

ACCESSION NUMBER: 2002:303798 USPATEFULL

TITLE: Coated particles, methods of making and using

INVENTOR(S): Anderson, David M., Petersburg, VA, United States

PATENT ASSIGNEE(S): Select Release, L.C., Midlothian, VA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6482517	B1	20021119
	WO 9912640		19990318
APPLICATION INFO.:	US 2000-297997		20000816 (9)
	WO 1998-US18639		19980908
			20000816 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-58309P	19970909 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Boykin, Terressa M.	
LEGAL REPRESENTATIVE:	Whitham, Curtis & Christofferson, P.C.	
NUMBER OF CLAIMS:	116	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	4264	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A particle coated with a nonlamellar crystalline material includes an internal matrix core having at least one nanostructured liquid phase, or at least one nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar crystalline material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 68737-67-7


(coated particles for delivery or uptake of materials)

RN 68737-67-7 USPATFULL

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (18Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

L57 ANSWER 54 OF 59 USPATFULL

ACCESSION NUMBER: 2001:114507 USPATFULL

TITLE: CATIONIC LIPID FORMULATION DELIVERING NUCLEIC ACID TO PERITONEAL TUMORS

INVENTOR(S): SMITH, JANET G., REDWOOD CITY, CA, United States  
NIVEN, RALPH W., REDWOOD CITY, CA, United States  
ZHANG, YILIN, SAN MATEO, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001008772	A1	20010719
	US 6271209	B2	20010807
APPLICATION INFO.:	US 1999-283543	A1	19990401 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80450P	19980403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1547	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of transfecting cells in vivo, including tumor cells in the peritoneal cavity are provided. Related lipid:nucleic acid formulations adapted to transfecting cells in the peritoneal cavity are provided. Assays, including high-throughput assays for screening lipid:nucleic

acids are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 183283-19-4, EDMPC

(cationic lipid formulation for delivering nucleic acids to peritoneal tumors)

RN 183283-19-4 USPATFULL

CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-ethoxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 55 OF 59 USPATFULL

ACCESSION NUMBER: 2001:162865 USPATFULL

TITLE: N-acyl phosphatidylethanolamine-mediated liposomal drug delivery

INVENTOR(S): Meers, Paul R., Princeton Junction, NJ, United States  
Shangguan, Tong, Princeton, NJ, United States  
Ali, Shaukat, Monmouth Junction, NJ, United States  
Janoff, Andrew, Yardley, PA, United States  
Pak, Charles, Plainsboro, NJ, United States

PATENT ASSIGNEE(S): The Liposome Company, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6294191	B1	20010925
APPLICATION INFO.:	US 2000-487053		20000119 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-951056, filed on 15 Oct 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-28557P	19961015 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Goodman, Rosanne	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1062	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides liposomes containing one or more N-acylated phosphatidylethanolamines, such liposomes being useful for localizing the delivery of bioactive agents to cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 4235-95-4

(N-acyl phosphatidylethanolamine-mediated liposomal drug delivery)


RN 4235-95-4 USPATFULL



CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[ (9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

L57 ANSWER 56 OF 59 USPATFULL

ACCESSION NUMBER: 2001:72305 USPATFULL

TITLE: Ring networks utilizing wave division multiplexing

INVENTOR(S): Lahat, Amir, Brenner, Iceland

Sfadya, Yakov, Kfar Sabe, Iceland

PATENT ASSIGNEE(S): 3Com Corporation, Santa Clara, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6233074	B1	20010515
APPLICATION INFO.:	US 1998-80450		19980518 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Pascal, Leslie		
LEGAL REPRESENTATIVE:	Zaretsky, Howard, Weitz, David J. Wilson Sonsini Goodrich & Rosati		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	925		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An optical add drop module (OADM) to enable the construction of ring networks. WDM is utilized to construct a ring type network suitable for use in both WAN and LAN environments. The network is constructed having a ring topology with a plurality of nodes connected around the ring in daisy chain fashion. Direct connections between any two end users can be established to permit unicast connections. Multicast connections are also possible from a source to several destinations. Each unicast or multicast connection between nodes utilizes a separate specific wavelength. Devices are connected to the ring network via an optical add drop module. Wavelengths pass optically through the OADM device on nodes that are intermediary to the two end nodes on either side of the

connection. Only the two end nodes transmit or pickup the optical signals on that particular wavelength corresponding to the connection. Capacity in the network is easily increased by adding more optical channels on the fiber, with each channel comprising a different wavelength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 183283-19-4, EDMPC

(cationic lipid formulation for delivering nucleic acids to peritoneal tumors)

RN 183283-19-4 USPATFULL

CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-ethoxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 57 OF 59 USPATFULL

ACCESSION NUMBER: 2000:124576 USPATFULL

TITLE: N-acyl phosphatidylethanolamine-mediated liposomal drug delivery

INVENTOR(S): Meers, Paul R., Princeton Junction, NJ, United States  
Shangguan, Tong, Princeton, NJ, United States  
Ali, Shaikat, Monmouth Junction, NJ, United States  
Janoff, Andrew, Yardley, PA, United States  
Pak, Charles, Plainsboro, NJ, United States

PATENT ASSIGNEE(S): The Liposome Company, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6120797		20000919
APPLICATION INFO.:	US 1997-951056		19971015 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-28557P	19961010 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Goodman, Rosanne	
NUMBER OF CLAIMS:	51	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 9 Drawing Page(s)	
LINE COUNT:	1054	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides liposomes containing one or more N-acylated phosphatidylethanolamines, such liposomes being useful for localizing the delivery of bioactive agents to cells.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 4235-95-4

(N-acyl phosphatidylethanolamine-mediated liposomal drug delivery)  
RN 4235-95-4 USPATFULL  
CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-  
10-oxo-7-[[ (9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide,  
(7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

L57 ANSWER 58 OF 59 USPATFULL

ACCESSION NUMBER: 2000:109364 USPATFULL  
TITLE: Modulation of drug loading in multivesicular liposomes  
INVENTOR(S): Ye, Qiang, San Diego, CA, United States  
Katre, Nandini, Solana Beach, CA, United States  
Sankaram, Mantripragada, San Diego, CA, United States  
PATENT ASSIGNEE(S): SkyePharma, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6106858		20000822
APPLICATION INFO.:	US 1997-925532		19970908 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kishore, Gollamudi S.		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1466		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method for making liposomes, for example multivesicular liposomes (MVLs), containing one or more biologically active agents, wherein the loading of the active agents into the liposomes is modulated by adjusting the osmolarity of the aqueous component into which the agents are dissolved prior to encapsulation. To increase the loading of the active agent, the osmolarity of the aqueous component is reduced, and to decrease the loading of the active agent, the osmolarity of the aqueous component is increased. In the making of MVLs, the process involves dissolving the active agent and an optional osmotic excipient

in a first aqueous component encapsulated within the liposomes. For any given concentration of drug, the osmolarity of the first aqueous component can be adjusted by increasing or decreasing the concentration or molecular weight of the osmotic excipients used therein. The rate of release of the active agent into the surrounding environment in which the liposomes are introduced can be simultaneously controlled by incorporating into the lipid component used in the formulation at least one long chain amphipathic lipid. For example, the amphipathic lipid can have from about 13 to about 28 carbons in its carbon chain. Use of the long chain amphipathic lipid in the lipid component is particularly helpful in controlling the release rate and encapsulation efficiency for high drug load formulations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 63-89-8 4235-95-4 51779-95-4

(modulation of drug loading in multivesicular liposomes)

RN 63-89-8 USPATFULL

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 4235-95-4 USPATFULL

CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Me


RN 51779-95-4 USPATFULL  
 CN 3,5,9-Trioxa-4-phosphahentriacont-22-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[[(13Z)-1-oxo-13-docosenyl]oxy]-, inner salt, 4-oxide, (7R,22Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L57 ANSWER 59 OF 59 USPATFULL  
 ACCESSION NUMBER: 1999:155234 USPATFULL  
 TITLE: Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances  
 INVENTOR(S): Sankaram, Mantripragada B., San Diego, CA, United States  
 Kim, Sinil, Solana Beach, CA, United States  
 PATENT ASSIGNEE(S): SkyePharma Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5993850		19991130
APPLICATION INFO.:	US 1994-305158		19940913 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kishore, Gollamudi S.		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	42		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1006		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are multivesicular liposomes (MVL's) containing biologically active substances, the multivesicular liposomes having defined size distribution, adjustable average size, adjustable internal chamber size and number, and a controlled and variable release rate of the biologically active substance. The process involves encapsulating at least one biologically active substance and optionally an osmotic spacer in a first aqueous component encapsulated within the liposomes. The rate of release of the active substance into the surrounding environment in

which the liposomes are introduced can be decreased by increasing the osmolarity of the first aqueous component or increased by decreasing the osmolarity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 10015-85-7, Dioleoyl phosphatidylcholine

(prepn. of multivesicular liposomes for controlled release of active agents)

RN 10015-85-7 USPATFULL

FILE 'HOME' ENTERED AT 14:27:29 ON 03 JAN 2003